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Abstract 
 
 
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that function 
as ligand activated transcription factors.  There are three identified isotypes: PPARα, 
PPARγ and PPARδ, together controlling the expression of genes involved in 
inflammation, cell differentiation, proliferation, lipid and carbohydrate metabolism and 
energy homeostasis.  The PPARs are potential targets for the treatment of dyslipidaemia, 
type II diabetes mellitus and the metabolic syndrome.  This thesis uses a multi-platform 
metabolomics approach, 13C-isotope substrate flux analysis, respirometry and 
transcriptomics to determine the role PPARδ and PPARγ play in metabolic control both 
in adipose tissue and systemically.  To achieve this, the metabolic phenotype of the 3T3-
L1 adipocyte cell line was defined to generate a metabolically phenotyped in vitro model 
of adipose tissue.  The importance of fatty acid α-oxidation in the differentiation of 
adipocytes was emphasised  The effects of PPARδ and PPARγ activation in white 
adipose tissue from the ob/ob mouse model of insulin resistance, and in the phenotyped 
3T3-L1 adipocyte model, were investigated.  PPARδ activation was distinguished by 
oxidative catabolism of fatty acids and citric acid cycle intermediates.  Conversely, 
PPARγ activation was identified by the sequestration of lipids into adipose tissue.  
Moreover, to address the systemic influence of PPAR activation, with a focus on the Cori 
cycle and the interactions of the liver and skeletal muscle, the metabolic changes that 
occur in these tissues following PPARδ and PPARγ activation in the ob/ob mouse were 
examined.  PPARδ activation was characterised by the mobilisation and release of 
triacylglycerols (TAGs) into circulation as an energy source for peripheral tissues 
whereas PPARγ activation was defined by a reduction and sequestration of circulating 
TAGs.  This thesis has better characterised the role of the PPARs as master regulators of 
metabolism and emphasised their potential as therapeutic targets for metabolic diseases 
of global importance. 
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Chapter 1 
 
Introduction 
 
 
1.1 Metabolomics 
 
1.1.1. The Omics Revolution and Metabolomics 
The central biochemical and molecular biological dogma declares that information flows 
directionally from the genomic DNA through mRNA transcripts, which are then 
translated to protein.  The protein products, amongst them enzymes, then influence the 
concentrations of their substrates and products which are integrated in tightly controlled 
metabolic pathways.  It is the flux of these small molecular weight metabolites within a 
cell, tissue or organism that generates the phenotype.  Whilst much of this holds true it is 
now understood that the movement of information is far from unidirectional.  Cellular 
communication is now known to occur via a complex system of interactions between 
DNA, RNA, protein and metabolite with feed forward and negative feed back loops in 
play (Figure 1.1); the new methodologies of the omics revolution of the 1980s and 
1990s, in particular genomics, provided invaluable tools for the study of these 
interactions on a global level and offered an alternative means of investigation to that of 
the more reductionist molecular biology approaches.   
 
Genomics, that is the determination of the entire genetic DNA sequence of organisms 
accounting for the often indefinite line between genetic and non-genetic regions of DNA, 
fine-scale genetic mapping, and intragenomic interactions between loci and alleles within 
Chapter 1 
 
   
2 
the genome of an organism, gave rise to the related field of functional genomics.  The 
fundamental goal of functional genomics is the exploration of gene function on a global 
scale by elucidating the functions of genes, their products and how they interact to 
translate into the complex organisation of cells, tissues and organisms.  The importance 
of such a stratagem becomes clear when it is considered that approximately 40% of all 
open reading frames have no known function1; functional genomics is an ideal device for 
mining these potential genes. A common approach in functional genomics involves gene 
modification which disturbs the system and generates an altered phenotype; the adapted 
phenotype can then be characterised and compared to that of the wild type.  Functional 
analysis at the gene expression level is known as transcriptomics and examines the 
expression level of mRNAs in a population of cells or tissue using high-throughput 
techniques often based on microarray technology.  Investigations at the level of protein 
translation, defined as proteomics aims to identify and localise proteins and determine 
protein pathways within an organelle, cell, or organism2, 3.  More recently study of 
metabolic network interactions have been designated as metabolomics.  When integrated, 
the variety of approaches in functional genomics can contribute to research in systems 
biology, which examines the interactions between the components of the central dogma, 
and how these interactions give rise to the function and behaviour of the biological 
systems to which they belong. 
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Figure 1.1: The central molecular biological dogma states information flows 
directionally from genomic DNA through mRNA transcripts, to 
protein.  However, each tier of organization is now known to 
depend on the other.  In addition, the environment has a vital 
impact on expression and concentrations of mRNA transcripts, 
proteins, metabolites and even affects the genome. 
 
1.1.2 Metabolomics 
Metabolomics was defined in the late 1990s as a term which describes techniques aimed 
at measuring the metabolites present within a cell, tissue or organism during a genetic 
alteration or physiological stimulus4, 5.  Measurement of time-related metabolic changes 
in animal models in response to genetic manipulation can be used to define the varying 
phenotypes6.  Through this methodology metabolomics has proved complementary to the 
other omic techniques; identifying so called silent phenotypes, genes that when perturbed 
have no influence on apparent physical characteristics or behaviour7.   
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The metabolome is the terminal downstream product of the genome and consists of the 
total complement of all the low molecular weight molecules (metabolites) in a cell, tissue 
or organism required for growth, maintenance or normal function in a specific 
physiological state8, 9.  However when the potential size of the metabolome is considered, 
it is often heavily disputed, with an estimated range from ~ 600 metabolites in S. 
Cerevisiae
10 to ~200,000 metabolites in the plant kingdom11.  Alongside the variety of 
chemical classes and physical properties (small polar volatiles through to large 
hydrophobic lipids) that constitute metabolites and the dynamic range of metabolite 
concentrations across large orders of magnitude (from picomolar to millimolar) it 
becomes clear why it is necessary to employ an extensive array of analytical techniques 
within metabolomics research.   
 
Analytical approaches used within metabolomics to identify the changes in the 
concentrations and fluxes of endogenous metabolites include, but are not limited to, 1H-
Nuclear Magnetic Resonance (1H-NMR) Spectroscopy, 13C-Nuclear Magnetic Resonance 
(13C-NMR) Spectroscopy, Gas Chromatography-Mass Spectrometry (GC-MS), Gas 
Chromatography-Flame Ionisation Detection (GC-FID), Direct Infusion-Mass 
Spectrometry (DI-MS) and Liquid Chromatography-Mass Spectrometry (LC-MS).   
 
Given the extensive amount of raw data that is generated using these spectroscopic and 
spectrometric techniques, robust chemometric techniques and bioinformatic tools are a 
necessity.  Pattern recognition allows the description of inherent patterns of changing 
metabolites. Through multivariate techniques such as the unsupervised principal 
components analysis (PCA) and supervised techniques such as projection to latent 
structures through partial least squares discriminate analysis (PLS-DA) metabolites that 
vary between treatment groups can be identified12.   
 
Due to the wide array of metabolites and the dynamic nature of their concentrations 
within the cell, a complete analysis of the metabolome has thus far eluded description 
even when a range of analytical approaches have been employed.  Despite this 
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disadvantage metabolomics has been used successfully within the field of functional 
genomics to understand gene function in a range of model organisms.   
 
1.1.3 Lipidomics 
Although the lipidome is a sub fraction of the metabolome, the complexity of lipid 
classes and their distinct chemical properties has necessitated focused approaches to the 
study of these constituents of the metabolome.  Lipidomics has been defined as “the full 
characterisation of lipid molecular species and of their biological roles with respect to 
expression of proteins involved in lipid metabolism and function, including gene 
regulation”13.  A distinction is drawn between lipidomics and lipid profiling by some but 
the differences are subtle and the terms are extensively used interchangeably14, 15.  The 
interest in lipidomics has also been driven by the widening knowledge of the role of lipid 
species in the cell.  In the past the majority of lipids were considered to be either 
membrane components or an energy store.  However, these molecules are now known to 
have diverse roles in transcriptional and translational control, cellular signalling, cell-cell 
interactions, and as indicators of changes to the environs of a cell or organism over time.  
To study the various functions of lipids a multidisciplinary approach has been employed 
within lipidomics.  These have encompassed: profiling of the lipid species using a range 
of chromatographic and spectrometric techniques (many of which are well established 
metabolomic methods) and multivariate statistical data analysis16, use of traditional 
biochemical techniques to study lipid-lipid or lipid-protein interactions such as 
immobilised lipid assays17 and lipid-protein complex antibody assays18, and localisation 
of lipids using imaging methods, for instance fluorescently tagged lipids or optical probes 
for their detection19.  Lipidomics has also proved a powerful means of defining the part 
lipids play in pathological states, both for diseases where lipids are known to play a 
prominent role such as diabetes20 and where their roles are less well characterised such as 
Alzheimer’s disease21.  The development of the lipidomic field has composed an 
additional tier to data from proteomics and genomics and metabolomics of small 
molecules, furthering our knowledge of the function of lipids within the cell22. 
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1.1.4 Application of Metabolomics and Lipidomics 
In the interest of relevance to this thesis the applications discussed will primarily relate to 
the instances in which metabolomics has been utilised in the investigation of 
cardiovascular disease, the metabolic syndrome, pharmacological studies and 
phenotyping chemotaxonomy.  However, it is worthy of note that metabolomics has been 
employed in the investigation of a diverse range of other fields including neuroscience23, 
24, cancer biology25,  26, microbiology27 and cellular lipid signalling28. 
 
To a significant extent metabolomics has been an application driven discipline and much 
of the momentum within the field can be attributed to the study of diseases.    An early 
progression from single metabolite analysis was the attempted exploitation of 
metabolomics to find biomarkers of disease; the hope being that in finding valid 
biomarkers, metabolomics could be used as a viable diagnostic tool.  A prominent 
example of this premise has employed 1H-NMR spectroscopy analysis to blood serum, 
followed by pattern recognition analysis to examine the changes in lipoprotein 
metabolism associated with coronary artery disease and diabetes29.  The pattern 
recognition models generated from this study predicted that pre-diabetic serum is 
characteristic of a pro-atherogenic state in which there is a decrease in small high density 
lipoprotein (HDL) particles and an increase in very low density lipoproteins (VLDL).  
The authors continue to suggest that lipoprotein profiling may assist in diagnosing 
patients at an increased risk of developing diabetes.  In the study of clinical cardiology, a 
targeted mass spectrometry metabolomics investigation was utilised in the study of 
patients subjected to exercise stress testing with myocardial perfusion imaging30.  The 
study aimed to investigate whether metabolomics could be used to discriminate the 
occurrence of ischaemia in coronary artery disease; a goal that could aid the diagnosis, 
selection of therapy and understanding of disease mechanism. The study employed a 
control group of 18 patients with no evidence of ischaemia and a case group of 18 
patients with inducible ischaemia.  Plasma was analysed by LC-MS using a triple 
quadrupole mass spectrometer operating under selected reaction monitoring conditions.  
Metabolites involved in skeletal muscle AMP catabolism, lactic acid, as well as 
Chapter 1 
 
   
7 
hypoxanthine and inosine, increased in both the inducible ischaemic and non-ischaemic 
groups.  However there was a significant difference in a number of the metabolic changes 
between control and case groups.  The TCA cycle was profoundly effected and 6 of the 
23 most significantly changed metabolites were intermediates in this pathway.  Six 
metabolites displayed significant discordant changes in case and control groups, using 
these metabolites, case subjects could be distinguished from control subjects with a high 
degree of accuracy (p < 0.0001; c-statistic = 0.83).  Metabolomics has also been 
employed in the correlation of metabolite changes within blood plasma to measure blood 
pressure31.  
 
The applications of metabolomics in the study of disease are not limited to its diagnostic 
and biomarker identification properties; the metabolomic method has been employed in 
the study of a diverse range of diseases to elucidate mechanisms of pathology. Salek et al 
employed an NMR-based metabolomic analysis to examine urinary metabolic changes in 
the Zucker rat (fa/fa) and db/db mouse, models of type II diabetes mellitus (TIIDM), as 
well as in human diabetes patients32.  Disease dependent metabolic changes were 
identified in the subjects, demonstrating similarity in metabolic perturbation between the 
three species examined.  Of significance were metabolic disturbances related to systemic 
stress, the TCA cycle, nucleotide metabolism and methylamine metabolism.  Lipidomic 
analysis has also enabled new insights into biological disease processes33.  The potential 
application of LC-MS lipidomic analysis in both preclinical and clinical research has not 
gone unnoticed due to the importance of lipids in cardiovascular, TIIDM and related 
inflammatory disorders34.  For example, LC-MS analysis of liver tissue from the ob/ob 
mouse, a classic model of obese insulin resistance and hepatic steatosis, using reversed-
phase LC-MS revealed an increase of tri- and di-acylglycerols, diacylphosphoglycerols 
and certain ceramides and a decrease in the concentration of sphingomyelins35.  
Pietilainen et al used reversed phase LC-MS lipidomics to study the serum lipid profiles 
from monozygotic twins, determining that acquired obesity, independent of genetic 
influences, was linked with an increase in the concentration of 
lysophosphatidylcholines36.  These results were correlated and considered alongside 
clinical measurements revealing the propriety of LC-MS lipidomic analyses in human 
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studies.  Lipidomic investigation by normal phase LC-MS has also been exploited in the 
determination of lipid changes associated with the conversion of normal HDL to pro-
inflammatory HDL (acute-phase HDL) associated with cardiovascular disease.  
Phosphatidylcholine and sphingomyelin ratios were increased and diacyl and alkenylacyl 
glycerophosphatidylethanolamine and phosphatidylinositol were decreased, which may 
be indicative of proinflammatory and proatherogenic roles37.  In addition a LC-MS based 
lipidomics approach has been applied in a clinical study of TIIDM patients38.  The study 
identified over 100 phospholipids in the blood plasma and demonstrated changes in the 
plasma phospholipid profile that distinguished patients from control subjects.  An 
increased concentration of two phosphoethanolamine species (phosphoethanolamine 
C16:0/C22:6 and C18:0/C20:4) and a decrease in the concentration of two lyso-
phosphocholine species (lyso-phosphocholine C16:0 and C18:0) discriminated diabetic 
patients from controls.   
 
Metabolomics has also been successfully applied as a phenotyping device for laboratory 
model in vitro and in vivo biological mediums and chemotaxonomy, which is profiling 
for strain differences; this concept was initially proved in a 1H-NMR spectroscopy study 
of the metabolic changes induced in two yeast mutants of 6-phosphofructo-2-kinase 
which was capable of distinguishing between the silent phenotypes of the yeast39.  The 
phenotyping approach was then expanded upon by a study that demonstrated it could be 
applied to the media in which the yeast was grown, giving rise to the technique of 
metabolic footprinting40.  Plant biochemistry has also exploited the rigorous phenotyping 
capabilities of metabolomics; in a seminal paper Fiehn et al were able to use GC-MS to 
quantify 326 distinct metabolites from Arabidopsis using these to separate four 
genotypes41.  GC-MS metabolomic analysis has also been exploited to identify changes in 
lipid metabolism upon hormone induced differentiation of 3T3-L1 cells into mature 
adipocytes42.  A metabolic profiling approach has been utilised to phenotype mouse 
models of cardiac diseases43.  Analysis of cardiac tissue from mouse models of Duchenne 
muscular dystrophy, cardiac arrhythmia and cardiac hypertrophy using NMR 
spectroscopy in conjunction with multivariate statistics was capable of classifying mouse 
models of cardiac disease.  Strain background was identified as a substantial contributor 
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to the metabolic phenotype of the mouse models.  Independently of strain differences 
each mouse model could be separated from its control strain.  Numerous further examples 
of the application of metabolomics in this manner exist across a diverse range of species 
and include discrimination between different species of Ephedra44, use of DI-MS to 
determine different species of fungal strains45 and selection of pathogenic and non-
pathogenic species of Bacillus cereus isolated from meningitis patients46. 
 
The potential for developing metabolomics within the pharmaceutical industry has also 
been realised, especially in preclinical compound toxicology screening; these screens 
generate thoroughly definable end-points that are usually monitored over a relatively 
short period of time, providing robust candidates for metabolomic analysis which can 
associate metabolites with the distinct end-points.  Toxicological studies conducted in 
this manner have implicated phenyl-acetyl glycine as a candidate biomarker for drug 
induced phospholipidosis47, 2-aminoadipate as a mechanism associated biomarker for 
hydrazine induced neurotoxicity48 and urinary D-β-hydroxybutyrate or trimethylamine 
and dimethylamine as region specific markers of nephrotoxicity in the proximal tubules 
and renal papilla respectively49, 50.  One of the most significant studies in the area of drug 
toxicity was the COMET project which aimed to construct databases of drug toxicity 
using approximately 100,000 1H-NMR spectra of biofluids from animals treated with 
model toxins51. The COMET project has since been expanded to include COMET II 
which aims to elucidate the biological mechanisms behind drug toxicity with a 
combination of omics techniques.    
 
1.1.5 Integrated Omics 
The integration of genomics, transcriptomics, proteomics and metabolomics is a key goal 
of systems biology.  The potential benefit for integrating the omics has been realised in 
the fields of disease research, where for some conditions conventional approaches have 
been inconclusive, and population, nutrition and toxicogenomic studies, where 
integration allows connections between environmental factors (for example diet), 
exposure to toxic compounds and environmentally induced diseases to be drawn.  The 
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potential to use an integrated methodology to identify genes whose functions are as yet 
unknown remains a tempting research approach. However, reaching definitive 
conclusions from integrated omics approaches can be challenging; the generation of 
multiple metabolites from a single gene set can result from translational control of 
mRNA, transcriptional and translational processes that produce isoenzymes, or poor 
enzyme specificity and lead to confounding results. 
 
In the area of disease research a combined transcriptomic and metabolomic approach has 
been used to investigate fatty liver disease induced by orotic acid in Kyoto rats, 
identifying uridine metabolism, choline turnover and the stearoyl-CoA desaturase as key 
to disease progression52.  Integration of transcriptomics, proteomics and metabolomics 
has been employed to investigate the ApoE*3-Leiden transgenic mouse53.  The mouse 
model over expresses the human ApoE protein that is involved in the transport of fats in 
blood plasma, preventing the clearance of lipid from the blood, resulting in the 
development of atherosclerotic plaques by 25 weeks of age.  LC-MS analysis identified 
perturbation of lipid metabolism characterised by a decrease in plasma 
lysophosphocholine and increase in Triacylglycerols (TAGs) occurring pre-
symptomatically at 9 weeks in the ApoE mouse.  Transcriptomics, proteomics and 
metabolomic analyses were then applied to the liver tissue from the ApoE mouse; a total 
of 21,000 components were measured using the three approaches and facilitated the 
development of correlation networks to highlight perturbed metabolic pathways.  The 
identification of new mechanisms in cardiovascular disease is being realised by 
exploitation of the complementarities of the omic techniques.  Metabolomics and 
proteomics in combination have been employed to characterise atrial tissue that 
predispose patients to the development of atrial fibrillation54.  In addition there is the 
hope that future genome-wide association studies will identify genomic sequence variants 
precipitating the further integration of the omics.  At the forefront several loci have 
already been identified, which are associated with early-onset myocardial infarction55, 56, 
57.  
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An example of the integration of omics techniques in a toxicological study is provided by 
research conducted by Coen et al which examined acetaminophen induced hepatotoxicity 
in the mouse using transcriptomics and metabolomics58. The results from both the 
transcriptomics and metabolomics indicated increases in glycolytic flux, highlighting the 
complementarities of the omics for the use in the evaluation of drug safety.   
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1.2 Analytical Techniques 
 
To verify changes in low molecular weight metabolites from complex biological samples, 
analytical methods which are sensitive to a range of sample components, well resolved, 
robust, relatively cheap on a per sample basis, suitable for application and offer high 
throughput capabilities are required.  Recent and rapid developments in the areas of NMR 
spectroscopy, mass spectrometry and chromatography have lead to significant advances 
within the fields of metabolomics and lipidomics.  As a result an extensive range of 
profiling technologies is now available and their applications have proven to be diverse. 
 
Metabolomic analysis is most commonly performed using 1H-NMR spectroscopy and 
mass spectrometry, often coupled to a prior chromatographic technique, most commonly 
liquid or gas chromatography.  However other analytical techniques such as Fourier 
transform infrared spectroscopy59, capillary electrophoresis60 and high-performance 
liquid chromatography ultra violet detection61 have been applied.  Through a combined 
analytical approach utilising a range of technologies a more inclusive picture of the 
metabolome can be acquired by overcoming the limitations of individual techniques, 
although, due to the extensive variety and complex nature of metabolite species a fully 
comprehensive metabolomic map remains an unattained goal.  It seems likely that to 
achieve this formidable objective will require a collective approach allying traditional 
biochemistry, metabolomic profiling and the swiftly evolving area of bioinformatics. The 
principles behind and effectiveness of the techniques used within this thesis will now be 
explored.  
 
1.2.1 Mass Spectrometry in Metabolomics and Lipidomics 
The field of metabolomics and lipidomics in particular has been strongly influenced by 
developments in mass spectrometry. Mass spectrometric analysis comprises three distinct 
events: analyte ionisation, mass dependent ion separation and ion detection.  Ionic 
separation can be achieved by a variety of mass analysers including time-of-flight (TOF), 
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quadrupoles, magnetic and / or electric sectors, ion trap and Fourier transform ion 
cyncotron resonance62. The analysers vary in their dynamic range, resolution, suitability 
for tandem-MS (MS/MS) experiments and mass accuracy.  The identification and 
separation of analytes by mass to charge ratio (m/z) can be improved with higher 
resolution and mass accuracy instruments.  However, there is a correlation between the 
resolution of an instrument and its relative cost!  To a degree, lower resolution and mass 
accuracy can be compensated for by MS/MS capability, and this has meant an extensive 
range of instruments are utilised in metabolomic studies.   
 
The most common methods of analyte ionisation in metabolomic and lipidomic mass 
spectrometry are electrospray ionisation (ESI), electron impact (EI) ionisation and to a 
lesser extent matrix assisted laser desorption/ionisation (MALDI); the last of these has 
not been exploited in this thesis and will not be discussed further. 
 
EI ionisation is used almost exclusively in combination with GC as it requires the analyte 
to be volatile.  In EI high energy electrons bombard the volatile analyte causing analytes 
to fragment and generate a reproducible pattern of signals, which can be matched to 
spectral databases for the purpose of identification.  GC-MS within the context of 
metabolomics and lipidomics will be discussed in greater detail later. 
 
The late 1980s saw the development of the, so called, soft ionisation technique ESI63, 
which allowed the mass spectrometric detection of non volatile and high mass analytes, 
such as peptides, proteins or intact lipids.  The principal advantages of the soft ionisation 
techniques are that they do not require chemical derivatisation, although derivatisation 
can be used to enhance or enable ionisation64, and they minimise analyte fragmentation, 
which can assist in the analytical interpretation of complex mixtures. 
 
Briefly, ESI elutes the analyte by spraying it through a highly charged needle tip.  The 
charged analyte spray droplets are heated, evaporating the solvent and resulting in 
ionisation and entry of analyte ions into the mass separation unit65.  ESI is by far the most 
commonly applied ionisation technique in lipidomics, partially due to the ease of 
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coupling the eluent of an analytical LC experiment to the mass spectrometer.  The use of 
ESI, in metabolomics, to analyse polar aqueous soluble metabolites has lagged behind 
that of lipid analysis, although it has been employed extensively in drug pharmacokinetic 
analysis66. However the analysis of polar metabolites by LC-MS in metabolomics is now 
experiencing a rapid period of growth67,68.  DI-MS, LC-MS and ESI are explored more 
extensively in sections 1.2.2 and 1.2.3 of this thesis. 
 
1.2.2 Electrospray Ionisation and Direct Infusion-Mass Spectrometry in Lipidomics 
The development of the ESI and closely related nano-spray technique in the 1980s 
resulted from pioneering work, conducted in the laboratory of John Fenn, producing a 
novel atmospheric pressure interface for the coupling of a liquid chromatograph and a 
mass spectrometer69.  The ESI source functions as an electrochemical cell, generating 
gas-phase ions.  Analytes are typically dissolved in a polar or volatile solvent and 
pumped into a fine capillary with a diameter ranging from 75-150 µm with a flow rate 
ranging from 1 µl min-1 to 1 ml min-1 70.  A voltage, generally in the region of 1-4 kV 
depending on the elution solvent (typically 2-3 kV for methanol/acetonitrile and 4 kV for 
water), is applied to the capillary tip and results in a charge migration of species in 
solution to the capillary/solution interface producing an electric double layer; a novel 
adaptation meaning in ESI the pre-organisation of charges occurs in solution71.  
 
A Taylor cone is produced when the electrostatic forces on the preformed ions in the 
electric double layer of the capillary counterbalance the surface tension.  The Taylor cone 
is destabilised by the increase in voltage resulting in the sample emerging from the 
capillary being dispersed as a fine spray of charged droplets; this process is enhanced by 
the co-axial nebulising gas, frequently nitrogen, which flows around the capillary.  
Solvent evaporation then reduces the size of the charged droplet causing an increase in 
the concentration of charge on the droplet surface up to the Rayleigh limit72; at this point 
“Coulombic explosion” occurs as the Coulombic repulsion surmounts the surface tension 
of the droplet and the droplet explodes forming smaller droplets of lesser charge.  Solvent 
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evaporation and Coulombic explosion continues eventually forming individually charged 
solvent free analyte ions, creating the spray of charged species (Figure 1.2). 
 
There are two competing theories as to how gaseous ions are formed in ESI during 
droplet desolvation73. The charge residual model states that successive droplet fissions 
occur until individual ions are formed in the gas phase.  The second model, known as the 
ion evaporation model, proposes that ions are expelled from droplets to the gas phase 
prior to total droplet fissions. 
 
The spray of the charged analyte species can be introduced into a sampling cone, then 
into an intermediate sampling vacuum before entering the mass analyser of the mass 
spectrometer, which is maintained under high vacuum, where they are analysed for m/z. 
The charges are distributed along charge sites on the analyte, under certain conditions, 
resulting in the formation of multiply charged ions.    
 
Figure 1.2:  Gas phase ion formation by ESI. 
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ESI has been used effectively in DI-MS, in which the analyte mixture is directly infused 
into the mass spectrometer. Direct infusion ESI has also been dubbed "shotgun" in 
reference to the more frequently known shotgun proteomics74.  
 
The attention of the reader is also drawn to the capabilities of the different ionisation 
modes to measure varying lipid species.  In negative mode there is a preference for 
anionic lipid species to ionise.  After addition of lithium hydroxide, ammonium acetate or 
formic acid, negative ion mode can detect the weak anionic lipids and positive mode 
detects the neutral and polar lipids. 
 
Direct infusion lipidomics has facilitated identification and relative quantification of over 
450 phospholipids from mammalian cells75.  By means of a triple quadrupole mass 
spectrometer, Milne et al, were able to measure four major lipid classes in positive mode 
and 7 in negative ion mode in directly infused lipid extract from approximately 3x106 
WEHI-231 cells75.     
 
Mass spectrometry provides significant analyte separation, is highly sensitive76 and 
extremely versatile.  As a consequence it is utilised in a range of experiments.  The mass 
spectrum of a mixture may be used in metabolic “fingerprinting” experiments.  
Fingerprinting is so called as it necessitates a rapid biochemical ‘fingerprint’ of a sample 
without the time consuming process of metabolite identification11.  Koulman et al 
exploited whole spectra from raw plant metabolite extractions as fingerprints before 
carrying out further experiments to identify the signals with MS/MS in a high throughput 
manner77.  MS/MS isolates individual m/z species for fragmentation.  In a process known 
as collision induced dissociation (CID), the molecular ions are accelerated by an 
electrical potential increasing their kinetic energy.  The ions then collide with neutral gas 
molecules such as helium or nitrogen within a collision cell in the mass spectrometer.  As 
the molecules collide the kinetic energy is converted into internal energy, resulting in the 
breakage of chemical bonds and the fragmentation of the molecular ion.  The fragments 
are then separated by m/z in a second mass analyser.  The m/z values of the fragments aid 
the identification of the isolated ions.  For instance, phospholipid headgroups often give 
Chapter 1 
 
   
17 
characteristic fragment signals either in the form of a neutral loss or a characteristic 
signal at a specific m/z value74. The speed, relative robustness and potential for 
automation of this technique have been extensively exploited.  
 
As mentioned previously there is an array of mass analysers engaged in metabolomic and 
lipidomic analysis.  The DI-MS investigation conducted in this study utilised a 
quadrupole linear ion trap mass spectrometer.  The Thermo Finnigan linear ion trap mass 
spectrometer employed in investigations conducted in this study consists of an ion beam 
generated at an ESI source, directed through a heated capillary and focused through two 
successive rod arrays.  Entry into the ion trap is gated by a lens which pulses from 
positive to negative voltages to repel and attract the ions into the aperture leading to the 
ion trap.  The allowed entry time of ions into the ion trap maximises signal whilst 
reducing the unwanted space-charge effects which would result from an excessive 
quantity of ions entering the trap.  Three hyperbolic quadrupole rod arrays constitute the 
ion trap itself; ions are restrained radially by a two-dimensional radio frequency trapping 
field in the centre section of the ion trap.  Axial confinement is by direct current 
potentials applied to the front and rear end electrodes. The ion trap is filled with helium to 
a pressure of ~1 mtorr, as collisions with helium reduce the kinetic energy of the ions, in 
a process known as kinetic cooling, and contract the trajectories of molecular ions to the 
centre of the trap.  The ion trap functions as a mass spectrometer when the field within 
the device is altered, by dipole excitation generated with auxiliary alternating current 
voltages on the X-rods, destabilising the trajectories of concurrently trapped ions of 
successive m/z ratio; consequentially the ions leave the trapping field in order of their m/z 
ratio78.  On leaving the ion trap the ions strike a detector, typically a conversion diode and 
electron multiplier (Figure 1.3).  
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Figure 1.3:  Schematic diagram of the Thermo Finnigan Linear Ion Trap Mass 
Spectrometer. Ions pass through the instrument from left to right. 
 
The MS/MS function of the quadrupole linear ion trap operates in a pulsed mode and so 
mass selected ions can be accumulated over time.  Fragment ions arising from 90% of 
isolated ions can be confined using the ion trap and as a consequence several mass-
selective operations can be performed; ion traps are capable of performing MS/MS to the 
nth degree79. 
 
ESI can suffer from a number of disadvantages.  The most prominent being strong ion 
suppression effects when analysing complex molecular mixtures80.  Ion suppression is 
generated by analytes competing for charge during the ionisation process, with an 
individual analytes’ ionisation efficiencies based on their chemical characteristics81.   
Therefore, the observed ion count for a particular ion can change, depending on what 
other analytes or contaminants are being co-ionised.  The problem is compounded in that 
ion suppression can occur even when the interfering compound is not seen in the mass 
spectrum. Thus, measurement must assume the mixtures are roughly the same between 
the groups of samples analysed.  The drawback may be circumvented, to a degree, by 
separating the analytes via one or more chromatographic techniques prior to mass 
spectrometric analysis82. 
 
1.2.3 Liquid Chromatography-Mass Spectrometry 
It was previously mentioned that a number of metabolomic and lipidomic studies have 
utilised DI-MS, introducing a sample directly into an ESI source83, 84, 85, 86.  However the 
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ion suppression phenomenon caused by certain metabolites including prominent 
phospholipids, especially when using positive ionisation, can affect both low and high 
concentration analytes87.  Detrimental ionisation properties can be minimised with an 
initial, either offline or online, high performance liquid chromatography (HPLC) 
separation.  The use of HPLC for lipid analysis is a well established approach; normal 
phase chromatography in the separation of lipid classes, particularly phospholipids, is 
well documented, though HPLC was originally, and often still is, coupled to either 
evaporative light scattering detection88, 89 or ultra-violet detection90.  These detectors are 
susceptible to serious constraints in lack of selectivity and the choice of mobile phase91.  
As a consequence, metabolomic and lipidomic applications of HPLC often interface the 
liquid chromatograph to an ESI-MS detector92. 
 
LC-MS is suitable for the analysis of thermally labile, polar or high molecular mass 
compounds but is disposed to certain constraints with respect to these; the temperatures 
used in ESI may be limiting when analysing particularly labile compounds and due to the 
intrinsic nature of ESI there must be a degree of innate polarity in analyte molecules.  To 
aid the subsequent ionisation of analytes ammonium acetate can be added to the mobile 
phase to produce ammonium adducts.  In addition the volatile organic acid, formic acid 
can be included in the mobile phase to improve ionisation of analytes from the eluent in 
mass spectrometric investigation.   
 
The sample is injected onto a LC column which consists of a narrow tube packed with 
chemically modified silica.  Separation of analytes occurs due to their interaction with the 
stationary phase (the column packing) and the mobile phase (the solvent passing through 
the column).  There is an extensive range of column chemistries available including 
partition, normal phase, ion exchange, size exclusion, displacement and reversed phase 
chromatography and their ability to separate chemical classes of analyte varies.  LC-MS 
conducted in the course of this thesis has extensively employed reversed phase 
chromatography (RPC). 
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RPC column chemistry exploits a non-polar stationary phase and a moderately polar, 
aqueous mobile phase.  The stationary phase utilised in the LC-MS investigations 
detailed in this thesis is a silica based surface which was subsequently treated with 
C8H17Me2SiCl.  RPC relies on the principles of electrostatic and hydrophobic forces.  The 
column chemistry functions in such a way that the binding of analytes to the stationary 
phase relies on the contact surface area around the non-polar segment of the analyte 
molecule with the chemistry of the stationary phase within the aqueous eluent and is 
described by the solvophobic theory.  Retention of molecules by the stationary phase can 
be decreased by reducing the polarity of the mobile phase solvent and so lessening the 
water surface tension.  Elution of analytes from the column is brought about by reducing 
the polarity and surface tension of the mobile phase over a gradient.  Therefore, in 
reversed phase analysis the retention time for larger non polar molecules is longer when 
compared to polar molecules93, 36.  The use of columns with sub-2 µm particle size along 
with elevated column temperature or temperature gradients is favoured for higher 
resolutions and faster separations94.  It is worthy of note that the elevated column 
temperature is necessary; as flow rates increase with smaller column packing particles, 
resolution is improved but the pressure is increased due to the reduced particle size; by  
increasing the temperature the effective pressure is reduced. 
 
Following chromatographic separation the analytes are then introduced into a mass 
spectrometer via an ionisation interface, the most common of which is Atmospheric 
Pressure Ionisation (API), which includes ESI and Atmospheric Pressure Chemical 
Ionisation.  The LC-MS analysis conducted in this study was performed using ESI and a 
quadrupole-time-of-flight (QToF) mass spectrometer.  The ESI interface introduces the 
ions generated to a radio frequency quadrupole lens which functions as an ion guide and 
collisional dampening cell.  The ions are then accelerated into the second mass analyser 
quadrupole, which for single mass spectrometry functions to transmit the ions through the 
machine. A quadrupole is formed of four parallel metal rods.  One set of opposing rods 
have the applied potential (U+Vcos(ϖt)).  The other pair of rods have the potential -
(U+Vcos(ϖt)).  U is a direct current voltage and Vcos(ϖt) an alternating current voltage. 
Voltages applied to the rods are used to control the course of ions as they move along the 
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ion flight path at the centre of the four rods. By altering the voltages ions of a particular 
m/z are allowed through the quadrupole filter (Figure 1.4).   
  
Figure 1.4: Schematic Diagram of a Quadrupole Mass Analyser.  Ionisation occurs at 
the source.  Ions are then accelerated and focussed by a lens into the 
quadrupole.  Opposing rods have the same applied potential.  Voltages 
applied to the rods are used to control the course of ions as they move 
along the ion flight path at the centre of the four rods.  The green arrow 
represents the flight path of a resonant ion. The red arrow is the flight path 
of a non-resonant ion. 
 
However, in MS/MS mode, the quadrupole functions as a mass filter transmitting the ion 
of interest.  The ions are accelerated into a hexapole collision cell, operated in radio-
frequency only mode when performing single mass spectrometry.  When performing 
MS/MS the ion of interest is accelerated before it enters the collision hexapole, where the 
ion is subjected to CID.  In both single mass spectrometry and MS/MS mode the ions are 
reaccelerated as they leave the collision cell and focused using ion optics into the ion 
modulator of the TOF analyser.  A pulsed electric field pushes ions into the accelerating 
column from here the ions enter the field free space.  A reflectron is then employed to 
correct the kinetic energy distribution of the ions.  A constant electrostatic field reflects 
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the ion beam towards the detector.  The greater the kinetic energy of an ion the deeper it 
penetrates the reflectrons electrostatic field and therefore the longer its flight path to the 
detector; in this way the energy distribution of ions with the same m/z is corrected 
resulting in the simultaneous arrival of ions of identical m/z at the detector, referred to as 
time-of-flight focus.  Ions are detected with two microchannel plates and mass spectra are 
recorded with a time-to-digital converter95. (Figure 1.5).  
 
 
Figure 1.5:  Schematic Diagram of the Micromass QToF Ultima Mass Spectrometer 
operating in V-mode.  When the mass spectrometer is operated in W-mode 
higher resolution is achieved but as a consequence there is a decrease in 
sensitivity due to ion loss. 
 
LC-MS has many advantages as a technique for metabolomic analysis; it is a relatively 
high throughput method that combines a good dynamic range with the potential for 
metabolite identification from the spectral data.  LC-MS can also be very sensitive with 
good mass accuracy and resolution96.  
 
Libraries to assist in sample identification for LC-MS lipidomic and metabolomic data 
are limited, partly because ESI-MS is affected by the instrument type, ion source, ion 
source potentials, mobile phases and other factors affecting fragmentation patterns97.  
However, a number of resources are available.  These provide pertinent reference 
material and structural information of MS/MS fragmentation.  Examples of these include 
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LIPID MAPS (www.lipidmaps.org98), The Lipid Library (http://www.lipidlibrary.co.uk/), 
Cyber Lipid Center (http://www.cyberlipid.org/), LIPIDAT (http://www.lipidat.ul.ie/,99) 
and LipidBank (http://lipidbank.jp/). 
 
1.2.4 Gas Chromatography-Mass Spectrometry 
Gas-chromatography was first proposed in a 1941 paper by Martin and Synge in which it 
was suggested that the mobile phase in a liquid-liquid chromatography system could be 
replaced with a vapour100.  Following advances in technology, it became possible to 
couple the chromatographic technique to mass spectrometry.  During the 1950s Gohlke 
and McLafferty united a gas chromatograph to a TOF mass spectrometer founding the 
technique of GC-MS101.  GC-MS has since become a key research technique in a vast 
array of fields and is a core tool in lipid biochemistry, lipidomics and metabolomics.  
  
Since GC-MS requires the analytes to be volatile and thermally stable, derivatisation is 
used to reduce unwanted absorption effects, increase the volatility of polar compounds, 
remove polar functional groups or generate derivatives as an aid to identification.  The 
derivatisation of aqueous soluble metabolites has been conducted using a variety of 
methods; however a two step protocol using methoxylamine hydrochloride followed by 
N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) is most commonly used in 
metabolomic analysis102.   The initial methoxymation converts the keto group of 
monosaccharides to an oxime; limiting the monosaccharide to the syn and anti isomer 
reduces the tautomeric forms of monosaccharides from 5 to 2 and therefore reduces the 
complexity of a chromatogram and also improves subsequent derivatisation.  The 
subsequent silylation reaction using MSTFA diminishes the intrinsic dipole-dipole 
interactions of the analyte molecules by substituting the active hydrogens in hydroxyl 
(OH), amine (NH) and thiol (SH) groups with a silyl; thereby increasing the volatility of 
the metabolites. (Figure 1.6). 
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Figure 1.6: The reaction mechanisms for the derivatisation of aqueous phase 
metabolites. 1. Methoxymation of keto groups from monosaccharides. 2. 
Silylation of hydroxyls. 
 
The most frequent derivatisation of fatty acids is hydrolysis of complex lipids, to release 
esterified fatty acids, followed by the methylation of the fatty acids to form fatty acid 
methyl esters (FAMEs).  A range of methods have been described in the literature to 
perform methylation of fatty acids103, 104; research conducted in this thesis exploited 
acidic esterification using boron trifluoride and methanol.  Methylation increases the 
volatility of the fatty acids whilst masking their polar functional carboxyl group (Figure 
1.7). 
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Figure 1.7: The reaction mechanism for the methyl esterification of fatty acids. 
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The analyte mixture is injected, vaporised and introduced onto the GC column by a 
carrier gas.  The carrier gas, which functions as the mobile phase, pushes the sample 
through the heated column.  As different compounds dissolve to varying degrees in the 
stationary phase, a polymer layer bound to an inert solid (commonly a silicone liquid), 
they move through the column at differing rates which are dependent on the partition of 
the compounds between the stationary phase and the mobile carrier gas.  As separation is 
partially reliant on volatility, a programmed temperature gradient is applied.  The 
separation of compounds within the sample is dependent on carrier gas flow rate, column 
dimensions, stationary phase type, analyte chemistry and the temperature of the column. 
 
A key aspect of metabolomics and lipidomics is the ability to identify the metabolites 
once they have been detected.  The stationary phase of the GC column selected for 
analysis has a significant impact on the identification process.  For example non polar 
silicone phases separate fatty acid methyl esters based almost exclusively on molecular 
weight, whereas using high molecular weight hydrocarbons allow for separation of 
saturated and unsaturated components of the same chain length.  The use of polar 
polyester columns also permits the separation of esters of the same chain length to the 
extent that, using highly polar cyanoalkylpolysiloxane phases gives excellent 
discrimination of cis and trans isomers of monounsaturated fatty acids, albeit requiring 
relatively long chromatography times.  Given suitable chromatographic separation 
provisional identifications can be made using a comparison of the analyte retention times 
with those of commercially available standard mixtures.  However, these identifications 
must only be viewed as tentative and highlight the benefit of a combined 
chromatographic-spectrometric technique.  
 
In GC-MS analysis, the end of the GC column is interfaced with the mass spectrometer 
by passing the column through a heated transfer line to the ion source where the eluting 
compounds are ionised.  EI ionisation is most commonly used in GC-MS experimentation 
to ionise the analyte molecules (Figure 1.8).  The analyte is subjected to an energetic 
beam of electrons generated by a filament, which causes the analyte to lose an electron 
and a radical cation to be produced.  Ionised analytes can fragment as a relaxation 
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pathway removing the excess internal energy gained through ionisation and producing 
further smaller ions.  Fragmentation provides structural information in the form of a 
"finger print" which can then be used for identification62.  As a consequence of the 
amount of energy absorbed by the analytes and the low stability of the radical gas phase 
ions, fragmentation of analytes is extremely reproducible.  The ionisation energy 
typically used is 70 eV allowing standardisation of fragmentation libraries. There are a 
number of commercially available databases, for example the National Institute of 
Standards and Technology (NIST)/ Environmental Protection Agency (EPA)/ National 
Institutes of Health (NIH) mass spectral library, designed to aid the identification of 
metabolites from GC-MS analysis and are therefore well suited to metabolomic 
investigation. 
 
Figure 1.8: Schematic of Electron Impact Ionisation. 
 
The ions generated by EI are then repelled out of the ionisation chamber with a small 
positive charge.  The ions enter a mass analyser which functions to separate the ions 
based on their m/z.  Quadrupole mass analysers are the most commonly used and have 
been discussed previously.  Mass spectra are generated by examining the ions progressing 
through the quadrupole whilst the applied voltages are adjusted.  Once filtered, the ions 
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enter the detector where the electrical impulses are amplified and sent to a computer 
where the signal is converted into a visual display. 
    
GC-MS is a robust system that is highly sensitive and provides good resolution.  
Nevertheless, the technique is limited by its m/z range, preventing the analysis of larger 
metabolite species.  The technique also requires that compounds be thermally stable with 
high enough vapour pressure to volatilise during injection.  Chemical derivatisation for 
GC-MS has been used to overcome this problem but in itself can introduce variability to 
the samples and can mask metabolite structural information.  Chemical derivatisation also 
increases sample preparation and when combined with an extensive chromatographic run 
(as is often required in metabolomics to separate the variety of chemical classes of 
metabolites) reduces the throughput of GC-MS as an analytical technique.  The multiple 
procedures required prior to GC-MS analysis also increase the risk of contamination and 
recovery losses. However by using GC-MS in combination with other analytical 
techniques not only are these restrictions surmounted but the coverage of the metabolome 
can be significantly increased.   
 
1.2.5 
1
H-Nuclear Magnetic Resonance Spectroscopy 
Analysis of biofluids and tissue extracts using 1H-NMR spectroscopy is a well 
established technique that has diversified within the field of metabolomics105, 106.  The 
popularity of the technique arises partly from its application in the determination of the 
structures of small organic molecules allowing the identification of metabolites from 
biological samples, but also from its low cost per sample basis and, due to its 
spectroscopic, quantitative, robust and reproducible nature.  The technique is also non-
destructive allowing multiple analyses of samples.  The use of high-resolution NMR 
spectroscopy with field strengths greater than 9.4 Tesla are utilised to overcome some of 
the disadvantages of NMR due to low sensitivity and small chemical shift range for 1H-
NMR spectra.  The analysis of mouse tissue metabolite extracts using 1H-NMR typically 
detects 20-40 metabolites; when applied to urine the number of metabolites observed 
reaches 100-200107.  Despite the relatively low coverage of the metabolome 1H-NMR 
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analysis can be highly discriminatory; this arises because metabolic pathways are 
connected by a small number of metabolite nodes, which are observed using 1H-NMR 
analysis, whose concentrations are significant indicators of changes in the steady states of 
metabolic pathways43.  Much of the criticism directed at metabolomic studies using NMR 
spectroscopy has not been concentrated on the analysis itself but on biological 
discrepancy. However, within rodent studies variables such as diet, sex, choice of vehicle 
and strain can be controlled and therefore limit sources of variations. 
 
Nuclear magnetic resonance spectroscopy is reliant on magnetic nuclei having an 
intrinsic angular momentum called spin. Nuclei with non-zero spin are detectable by 
NMR; these include 1H, 13C and 31P. The magnitude of spin angular momentum is 
defined by the equation: [I(I+1)]1/2 ħ, where I is the spin quantum number of a nucleus.  
The nuclear spin quantum number of 1H is ½.  The spin angular momentum I is a vector 
that in a spin-I nucleus has 2I+1 projections onto an axis, this allows the quantisation of a 
particular axis component of I, known as Ix,y or z depending on the axis.  Therefore         
Ix,y or z= m ħ where the term m is the magnetic quantum number which has 2I+1 values at 
integral steps from +I to –I.  These parameters mean that for the 1H nucleus, which has 
I=½, the angular momentum has two allowed directions, Ix,y or z= ±½ ħ (Figure 1.9). 
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 Figure 1.9:  Space quantisation of spin-½ nuclei. 
 
2I+1 orientations of a spin-I nucleus have the same energy until a magnetic field is 
applied.  The energy of the nucleus is altered by an amount proportional to the strength of 
the magnetic field B, the gyromagnetic ratio and the axis component of the angular 
momentum.  Therefore the 2I+1 states for spin-I nuclei are spaced with an energy gap 
ħγB.  Since for NMR ∆m=±1 transitions occur between adjacent energy levels and 
therefore ∆E=hν= ħγB (Figure 1.10).  If electromagnetic radiation is applied at frequency 
ν the nuclei will move from the lower energy state to that of the higher energy state; this 
frequency is the Larmor frequency. 
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Figure 1.10:  A. The interaction between the magnetic field B, the nuclear magnetic 
moment µ and the projection of µ onto B, µx, y or z. B. Energy level for 
1H 
nuclei in a magnetic field. 
 
In a magnetic field, magnetic nuclei are separated between the 2I+1 energy levels 
according to the Boltzmann distribution with the ratio of the two levels given by 
nupper/nlower=e
-∆E/kT (where k is the Boltzmann’s constant) which is comparable to the 
thermal energy of the system at room temperature.  However, NMR signals are weak, 
with the intensity of the transition depending on the difference in the populations of the 
energy levels which are very small.  The population differences are often ≤0.001%, 
explaining the relative insensitivity of 1H-NMR.  By using stronger field strengths ∆E can 
be maximised and the sensitivity of NMR spectroscopy increased.   Regardless, the 
population difference between energy states is large enough to produce a net magnetic 
moment which aligns with the magnetic field.   
 
When a radiofrequency pulse is applied along the x-axis of the magnetisation its rotation 
can be moved away from its equilibrium position rotating about the z-axis so it is aligned 
by 90º into the x,y plane.  Short radiofrequency pulses, referred to as hard pulses, are 
large enough to excite a range of frequencies simultaneously, and therefore populations 
of all spin energy levels will be equalised.  Populations of higher spin levels will then 
resonantly emit energy as they slowly decay to their equilibrium positions.  The emission 
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of energy can be detected using a coil of wire that surrounds the sample and is mounted 
in the xy-plane; when the magnetisation precession intersects the wire it is detected as a 
current is induced.  This is known as the free induction decay (FID) which is Fourier 
transformed from the time to the frequency domain producing a spectrum (Figure 1.11).  
The chemical shift and coupling identified within the spectrum are used to assign 
resonances.      
 
 
Figure 1.11: A simple pulse sequence for a pulse-aquire experiment.  Post equilibration 
a 90º radiofrequency pulse is applied, rotating the magnetisation into the 
y-axis. The precession of the magnetisation generates the free induction 
decay signal.  
 
The resonance frequency of nuclei is dependent upon the position of the nucleus in a 
molecule.  This effect is known as the chemical shift and occurs because the external 
magnetic field causes electrons to circulate in their orbitals.  This motion generates a 
small magnetic field B’, in the opposite direction to B0 that shields the nucleus from the 
external field.  The magnetic field experienced by the nucleus (BN) is determined by the 
equation BN = B0 (1-σ), σ being the shielding constant.  For nuclei in molecules the 
motion of the electrons may induce fields that either augment or oppose the external field, 
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and so influence their resonant frequencies.  The frequency is presented as a shift in parts 
per million (ppm) from a reference nucleus. Besides the chemical shift additional data 
from NMR spectra can be obtained from magnetic interactions between nuclei which 
generate extra peaks in the spectra providing information on the arrangement of the 
nuclei in an analyte, known as spin-spin coupling.  Spin-spin coupling arises when non-
symmetrically equivalent adjacent nuclei interact, splitting the corresponding NMR 
signal.  The number of lines generated by a signal coupling is given by the equation 
(2nI+1), where n is the equivalent nuclei and I is spin of these nuclei.  The term J defines 
the difference between the components and is a measure of electronic overlap measured 
in Hz.  J aids in the identification of compounds analysed by NMR since it provides 
information about the bonds linking nuclei.  
 
1.2.6 Two-dimensional Heteronuclear Single-Quantum Coherence 
13
C-Nuclear 
Magnetic Resonance Spectroscopy 
Conventional one-dimensional NMR generates a spectrum which plots intensity against 
frequency; however two-dimensional NMR plots intensity against two frequency axes, 
meaning each peak in a two-dimensional spectrum has intensity and two frequency co-
ordinates, aiding greatly the separation of different resonances.  Two-dimensional NMR 
experiments start with a preparation period in which the equilibrium magnetisation is 
transformed into a coherence which evolves during the evolution period, t1.  The 
preparation period involves a 90º pulse generating a single-quantum coherence 
(transverse magnetisation).  The evolution, t1, is systematically incremented in a series of 
experiments.  During the mixing period the coherence present at the end of t1 is 
manipulated into an observable signal which is then recorded in the detection period, 
known as t2.  In the mixing period the magnetisation is transferred from one spin nuclei to 
another.  In a two dimensional NMR experiment the FID is detected at regular time 
intervals in t1 and t2 generating a series of data points representing the time-domain 
function.  Initially t1 is set to 0, the pulse sequence is run and the FID detected and 
recorded as a function of t2 (Figure 1.12).  The process is then repeated for ∆1 and then 
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2∆1 and so on.  Free inductions are generated for both t1 and t2 which are then Fourier 
transformed for both dimensions. 
 
Figure 1.12: General scheme for two-dimensional NMR. The preparation and mixing 
periods can be a single radiofrequency pulse.  Coherence generated during 
the preparation phase evolves for time t1, the signal is detected during t2. 
 
In a Heteronuclear Single-Quantum Coherence (HSQC) experiment one frequency co-
ordinate gives the 13C chemical shift, whilst the second frequency co-ordinate is that of 
the attached proton, the observed nuclei in this case is the proton.  Cross peaks in a 
heteronuclear correlation spectrum arise as a result of transfer through one bond 
heteronuclear coupling, identifying shifts of directly attached nuclei and aiding 
assignment (Figure 1.13).  The HSQC pulse sequence functions by first transferring 
magnetisation from the proton to the 13C nuclei making the approach more sensitive than 
NMR pulse sequences that detect 13C resonances directly.  The 13C spin magnetisation 
evolves for t1, acquiring a frequency label according to the offset of 
13C.  Magnetisation is 
then transferred back to 1H and observed.  The spectra produced have peaks centred at the 
offset of the 13C spin and at the offset of the 1H spin. 
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Figure 1.13: An example 1H-13C  HSQC spectrum recorded at 500 MHz.    
 
13C NMR spectroscopy has been used extensively to measure concentrations of 13C 
labelled metabolites and for mapping flux through metabolic pathways in biological 
systems both in vitro and in vivo.  Pioneering research using 13C NMR to track metabolic 
pathways using labelled substrates such as glucose tagged with the stable 13C isotope was 
first conducted in the 1970s108; these experiments were initially performed in 
microorganisms and perfused organs and determined rates of metabolic pathways by 
measuring the label appearance in pathway products as a function of time109.  The 1980s 
saw an expansion of the technique when it was first applied in animal models110 and with 
in vivo NMR spectroscopy in humans111.  13C labelled metabolite tracing studies provide 
a bridge between the distinct scientific approaches of reductionist molecular biochemistry 
and global systems biology, contributing to the elucidation of the mechanisms of 
metabolic regulation. 
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1.3 Multivariate Statistical Techniques 
1.3.1 Multivariate Statistics in Metabolomics 
As metabolomic analysis evolves the number of metabolites measured and the coverage 
of the metabolome will continue to increase.  The result is the generation of extensive 
amounts of raw data, containing the concentrations of a large array of metabolites, which 
must be contained in intricate data tables.  In order to mine these vast resources for 
statistically relevant variation in metabolism requires potent statistical techniques 
proficient in data reduction and simplification. 
 
Multivariate statistics, and especially pattern recognition processes, examine the 
relationships between multiple variables simultaneously permitting visualisation of the 
prominent trends within complex data sets.  In analysing large data sets, where the 
number of variables often exceeds the number of samples, especially when the variables 
are co-linear as is the case in metabolomic analysis, multivariate statistics becomes a 
superior tool to more traditional univariate analysis.  Multivariate analysis has a number 
of advantages over univariate techniques in that it concurrently analyses all variables, 
taking into account their co-linear nature, it can manage with omitted data and is robust to 
noise112; overcoming the risk of generating ambiguous results from monitoring and 
assessing each variable independently as is the case in univariate statistics.  
 
Multivariate statistical methods are commonly classed as either unsupervised or 
supervised.  Methods such as PCA and hierarchical cluster analysis (HCA) are classified 
as unsupervised techniques as they do not assume a priori knowledge of classification in 
the data set and so examine intrinsic variation of the data set.  Supervised methods 
include partial least squares (PLS), orthogonal signal correction (OSC) and PLS-DA; 
these statistical analyses exploit information on classification to distinguish the intrinsic 
variation from variation generated by class membership, optimising discrimination 
between classes113.  Within a metabolomics setting, where the variance of interest may 
not essentially be the greatest variance in the dataset, the supervised techniques can be 
valuable in distinguishing particular biological queries; particular illustrative examples 
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include differentiating drug treatment doses or severity of disease.  The principles behind 
multivariate statistical techniques used within this thesis are explored in further detail in 
Chapter 2 Materials and Methods (section 2.11 Data Handling for Metabolomics).  
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1.4 The Metabolic Syndrome 
1.4.1 Regulation of Metabolism, Insulin Resistance and the Metabolic Syndrome 
Insulin is the primary hormone regulator of intermediary metabolism in mammals, 
controlling the utilisation of fuels for storage or oxidation.  Insulin exerts its influence 
over carbohydrate and lipid metabolism, as well as on protein and mineral metabolism. 
As a consequence, perturbations in the systemic insulin signalling network will have 
severe detrimental effects, not only on specific target organs but also on the whole 
organism. 
 
The release of insulin, from the β-cells in the islets of Langerhans found in the pancreas, 
as a result of elevated levels of blood glucose facilitates uptake, utilisation and storage of 
glucose in a range of tissues.  Activation of the insulin receptor in muscle and adipose 
tissue leads to an increase in the recruitment of the GLUT 4 transporter on the surface of 
cells in these tissues and therefore increases the rate of entry of glucose into the cells114.  
Insulin also has a profound effect on liver metabolism; the hormone stimulates the uptake 
of glucose into hepatocytes and its conversion to glycogen, once glycogen stores are full, 
insulin also promotes the de novo synthesis of fatty acids from glucose in the liver.  The 
exposure of adipose tissue to insulin inhibits the intracellular lipase and therefore 
prevents the hydrolysis and release of fatty acids from TAGs, concomitantly the synthesis 
of glycerol from glucose is enhanced.  These processes lead to further accumulation of 
TAGs in the adipocytes. 
 
There is a distinctive variation in the concentration of insulin required to arbitrate the 
metabolic responses in tissues between individuals in a population115.  In the case of 
insulin insensitivity, referred to as insulin resistance, peripheral metabolic tissues fail to 
respond effectively to increases in the concentration of insulin in circulation116.  This can 
lead to hyperglycaemia. In some individuals the ability to produce enough insulin to 
negate insulin resistance is impaired and this gives rise to TIIDM.  Increased insulin 
resistance, when combined with hyperinsulinaemia and obesity, increases an individual’s 
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risk of associated disorders such as dyslipidaemia and microalbuminuria which in turn 
increase the prevalence of atherosclerosis and hypertension leading to cardiovascular 
morbidity and mortality117.  The increased risk of cardiovascular disease as a direct result 
of perturbed insulin pathway function in non-type I diabetics was first defined as 
metabolic syndrome in 1988118.  A number of biomarkers have been identified that 
decidedly correlate with the degree of insulin resistance; these include low density 
lipoprotein (LDL) particle size119 and fibrinogen120.  
 
1.4.2 Aetiology of the Metabolic Syndrome  
The aetiology of the metabolic syndrome is complex and poorly understood with roots 
likely to lie in both environmental and polygenic factors.  The theory that 
hyperinsulinaemia caused by a loss of insulin sensitivity is a primary contributing factor 
to the development of metabolic syndrome has become widely established121.  The 
syndrome associates insulin resistance, visceral obesity, dyslipidaemia and hypertension, 
which are known to be interrelated.  However there is continued controversy as to 
whether the condition is a homogeneous disorder or disease and whether it can be truly 
recognised as a syndrome122.  The pathophysiology is further complicated by the 
recognition that individuals with a lone component of the metabolic syndrome are not at 
as high a risk of cardiovascular disease or TIIDM demonstrating the individual 
components are more than additive. 
 
The principal contributing factors of the metabolic syndrome have been grouped together 
in four main categories: insulin resistance, visceral obesity, atherogenic dyslipidaemia 
and endothelial dysfunction.  The first two factors seem to be central and metabolic 
predisposition to insulin resistance and obesity appear to be necessary for the metabolic 
syndrome phenotype.  Dyslipidaemia often arises from the insulin resistance and obesity 
and is further broken down to include high serum TAG concentrations and decreased 
HDL particle concentrations.  Endothelial dysfunction is thought to come from 
adipokines and free fatty acids (FFAs) released by adipose tissue in the obese phenotype.  
Endothelial dysfunction manifests symptomatically as hypertension.  Together the 
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dyslipidaemia and hypertension contribute to the emergence of cardiovascular disease.  
Candidate genetic factors that may combine to the pathology of the metabolic syndrome 
have been identified in a number of large cohort patient studies123.  
 
1.4.3 Diagnosis and Current Definitions of Metabolic Syndrome 
As previously mentioned the etiology of the metabolic syndrome is complex and this has 
meant that the diagnosis and definitions of the disorder have controversially varied.  The 
most commonly used definitions for diagnosis come from the World Health Organisation 
(WHO), first developed in 1998, the European Group for the Study of Insulin Resistance 
(EGIR), who proposed an amendment to the WHO definition in 1999, the National 
Cholesterol Education Program (NCEP), who devised their definition in 2001 and which 
has since been amended by the National Heart Lung and Blood Institute in 2005, and the 
International Diabetes Foundation (IDF) whose definition was first published in 2005.  
These definitions are summarised in Table 1.1. 
 
Given the multiple definitions arising from the variation of emphasis, for example the 
WHO definition classifies individuals at risk of developing TIIDM whereas the IDF 
definition focuses on adiposity, the Food and Drug Administration, the European 
Association for the Study of Diabetes and the American Diabetes Association have 
questioned diagnosing patients as suffering from metabolic syndrome and instead called 
for the identification and treatment of individual risk factors124. 
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 NCEP 
(2005) 
WHO (1998) EGIR (1999) IDF 
(2005) 
Essential N/a Insulin Resistance 
(IGT or TIIDM) 
Hyperinsulinaemia 
(plasma insulin 
>75th percentile) 
Central 
obesity 
(waist 
>94cm 
male, >80 
cm female) 
Criteria Three of the 
five criteria 
defined 
below 
Insulin resistance 
or TIIDM and two 
of the five criteria 
below 
Hyperinsulinaemia 
and two of the four 
criteria below 
Obesity and 
two of the 
four criteria 
below 
Obesity 
Definition 
Waist >101 
cm male 
and >89 cm 
female 
Waist/hip ratio 
>0.9 Male and 
>0.85 Female or 
BMI >30 kg/m2 
Waist >94 cm 
Male and >80 cm 
Female 
Central 
Obesity 
required 
Hyperglycaemia Fasting 
glucose 
>5.6 mmol/l 
Insulin resistance 
required 
Insulin resistance 
required 
Fasting 
glucose 
>5.6 mmol/l 
Dyslipidaemia TAG >1.7 
mmol/l and 
HDL-
Cholesterol 
<1 mmol/l 
male and 
<1.3 mmol/l 
Female 
TAG >1.7 mmol/l 
or HDL-
Cholesterol <0.9 
mmol/l Male and 
<1 mmol/l Female 
TAG >2 mmol/l or 
HDL-Cholesterol 
<1 mmol/l 
TAG > 1.7 
mmol/l and 
HDL-
Cholesterol 
<1 mmol/l 
Male and 
<1.3 mmol/l 
Female 
Hypertension >130 
mmHg 
systolic of 
>85 mmHg 
diastolic 
>140/90 mmHg >140/90 mmHg >130 
mmHg 
systolic of 
>85 mmHg 
diastolic 
Additional  Microalbuminuria   
Table 1.1: Definitions of the metabolic syndrome. Impaired Glucose Tolerance 
(IGT). Microalbuminuria, >20 mg/min urinary albumin excretion or 
albumin-to-creatinine ratio of >30 mg/g. Adapted from Huang, P.L., 2009 
125. 
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1.5 Peroxisome Proliferator-Activated Receptors 
In 1990 a novel murine orphan receptor was cloned and characterised that was activated 
by a range of peroxisome proliferators126; this was the first peroxisome proliferator-
activated receptor (PPAR) isoform to be characterised and was named PPARα.  
Peroxisomes are cellular organelles involved in the β-oxidation of long-chain fatty acids 
and catabolism of cholesterol in the formation of bile acids.  The PPARs are a subgroup 
of the nuclear receptor superfamily and ligand-activated transcription factors that control 
the expression of genes involved in a range of vital biological processes127.  Since the 
discovery of PPARα further PPAR isoforms have been identified and named PPARγ and 
PPARδ, each demonstrating its own specific tissue distribution and ligand preference128.  
As opposed to PPARα neither PPARδ nor PPARγ are activated by peroxisome 
proliferators or increase the number or size of peroxisomes in rodent tissues129.  PPARδ is 
also known as PPARβ, a complexity resulting from the initial isolation of PPARβ in 
Xenopus oocytes130.  The mammalian PPARβ appeared to have little homology with that 
identified in amphibians and so was named PPARδ.  The mammalian genome was later 
revealed to only contain three PPAR isoforms; PPARδ was recognised as the mammalian 
ortholog of PPARβ131. 
 
The PPARs share a great deal of structural homology with other members of the nuclear 
receptor superfamily.  The DNA binding domain of the receptors is comprised of an 
approximately 70 amino acid binding domain containing two highly conserved zinc 
fingers.  The receptors also include a more variable ligand binding domain of 
approximately 250 amino acids which besides its ligand binding capacities includes 
dimerisation and transcriptional activation domains as well as the extensively studied 
transcriptional activation function 2 domain at the extreme C-terminal section of the 
receptor. 
 
Ongoing research into the physiological role of PPARs has revealed that they have a 
primary role as master regulators of metabolism and as nutritional sensors.  The three 
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PPAR isoforms are activated by a range of unsaturated fatty acids and essential fatty acid 
metabolic pathway products and their derivatives, the eicosanoid and prostaglandin 
classes.  As PPARs have been implicated in the metabolic control of pathways involving 
a number of their ligands it has been suggested that the ability of PPARs to act as 
nutritional sensors comes from their ability to function through these positive and 
negative feed back loops132.  However it has also been postulated that activation of the 
PPARs is less specific; a theory emanating from the discovery that the binding affinity 
fatty acids have for the PPARs is relatively low when compared to other hormone-
receptor couplings133 and from the elucidation of the structure of the binding domain of 
the receptor class which is large in comparison to other members of the nuclear receptor 
superfamily, and so binds promiscuously to a diverse range of heterogenic compounds134. 
 
1.5.1 PPAR Ligand Activated Transcription Factors 
The PPARs form obligate heterodimers with the 9-cis-retinoic acid receptor (RXR) and 
bind to two half sites of the direct repeat of the hexameric DNA consensus sequence, 
AGGTCA separated by one nucleotide135 (Figure 1.14).  The consensus binding 
sequences are known as Peroxisome Proliferator Response Elements (PPREs) and have 
been identified in numerous genes involved in organogenesis, inflammation, cell 
differentiation and proliferation and carbohydrate and lipid metabolism.  In the absence 
of ligand binding, the PPAR-RXR complex recruits co-repressors, associated histone 
deacetylases and chromatin-modifying enzymes that silence transcription by active 
repression136,137.  Upon ligand binding a conformational change occurs in the PPAR-RXR 
complex releasing transcriptional repressors in exchange for co-activators; these 
complexes function to recruit the basal transcriptional machinery enhancing the 
expression of target genes.  There is mounting evidence that the different functional 
properties of the three PPAR subtypes arises from subtle differences in binding site 
preference, tissue distribution and their ability to bind different co-repressors and co-
activators138.  
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Figure 1.14: The peroxisome proliferator-activated receptor mechanism for the 
activation of gene transcription. 
 
1.5.2 Peroxisome Proliferator-Activated Receptor α 
PPARα is primarily expressed in highly catabolic tissues such as the heart, liver, 
macrophages, intestines, kidneys and skeletal muscle139.  The receptor is bound by a 
range of saturated and unsaturated fatty acids including palmitoleate and oleate138, as well 
as polyunsaturated fatty acids and leukotriene B4140.  PPARα plays a crucial role in the 
regulation of FFA transport, uptake and catabolism141. 
 
The response to hypoglycaemic conditions is partially co-ordinated by PPARα.  The 
nuclear receptor increases the expression of a panel of genes including the fatty acid 
transporter, fatty acid transport protein, acyl-CoA oxidase, and keto-acyl-CoA thiolase.  
The result is an increase in uptake of fatty acids into the liver accompanied by 
upregulation of peroxisomal β-oxidation of these fatty acids, shortening their chain length 
and facilitating entry into the mitochondria.  The mitochondrial β-oxidation pathways 
also come under PPARα transcriptional control with increased expression of carnitine 
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palmitoyltransferase I142 and medium-chain-acyl-CoA dehydrogenase143.  As a 
consequence circulating TAG concentrations are reduced and lipidaemic profiles 
normalised by PPARα activation. 
 
Due to the low levels of expression of PPARα in white adipose tissue the receptor is 
thought to play a limited role in adipogenesis.  Activation of PPARα in 3T3-L1 
preadipocytes fails to stimulate their differentiation144; however when the receptor is co-
expressed with the transcriptional co-activator PPARγ-coactivator 1 in this cell line the 
expression of enzymes participating in the β-oxidation pathway is increased145.  Rat 
primary adipocytes were also found to respond in a similar way to PPARα activation by 
fibrates in a process involving the upregulation of fatty acid uptake and β-oxidation146. In 
vivo mice lacking the PPARα gene appear to have normal white adipose tissue; however 
they are susceptible to spontaneous late onset obesity and adipocyte hypertrophy147.  
 
It is worthy of note that PPARα is also the target for the fibrate pharmacological 
compound class used in the treatment of hypercholesterolaemia and hyperlipidaemia.  
Members of this class include fenofibrate and bezafibrate.  Activation of PPARα by 
fibrates results in a decrease in very low-density lipoprotein-cholesterol, chylomicrons 
and circulating TAGs through a mechanism involving increased expression of lipoprotein 
lipase and apolipoprotein A-V148.  HDL-Cholesterol concentrations also increase 
following fibrate treatment, a result of increased transcription and subsequent translation 
of apoA-I and apoA-II149 and ABC binding cassette transporter A1 induction, which 
stimulates macrophage cholesterol efflux150; since macrophages containing high 
concentrations of lipids are primary facilitators of inflammation and atherosclerotic 
plaque formation in the vasculature these processes contribute to a reduction in the risk of 
cardiovascular disease151. 
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1.5.3 Peroxisome Proliferator-Activated Receptor γ  
PPARγ was initially identified using homology cloning in Xenopus130 and then mice152, 
before it was isolated by identification and cloning of the ARF6 factor controlling the 
function of the adipose-specific enhancer of the aP2 gene153.  ARF6 was discovered to be 
PPARγ associated with its heterodimeric partner RXR153.  The PPARγ gene is transcribed 
to give three mRNAs, termed PPARγ1, PPARγ2 and PPAR γ3, which are generated by 
alternative splicing and differential promoter utilisation.  Only the PPAR γ1 and PPARγ2 
isoforms are expressed as proteins in mice and humans.  The PPARγ2 protein is larger 
than PPARγ1, comprising of an additional 30 amino acids located at the N-terminus.  The 
function of the extended N-terminus in PPARγ2 is as yet unknown but several studies 
have suggested that it may play a role in adipogenesis154, 155.  The tissue expression of the 
two isoforms also differs; PPARγ2 is primarily expressed in the white and brown adipose 
tissue whereas PPARγ1 is more ubiquitously expressed with higher concentrations of the 
mRNA found in kidneys, pancreas, heart, intestines and adipose tissue139, 156.  
 
PPARγ has been established as the master regulator of adipogenesis; no other 
transcriptional regulator has yet been shown to promote adipogenesis in the absence of 
the nuclear receptor.  However, in vivo study of PPARγ null mice has proven difficult due 
to embryonic lethality arising from placental insufficiency157.  The generation of chimeric 
mice containing PPARγ null cells demonstrated that these cells do not contribute to 
adipocyte formation158.  Later research has shown that inactivation of PPARγ specifically 
in embryonic cells rather than trophoblasts lead to the production of mice with PPARγ 
deficiency that demonstrated lipodystrophy, insulin resistance and hypotension.  In 
addition PPARγ selective ablation in adipose tissue verified the nuclear receptor’s 
importance for post-differentiation adipocyte survival159.  In vitro studies have also 
emphasised the importance of PPARγ for adipogenic processes; PPARγ knock out 
fibroblasts and embryonic stem cells have been shown to be differentiation 
incompetent158 whilst pre-adipocytes carrying a dominant negative PPARγ mutation 
failed to undergo adipogenesis160.   
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Besides PPARγ’s critical role in adipogenesis, the nuclear receptor is also a principle 
regulator of fatty acid metabolism in white adipose tissue.  The receptor promotes FFA 
uptake and consequent storage as TAGs.  Activation of PPARγ increases expression of an 
array of genes required for a range of lipid metabolic pathways in adipocytes; the genes 
regulated by PPARγ include fatty acid transport protein 1, crucial for FFA uptake, 
lipoprotein lipase, necessary for the release of FFA from TAGs, fatty acid binding protein 
4, required for intra-cellular FFA transport, as well as acyl-CoA synthase and 
phosphoenolpyruvate carboxykinase 1, essential for FFA activation and esterification, via 
glyceroneogenesis, respectively161.  The active nuclear receptor also promotes storage of 
TAGs in unilocular lipid vesicles within adipocytes162. 
 
PPARγ activation is of clinical importance in the treatment of TIIDM and the metabolic 
syndrome; the thiazolidinedione (TZD) class of antidiabetic drugs are PPARγ agonists.  
Two members of the TZD pharmacological compound class, rosiglitazone and 
pioglitazone are currently utilised in the clinic.  TZDs were of interest initially due to 
their ability to lower blood glucose levels in rodents and later in humans163; subsequently 
it was discovered that the TZDs were direct pharmacological agonists for PPARγ164.  The 
mechanism by which activation of PPARγ by TZDs brings about insulin sensitisation and 
normalisation of hyperglycaemia has been the focus of a great deal of research over the 
last decade.  Evidence thus far supports the conviction that adipose tissue is the primary 
target and mediator for the systemic effects of TZD treatment, a theory described by the 
“lipid steal” hypothesis165,166.  The hypothesis states that PPARγ activation in white 
adipose tissue enhances dietary fatty acid storage.  TIIDM is characterised by increased 
plasma FFA concentrations and inappropriate deposition of lipids in peripheral and 
metabolic tissues such as liver and skeletal muscle, which is associated with insulin 
resistance and impaired glucose utilisation167.  Therefore PPARγ activation in the adipose 
tissue is thought to facilitate sequestration of the FFAs into the white adipose tissue, as a 
safe storage depot, and away from the peripheral tissues where their deposition is 
deleterious.  However, the theory is less than comprehensive since the insulin sensitising 
effects of TZDs are not shared by alternative drug classes that also lower circulating 
Chapter 1 
 
   
47 
plasma FFA concentrations, suggesting additional mechanisms are involved in the 
antidiabetic processes initiated by PPARγ activation.     
 
1.5.4 Peroxisome Proliferator-Activated Receptor δ  
In comparison to PPARα and PPARγ, the third member of the family, PPARδ has come 
under a lesser degree of scrutiny.  However, the research that has been conducted thus far 
indicates PPARδ may be a potential clinical target for the treatment of obesity, the 
metabolic syndrome and TIIDM.  PPARδ is expressed almost ubiquitously, though some 
tissues express higher concentrations of the mRNA including the brain, adipose tissue, 
skin, liver and skeletal muscle139.  In addition PPARδ protein expression has recently 
been shown to be high in liver, colon, small intestine and keratinocytes168.  PPARδ is 
activated by several 14 to 18 carbon containing polyunsaturated fatty acids, including 
eicosanoids such as prostaglandin A1, iloprost and carbaprostacyclin, in the micromolar 
range132. Nevertheless, the physiological ligands of PPARδ remain undefined.   
 
In vivo studies using PPARδ null rodents have proven difficult since deficiency of the 
receptor results in embryonic lethality of over 90% due to placental defects.  However, 
the surviving animals have been found to expend less energy than the wild type and 
consequently are more susceptible to weight gain169.  The development of a number of 
high affinity synthetic PPARδ ligands has identified the receptor as a potential 
therapeutic target for the metabolic syndrome; PPARδ ligands retard weight gain in 
models of high-fat diet induced obesity.  Insulin resistant obese rhesus monkeys treated 
with the selective PPARδ agonist GW501516 demonstrated significant increases in HDL-
cholesterol with concomitant decreases in TAGs and LDL-cholesterol170.  PPARδ is 
expressed at 10 and 50 times the concentrations of PPARα and PPARγ, respectively, in 
skeletal muscle and administration of PPARδ agonists to rodents results in an increase in 
expression of genes involved in fatty acid oxidation, mitochondrial respiration, oxidative 
metabolism and slow twitch contractile apparatus171. These changes would be expected to 
bring about a decrease in muscle fatigability and positively impact fatty acid homeostasis.   
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The role of PPARδ in adipose tissue appears to be that of a regulator of tissue metabolism 
and energy homeostasis.  In vitro investigation has shown that expression of PPARδ is 
induced early in the differentiation of the 3T3-L1 murine clonal white preadipocyte cell 
line172 and during early brown adipogenesis173.  PPARδ is also implicated in the 
stimulation of adipogenesis via the induction of PPARγ expression and mitotic clonal 
expansion174, 175.  In vivo targeted activation of PPARδ in white adipose tissue results in 
increased expression of genes involved in FFA oxidation and the electron transport chain 
uncoupling protein 1; these transcriptional changes coincided with a reduction in 
adiposity through reduced intracellular TAG accumulation and improved lipid profiles169. 
   
However, the ubiquitous expression of PPARδ may result in diverse and unwanted side 
effects upon activation of this receptor.  PPARδ has been the subject of contrasting 
studies relating to its role in carcinogenesis.  The nuclear receptor has been implicated in 
the acceleration of intestinal adenoma growth and increased growth in breast and prostate 
cancer cell lines, but contradictory to these studies PPARδ has also been shown to 
attenuate colon cancer176, 177, 178. The role of PPARδ in development and carcinogenesis is 
complex and has been extensively reviewed elsewhere179.  Given the ubiquity of 
expression of PPARδ and its apparent diverse effects, an unambiguous comprehension of 
the global effects of activation of the nuclear receptor is necessary before it can be 
considered as a therapeutic target. 
 
1.5.5 The Application of Metabolomics to the Study of the PPARs 
Metabolomics has been employed to study mouse models of PPAR function.  13C isotope 
labelling strategies identified hypoglycaemia and impaired liver fatty acid β-oxidation in 
fasting PPARα null mice, demonstrating that the receptor regulates hepatic 
gluconeogenesis in both fed and fasted mice180, 181.  Atherton and colleagues used a 
combined 1H-NMR spectroscopy and GC-MS metabolomics strategy to analyse the effect 
of the ageing process on metabolism in the liver, heart, skeletal muscle and adipose tissue 
of PPARα null mice and wild-type mice between 3 and 13 months of age182.  The 
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PPARα null mouse was characterised by hepatic steatosis and reduced glucose and 
glycogen liver and muscle concentrations.  The hepatic concentrations of glucose and 
glycogen also decreased in an age dependent manner in both mouse genotypes.  The 
study highlighted the role the receptor plays in the ageing process and provides a model 
for the investigation of the interaction between age and genotype.  
 
The functions of the PPARs have also been investigated using synthetic agonist 
compound treatment studies of model organisms.  PPARγ activation by rosiglitazone in 
the heart, adipose tissue, liver and plasma of the NZO x NON mouse, a model of TIIDM, 
has also been investigated using a lipidomics platform183.  The mass spectrometry based 
study employed thin layer chromatography to separate lipids into their chemical classes 
followed by GC-MS to investigate constituent fatty acids that were esterified to each 
complex lipid class.  There was a detected decrease in several lipid classes in the serum, 
alterations in cardiolipin, and an accumulation of polyunsaturated fatty acids in adipose 
tissue.  The metabolomic changes were also correlated with transcriptional changes 
analysed by reverse transcriptase polymerase chain reaction.  The metabolic effect on 
exposure of rats to two PPARα agonists, a PPARγ agonist and a PPARδ agonist has been 
studied using a 1H-NMR spectroscopy based metabolomics investigation of urine184.  
Two biomarkers from the tryptophan-NAD+ pathway, N-methyl-4nicotinamide and N-
methyl-4-pyridone-3-carboxamide, were found to correlate with peroxisome proliferation 
measured by electron microscopy of liver tissue.  
 
1.5.6 Selective Pharmacological PPAR Agonists 
The research conducted within this thesis employs two high affinity, specific and 
extensively characterised PPAR agonists.  GW347845 is a specific PPARγ agonist with 
an EC50 value of 1.2 nM for murine PPARγ.  GW610742 is a PPARδ agonist with an  
EC50 value of 28 nM for murine PPARδ compared to 8900 nM and >10,000 nM for 
PPARα and PPARγ respectively185. 
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1.6 Project Aims 
Given the crucial role of both PPARδ and PPARγ in white adipose tissue, it is the aim of 
this thesis to use a metabolomics approach to investigate and define the metabolic effects 
of PPARδ and PPARγ activation in both in vivo adipose tissue and in an in vitro model of 
adipose tissue. 
 
To achieve the outlined aim the metabolic phenotype of the adipose tissue specific cell 
line, differentiating 3T3-L1 preadipocytes, as they mature into adipocyte cells will be 
defined and compared to differentiating murine primary cells using metabolomics to 
generate a metabolically phenotyped in vitro model of adipose tissue.  
 
The effects of PPARδ and PPARγ activation in white adipose tissue from a mouse model 
of insulin resistance, and in the adipose tissue specific cell line within a cell culture 
system, will then be investigated in order to generate an in vivo and an in vitro model of 
adipose tissue specific PPAR activation.  In addition the thesis aims to deconvolute the 
metabolic mechanisms by which PPARδ and PPARγ alter the metabolism of the adipose 
tissue specific cell line using stable isotope labelling, transcriptomics and additional 
complementary methodologies.   
 
Further to these aims it is intended to use a metabolomics approach to investigate and 
define the global physiological and pharmacological effects of PPARδ and PPARγ 
activation through the characterisation of a range of tissues from a pharmacological 
compound treatment study performed in a mouse model of insulin resistance.   
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AIM  
To metabolically phenotype the 3T3-L1 adipocyte model of 
differentiation and compare the model to differentiating murine 
primary preadipocytes using metabolomic techniques. 
Chapter 3 
To investigate the metabolic effects of pharmacological PPARδ 
activation in white adipose tissue from the ob/ob mouse model of 
insulin resistance, and in the 3T3-L1 adipose tissue specific cell line 
within a cell culture system, to generate an in vivo and an in vitro 
model of adipose tissue specific PPARδ activation.  
Chapter 4 
To deconvolute the metabolic mechanisms by which PPARδ activation 
alters the metabolism of the 3T3-L1 adipose tissue specific cell line 
using stable isotope labelling, transcriptomics and respirometry.   
Chapter 4 
To investigate the metabolic effects of pharmacological PPARγ 
activation in white adipose tissue from the ob/ob mouse model of 
insulin resistance, and in the 3T3-L1 adipose tissue specific cell line 
within a cell culture system, to generate an in vivo and an in vitro 
model of adipose tissue specific PPARγ activation.  
Chapter 5 
To deconvolute the metabolic mechanisms by which PPARγ activation 
alters the metabolism of the 3T3-L1 adipose tissue specific cell line 
using stable isotope labelling and transcriptomics.   
Chapter 5 
To use a metabolomics approach to investigate and define the global 
physiological and pharmacological effects of PPARδ and PPARγ 
activation through the metabolic characterisation of blood serum, 
skeletal muscle and liver tissue from a pharmacological compound 
treatment study performed in the ob/ob mouse model of insulin 
resistance.   
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Chapter 2 
 
Materials and Methods 
 
 
2.1 3T3-L1 and Primary Murine Adipocyte Cell Culture Techniques 
 
2.1.1. 3T3-L1 Cell Culture and Adipocyte Differentiation 
3T3-L1 preadipocytes were grown in T75 flasks and maintained in Dulbecco’s modified 
Eagles media (DMEM) (high glucose 4.5 g/l; Sigma-Aldrich) supplemented with 10% 
(v/v) new born calf serum (Sigma-Aldrich), 50 units/ml penicillin, and 50 µg/ml 
streptomycin (Sigma-Aldrich) in a humidified 5% CO2 incubator at 37ºC.  At 2 days 
post-confluence cells were induced to differentiate with DMEM supplemented with 10% 
v/v FBS, 1 µM dexamethasone (Sigma-Aldrich), 0.5 mM isobutylmethylxanthine 
(Sigma-Aldrich), 100 nM insulin (Sigma-Aldrich), 50 units/ml penicillin, and 50 µg/ml 
streptomycin. The cells were maintained in this media for 72 h as this was found to 
improve the reproducibility of differentiation between flasks. After 72 h the media was 
replaced with DMEM supplemented with 10% FBS, 100 nM insulin, 50 units/ml 
penicillin, and 50 µg/ml streptomycin. The media was subsequently changed for DMEM 
supplemented with 10% FBS, 50 units/ml penicillin, and 50 µg/ml streptomycin every 48 
h. 
 
2.1.2. Primary Adipocyte Cell Isolation and Differentiation 
The gonadal fat pad was isolated from four week old mice post mortem.  Four mice were 
required per primary adipocyte culture.  The adipose tissue was finely ground and then 
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digested in a solution of Hanks Balanced Salt Solution (7 ml) containing collagenase type 
II  (10 mg; Sigma-Aldrich) and Bovine Serum Albumin (BSA 7.5% w/v 3 ml) in an 
incubator for 35 min at 37 ºC.  Following digestion, the solution was filtered through a 
250 µm mesh (BD Biosciences, San Jose, CA.).  The solution was left to settle on ice for 
20 min.  The upper white adipose tissue layer, containing mature adipocytes, was 
removed.  The next stratum, which contains the preadipocytes, was then filtered through 
a 100 µm mesh.  The filtered digest media was diluted 1:1 with 10% FBS media.  The 
cells were centrifuged at 700 g for 10 min.  The cell pellet was re-suspended in plating 
media constituting DMEM supplemented with 10% v/v NCS (newborn calf serum), 50 
units/ml penicillin, 50 µg/ml streptomycin, 2.4 nM insulin and 250 µΜ sodium ascorbate 
(Sigma-Aldrich).  The cells were then centrifuged at 700 g for 10 min and once again 
resuspended in plating media.  Cells were plated on four well plates.  The media was 
changed every 24 h for the first three days and subsequently every 48 h up to day 7. 
 
2.1.3. Activation of PPARδ in 3T3-L1 Adipocytes 
At day 11 post differentiation induction the media on the cells was replaced with DMEM 
supplemented with 10% FBS, 100 nM insulin, 50 units/ml penicillin, and 50 µg/ml 
streptomycin containing either dimethylsulphoxide DMSO (Sigma-Aldrich) (control, 
n=6) or GW610742 PPARδ selective agonist (GlaxoSmithKline plc.) (n=6 at 100 nM and 
1 µM) for 2 days prior to cell collection and metabolite extraction described in sections 
2.1.6 and 2.3. 
 
2.1.4. Activation of PPARγ in 3T3-L1 Adipocytes 
At day 11 post differentiation induction the media on the cells was replaced with DMEM 
supplemented with 10% FBS, 100 nM insulin, 50 units/ml penicillin, and 50 µg/ml 
streptomycin containing either DMSO (control, n=7) or GW GW347845 PPARγ 
selective agonist (GlaxoSmithKline plc.) (n=7 at 10 nM and 100 nM) for 2 days prior to 
cell collection and metabolite extraction described in sections 2.1.6 and 2.3. 
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2.1.5. Oil Red O Staining and Intracytoplasmic Lipid Accumulation 
Cell cultures were washed with phosphate buffered saline (PBS; Severn Biotech Ltd) and 
fixed overnight with 10% formalin in PBS at 4 °C. The cultures were then incubated for 
1 h with 0.3% Oil Red O (Sigma-Aldrich) in 60% isopropanol at room temperature and 
washed with PBS. Digital images of the cells were taken using a Nikon D100 camera.  
The stain was extracted from the cells with 60% isopropyl alcohol for 1 h (10 mL/flask) 
and 1 ml measured at 510 nm in a spectrophotometer.  
 
2.1.6. Adipocyte Cell Collection 
Cells were collected by removing the media and washing each T75 flask with 10 ml of 
PBS.  Cells were then washed with 1.5 ml trypsin-EDTA solution (5 BAEE units 
trypsin/ml, 1.8 µg EDTA/ml; Sigma-Aldrich) for 2 min at 37ºC to remove the cells from 
the surface of the flask. 8.5 ml DMEM supplemented with 10% (v/v) new born calf 
serum, 50 units/ml penicillin, and 50 µg/ml streptomycin was added to each flask. The 
DMEM containing the cells was transferred to a falcon tube and centrifuged at 200 g for 
2 min to pellet the cells. The remaining media was removed and the cells washed with 
physiological saline (0.9% NaCl) solution. 
 
2.2 Animal and Tissue Handling 
2.2.1. Animal Handling 
All animal studies were performed by GlaxoSmithKline (Research Triangle Park, N.C., 
U.S.A) within the relevant local legislation.  Two month old male ob/ob mice (Jackson 
Labs, Bar Harbor, ME),  were fed standard laboratory chow ad libitum and housed 4 per 
cage on alpha-dri bedding under controlled temperature, lighting and humidity (20-22 ºC, 
12-h light/dark cycle, Humidity 48-50%). Prior to selection for the study, all mice were 
examined ensuring they were physically normal and exhibited normal activity.  During 
the studies, body weight and food consumption (cage average) were recorded. 
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The ob/ob mice were assigned to six groups of eight and dosed orally daily at 8 am with 
0.5% Hydroxypropylmethylcellulose/0.1% Tween80 vehicle control, a PPARδ agonist, 
GW610742 (30 mg/kg) and a PPARγ agonist GW347845 (5 mg/kg).  Injection volume 
was adjusted daily according to body weight at 10 ml/kg.   
 
2.2.2. Clinical Chemistry 
All clinical chemistry measurements were performed using an Olympus AU 400e 
analyser at GlaxoSmithKline (Research Triangle Park, N.C., U.S.A)186.  Plasma was 
analysed for the following parameters: alkaline phosphatase, alanine transaminase, total 
bilirubin, thymidine phosphorylase, albumin, blood urea nitrogen, creatine, glucose, 
cholesterol, high density lipoprotein-cholesterol, triacylglycerides, non-esterified fatty 
acids, creatine kinase, lactate dehydrogenase, sodium, potassium and β-hydroxybutyrate.  
Insulin measurements were performed by ELISA (Millipore Mouse Insulin ELISA kit).  
 
2.2.3. Oral Glucose Tolerance Test (OGTT) 
The OGTT was performed at GlaxoSmithKline (Research Triangle Park, N.C., U.S.A). 
Animals were fasted overnight prior to the OGTT (day 12). Glucose concentrations were 
measured using the FreeStyle Blood Glucose Monitoring System (TheraSense, U.K.). 
Animals were dosed orally with 1 g/kg glucose. Baseline fasted glucose values were 
collected at the 0 min time point. Glucose concentrations were collected at 15, 30, 60 and 
90 min intervals. All samples were collected via tail snips. 
 
2.2.4. Tissue Handling 
Serum was collected via cardiac stick under isofluorane anaesthesia at completion of the 
study (day 15).  Skeletal muscle (gastrocnemius) white adipose and liver tissue were 
rapidly dissected (<60 s post mortem), snap frozen in liquid nitrogen and stored at -80 ºC 
until extraction. 
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2.3 3T3-L1 Cell, Primary Adipocyte and Tissue Metabolite Extraction 
Metabolites were extracted from serum, liver, skeletal muscle, white adipose tissue, 3T3-
L1 cells and primary adipocyte cells using a modified Bligh and Dyer method187.  Frozen 
tissue was pulverised with liquid nitrogen.  Methanol-chloroform (2:1 600 µl) was added 
to the tissues (100 mg for NMR and 50 mg for GC-MS analysis), serum (50 µl), 5 mg cell 
pellets (3T3-L1 cells) or 1 mg cell pellets (primary cells) and the samples were sonicated 
for 15 min. Chloroform-water (1:1) was then added (200 µl of each). Samples were 
centrifuged (16,100 g, 20 min) and the organic and aqueous phases were separated and 
stored at -80°C until analysis. Of these fractions, 100 µl of the organic phase was used for 
LC-MS, and the remaining organic phase was used for GC-MS. Prior to analysis the 
organic fractions were dried in a fume hood. For the aqueous phase, 100 µl of the 
aqueous phase was taken for GC-MS analysis, and the remaining aqueous phase sample 
was used for 1H-NMR spectroscopy. Prior to further analysis the aqueous fractions were 
dried in an evacuated centrifuge overnight (Eppendorf, Hamburg, Germany). 
 
2.4. 
13
C Substrate Labelling Studies 
2.4.1 
13
C-glucose Substrate Labelling Study in PPARδ Activated Cells  
At 2 days post differentiation media was removed from the T75 flasks and replaced with 
DMEM (10% (v/v) FBS, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 
4.5 g/l 12C unlabelled glucose with DMSO (control, n=6) or with 1µM GW610742 
PPARδ selective agonist (n=7) or 4.5 g/l 1-13C-glucose with (DMSO control, n=7) or 
with 1 µM GW610742 PPARδ selective agonist (n=7).  After 2 days cells were collected 
and metabolites extracted as previously described in sections 2.1.6 and 2.3.  
 
2.4.2. 
13
C-glucose Substrate Labelling Study in PPARγ Activated Cells 
At 2 days post differentiation media was removed from the T75 flasks and replaced with 
DMEM (10% (v/v) FBS, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 
4.5 g/l 12C unlabelled glucose with DMSO (control, n=6) or with 1 µM GW347845 
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PPARγ selective agonist (n=7) or 4.5 g/l 1-13C-glucose (Cambridge Isotope Laboratories, 
Andover, MA) with DMSO (control, n=7) or with 1 µM GW347845 PPARγ selective 
agonist (n=7).  After 2 days cells were collected and metabolites extracted as previously 
described in sections 2.1.6 and 2.3.  
 
2.4.3. Preparation of 
13
C and 
12
C-palmitate Solution 
75 ml of PBS was heated to 37 ºC. BSA (20g) was added to the PBS.  Separately 
deionised water (15 ml), 95% ethanol solution (10 ml) and Na2CO3 (0.106 g) (Sigma-
Aldrich) were mixed under nitrogen. Either unlabelled palmitate (0.2115 g) or U-13C 
labelled palmitate (0.2247 g) (Cambridge Isotope Laboratories, Andover, MA) was 
added, and then heated to ~78 ºC to evaporate the ethanol. The fatty acid solution was 
added to the albumin solution and well mixed. The palmitate/albumin mixture was 
dialysed (Spectra/Por dialysis tubing; Molecular weight cut off 6000-8000) in deionised 
water at 4 ºC overnight.  
 
2.4.4. 
13
C-palmitate Substrate Labelling Study in PPARδ Activated Cells 
At 2 days post-differentiation media was removed from the T75 flasks and replaced with 
DMEM (serum free, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 70 µM 
unlabelled palmitate (n=6) with DMSO (control, n=6) or with 1 µM GW610742 PPARδ 
selective agonist (n=7)  or 70 µM U-13C labelled palmitate (n=7) with DMSO (control, 
n=6) or with 1 µM GW610742 PPARδ selective agonist (n=7). After 2 days cells were 
collected and metabolites extracted as previously described in sections 2.1.6 and 2.3. 
 
2.4.5. 
13
C-palmitate Substrate Labelling Study in PPARγ Activated Cells 
At 2 days post-differentiation media was removed from the T75 flasks and replaced with 
DMEM (serum free, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 70 µM 
12C-U-palmitate (n=6) with DMSO (control, n=6) or with 1 µM GW347845 PPARγ 
selective agonist (n=7) or 70 µM U-13C labelled palmitate (n=7) with DMSO (control, 
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n=6) or with 1 µM GW347845 PPARγ selective agonist (n=7). After 2 days cells were 
collected and metabolites extracted as previously described in sections 2.1.6 and 2.3. 
 
2.5. Respirometric Analysis of PPARδ Agonist Treated 3T3-L1 Cells 
Cells were grown, treated with GW610742 PPARδ agonist and collected as has already 
been described in sections 2.1.1, 2.1.3 and 2.1.7 with the exception that they were 
collected into respiration medium (100 mM KCl, 50 mM MOPS, 1.0 mM KH2PO4, 
1.0 mg/ml defatted BSA, pH 7.4). Respiratory rates of in situ permeabilised control and 
PPARδ agonist treated 3T3-L1 cells were measured using a Clark-type oxygen electrode 
(Strathkelvin Instruments Ltd, Glasgow, UK) with methods developed by Kuznetsov et 
al
188
. Respiration rates were recorded and quantified using 782 Oxygen System v3.0 
software (Strathkelvin Instruments). Oxygen concentrations were measured continuously 
in 0.5 ml respiration medium containing 250,000 cells in a respiration chamber 
maintained at 37 °C.  The cells were initially permeabilised with the addition of digitonin 
(25 µg/ml), before malate (5 mM) plus palmitoyl-carnitine (0.04 mM) were added as 
respiratory substrates to measure the fatty acid oxidation rates. Respiration was 
stimulated by the addition of a saturating concentration of ADP (2 mM) plus MgCl2 (0.6 
mM) and subsequently measured.  Antimycin (5 µM) was then added to inhibit complex 
III of the electron transport chain, and respiration ceased. Complex IV respiration was 
stimulated by addition of the artificial substrates TMPD (N,N,N’,N’-tetramethyl-p-
phenylenediamine dihydrochloride, 0.5 mM) and ascorbate (2 mM).  Finally respiration 
was terminated by addition of the complex IV inhibitor, sodium azide (3 mM). 
 
2.6. Metabolomic Analysis by Nuclear Magnetic Resonance 
2.6.1. Spectrometer 
All samples were analysed using a Bruker AVANCE II+ spectrometer operating at 
500.13 MHz for the 1H frequency (Bruker BioSpin GmbH, Rheinstetten, Germany) using 
a 5mm Broadband TXI Inverse Automatic Tuning and Matching (ATMA) probe. 
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2.6.2. Sample Preparation 
Dried extracts were dissolved in 600 µl of D2O and buffered in 0.24 M sodium phosphate 
(pH 7.4) containing 1 mM sodium-3-(trimethylsilyl)-2,2,3,3-tetradeuteriopropionate 
(TSP; Cambridge Isotope Laboratories, Andover, MA) and 0.02 M sodium azide. 
 
2.6.3. 1-dimensional 
1
H-Nuclear Magnetic Resonance Spectroscopy Experimental 
Method 
A presaturation pulse sequence for water suppression based on a one-dimensional nuclear 
Overhauser effect spectroscopy pulse sequence was used to saturate the residual water 
proton signal (relaxation delay = 2 s, t1 = 4 µs, mixing time = 50 ms, presaturation applied 
during the relaxation time and mixing time).  128 and 256 transients were collected for 
tissue extracts and 3T3-L1 cell extracts, respectively, into 64k data points over a spectral 
width of 8000 Hz at 300K.   
 
2.6.4. Processing 1-dimensional 
1
H-Nuclear Magnetic Resonance Data 
NMR spectra were processed in ACD 1D NMR Manager (version 8; Advanced 
Chemistry Development Inc, Toronto, Canada), multiplied by an exponential weighting 
function of 1 Hz, Fourier transformed, phased, baseline corrected and referenced to TSP 
at 0.0 ppm.  The NMR spectra were integrated using 0.04-ppm integral regions between 
0.2 and 9.56 ppm (excluding water resonance between 4.20 and 5.08 ppm). Spectra were 
normalised to total integrated area to account for differences in concentration between 
samples and assigned by comparison with previous literature and, in the case of 3T3-L1 
cells, Chenomx NMR suite 5.0 libraries.  
 
2.6.5. 2-dimensional Heteronuclear Single-Quantum Coherence 
13
C-Nuclear 
Magnetic Resonance Experimental Method 
Dried 3T3-L1 adipocyte cell organic phase extracts from 13C-labelling studies were 
dissolved in 600 µl of deuterated Chloroform. Samples were analyzed using a DRX 
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Avance II+ spectrometer interfaced to a 5-mm TXI ATMA probe.  Analysis was 
performed using 2D H-1/X correlation via double inept transfer with sensitivity 
improvement. Phase sensitive using Echo/Antiecho-TPPI and gradient selection with 
decoupling during acquisition. Trim pulses in inept transfer using shaped pulses for all 
180 degree pulses on f2-channel with gradients in back-inept.  Spectral widths of 10.00 
ppm and 160 ppm were used in the F2 (1H) and F1 (13C) dimensions respectively with 
an offset of 75.00 ppm. Spectra were acquired using 96 scans with a relaxation delay of 
1.0 s. Datasets were zero-filled and multiplied by sine bell squared functions prior to 
fourier transformation. 
 
2.6.6. Processing 2-dimensional Heteronuclear Single-Quantum Coherence
 13
C-
Nuclear Magnetic Resonance Data 
2D-NMR spectra were processed in Bruker TOPSPIN (version 2.0, Bruker BioSpin 
GmbH, Rheinstetten, Germany).  Peaks were selected using the automated peak picking 
algorithm with the sensitivity set to lowest contour level.  The peaks were then integrated 
and normalised to total integrated area and assigned by comparison with previous 
literature. 
 
2.7. Analysis by Gas Chromatography-Mass Spectrometry 
2.7.1. Derivatisation of Aqueous Phase Metabolites 
Dried aqueous phase samples were derivatised by adding 30 µl of methoxyamine 
hydrochloride solution (20 mg/ml in pyridine, Sigma-Aldrich Ltd), vortex mixed for 1 
min then incubated at 25 ºC for 17 h.  Samples were silylated with 30 µL of N-methyl-N-
trimethylsilyltrifluoroacetamide (MSTFA; Macherey-Nagel, Germany) for 1 h at 25 
ºC189. The tissue samples were diluted by addition of 200 µL of analytical grade hexane 
prior to GC-MS analysis.  
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2.7.2. Derivatisation of Organic Phase Metabolites 
Acid-catalysed esterification was used to derivatise the organic phase samples.  
Chloroform-methanol (1:1, 0.25 ml) and BF3-methanol (10%; 0.125 ml) (Sigma-Aldrich) 
was added to the organic phase and incubated at 90 ºC for 90 min. Water (0.15 ml; mQ) 
and hexane (0.3 ml) were added and the samples vortex mixed for 1 min and left to form 
a bilayer.  The aqueous phase was discarded and the organic layer evaporated to dryness 
prior to reconstitution in analytical grade hexane (200 µl) before GC-MS analysis. 
 
2.7.3. Gas Chromatography-Mass Spectrometry Methods 
All GC-MS analyses were made using a Trace GC Ultra coupled to a Trace DSQ II 
single-quadrupole mass spectrometer (Thermo Scientific, Cheshire, UK).   
 
2.7.3.1 Gas Chromatography-Mass Spectrometry methods for aqueous phase samples 
Derivatised aqueous samples were injected splitless onto a ZB-5ms column (30 m x 0.25 
mm, 0.25 µm 5%-Phenyl-Arylene - 95% Dimethylpolysiloxane stationary phase, with an 
integral 5 m Guardian guard column; Phenomenex).  The injector temperature was 230 ºC 
and the helium carrier gas was used at a flow rate of 1.2 mL/min. The initial column 
temperature of 70 ºC was increased by 10 ºC/min to 130 ºC and then increased at a rate of 
5 ºC/min to 230 ºC followed by an increase of 20 ºC/min to 310 ºC and held for 5 min 
(transfer line temperature = 250 ºC;  ion source = 250 ºC; electron ionisation = 70 eV).  
The detector was turned on after 240 s and full-scan spectra were collected using 3 
scans/s over a range of 50-650 m/z.   
 
2.7.3.2 Gas Chromatography-Mass Spectrometry methods for organic phase samples 
The derivatised organic samples were injected with a split ratio of 60 for white adipose 
tissue and 8 for 3T3-L1 cells, liver, skeletal muscle and serum onto a 30 m × 0.25 mm 
70% cyanopropyl polysilphenylene-siloxane 0.25 µm TR-FAME stationary phase 
column (Thermo Electron).  The injector temperature was set to 230 ºC and the helium 
carrier gas was at a flow rate of 1.2 mL/min.  The column temperature was 60 ºC for 2 
min, increased by 15 ºC/min to 150 ºC and then increased at a rate of 4 ºC/min to 230 ºC 
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(transfer line = 240 ºC; ion source = 250 ºC, EI = 70 eV).  The detector was set as above 
for the ZB-5ms column. 
 
2.7.4. Gas Chromatography-Mass Spectrometry Analysis, Processing and Data 
Handling for 3T3-L1 Adipocyte 
13
C-labelled Substrate Studies. 
Analysis of organic and aqueous phases was carried out as previously described in 
sections 2.7.1, 2.7.2 and 2.7.3.  Enrichment of metabolites was identified by calculating 
isotope ratios of the M and M+1 ions for the parent ion of the fragmentation pattern in the 
case of 13C-Glucose metabolism analysis and TCA cycle intermediates originating from 
13C-Palmitate oxidation.  For fatty acid synthesis and desaturation products from 13C-
labelled palmitate an ion ratio of M+16/M was used and for fatty acids originating from 
oxidation of 13C-labelled palmitate an ion ratio of M+n/M, where n = the carbon chain 
length of the fatty acid was used.  Statistical analysis was performed using a univariate 
Student’s t-test. 
 
2.7.5. Processing Gas Chromatography-Mass Spectrometry Data 
GC-MS chromatograms were processed using Xcaliber (version 2.0; Thermo Electron).  
Each individual peak was integrated and then normalised so that the total sum of peaks in 
a chromatogram was set to 10000.  Overlapping peaks were separated using traces of 
single ions.  Peak assignment was based on mass fragmentation patterns matched to the 
NIST/ EPA/NIH mass spectral library and to previously reported literature.  Identification 
of metabolites from organic phase GC-MS analysis was supported by comparison with a 
FAME standard mix (Supelco 37 Component FAME Mix; Sigma Aldrich). 
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2.8. Analysis by Ultra Performance Liquid Chromatography-Mass 
Spectrometry 
2.8.1. Chromatography and Mass Spectrometry Parameters 
Chromatography was performed using an ACQUITY UPLC® system (Waters 
Corporation, Centennial Park, Elstree, Hertfordshire) equipped with an Acquity UPLC 
1.7 µm Bridged Ethyl Hybrid (BEH) C8 column (2.1×100 mm Waters) which was kept at 
65 ºC and coupled to a Micromass QTof-Ultima™ with a Z-spray™ electrospray source.  
The electrospray source was operated in positive ion mode with the source temperature 
set at 100 ºC and a cone gas flow of 50 L/h.  The desolvation gas temperature was 300 ºC 
and the nebuliser gas flow rate was set at 600 L/h.  The capillary voltage was 3 kV and 
the cone voltage was 50 V.  Reserpine was used as the lock reference and was introduced 
into the LockSpray interface at a concentration of 50 µM in 1:1 methanol-water 0.1% 
formic acid (Fluka). Centroid mode was used for data collection. The lock reference 
sampling frequency was 10 s and the lock mass data was averaged over 10 scans.  The 
binary solvent system used was solvent A: HPLC grade water (chromosolv plus Sigma-
Aldrich), 1% 1 M ammonium acetate (NH4Ac; Fluka), 0.1% formic acid and solvent B: 
HPLC grade acetonitrile (chromosolv Sigma-Aldrich)/isopropanol (Fisher Scientific) 5:2, 
1% 1 M NH4Ac, 0.1% formic acid
190.  The temperature of the sample organiser was set at 
4 °C. Mass spectrometric data was collected in full scan mode from 100-1350 m/z for 
tissue and 100-1500 m/z for 3T3-L1 cells from 0-14 min with a scan duration of 0.5 s and 
an interscan delay of 0.1 s. 
 
2.8.2. Sample Preparation and Chromatographic Gradient 
2.8.2.1 Adipose tissue preparation and chromatographic gradient 
The organic phase of adipose tissue extracts was reconstituted in methanol-chloroform 
(2:1, 500 µl).  This was further diluted 10-fold prior to injection onto the C8 column (5 
µl).  The column mobile phase was held at 85% solvent B for 0.5 min followed by an 
increase from 85%-100% solvent B over 0.5-8 min.  The mobile phase was then held at 
100% B for 4 min.  Between 12 and 12.25 min the mobile phase was returned to 85% B 
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held for 1.75 min to re-equilibrate the column.  The total UPLC cycle was 14 min and the 
eluent flow rate was 600 µl/min. 
 
2.8.2.2 Liver tissue preparation and chromatographic gradient 
The organic phase of liver was reconstituted in methanol-chloroform (2:1, 500 µl).  This 
was further diluted 7.5-fold prior to injection onto the C8 column (5 µl).  The column 
mobile phase was held at 70% solvent B for 0.5 min followed by an increase from 70%-
100% solvent B over 0.5-6.5 min.  The mobile phase was then held at 100% B for 3.5 
min.  Between 10 and 10.25 min the mobile phase was returned to 70% B held for 3.75 
min to re-equilibrate the column.  The total UPLC cycle was 14 min.  The eluent flow 
rate was 600 µl/min.   
 
2.8.2.3 Serum preparation and chromatographic gradient 
The organic phase of serum was reconstituted in methanol-chloroform (2:1, 500 µl).  This 
was further diluted 4 fold prior to injection onto the C8 column (10 µl).  The column 
mobile phase was held at 70% solvent B for 0.5 min followed by an increase from 70%-
100% solvent B over 0.5-6.5 min.  The mobile phase was then held at 100% B for 3.5 
min.  Between 10 and 10.25 min the mobile phase was returned to 70% B held for 3.75 
min to re-equilibrate the column.  The total UPLC cycle was 14 min.  The eluent flow 
rate was 600 µl/min.   
 
2.8.2.4 3T3-L1 adipocyte preparation and chromatographic gradient 
3T3-L1 Cell Organic phase metabolites were reconstituted in methanol-chloroform (2:1, 
1 ml).  Aliquots of diluted organic phase sample (5 µl) were injected onto the C8 column.  
The column mobile phase was held at 50% solvent B for 0.5 min followed by an increase 
from 50%-100% solvent B over 0.5-6.5 min.  The mobile phase was then held at 100% B 
for 3.5 min.  Between 10 and 10.25 min the mobile phase was returned to 50% B held for 
3.75 min to re-equilibrate the column.    The total UPLC cycle was 14 min and the eluent 
flow rate was 600 µl/min.  
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2.8.3 Tandem Mass Spectrometry Method 
Tandem mass spectrometry was used for the identification of selected lipids. MS/MS runs 
were performed using ESI+ mode and collision energies of 16, 18, 20, 25, 28 V and a 
mass range of 80-1500 m/z. Other conditions were as described in section 2.8.1. 
 
2.8.4. Processing Liquid Chromatography-Mass Spectrometry Data 
Data was processed using Micromass Markerlynx Applications Manager (Waters 
Corporation).  Each peak was detected, deconvoluted, noise-reduced and integrated. The 
ion-intensities for each peak are detected and normalised. Individual peaks were 
normalised to the total integrated area of the sample.  Lipids were identified using the 
tandem mass spectrometry data.  
 
2.9. Analysis by Direct Infusion-Mass Spectrometry 
Direct infusion mass spectrometric analysis was performed using a Thermo Finnigan 
LTQ linear ion trap mass spectrometer equipped with a Finnigan Surveyor pump and 
Finnigan Micro AS Autosampler (Thermo Scientific, Waltham, MA). 
 
2.9.1. Sample Preparation 
2.9.1.1 3T3-L1 adipocytes 
The 3T3-L1 organic phase samples for DI-MS were reconstituted in 500 µl 
methanol:tetrahydrofuran (THF) (2:1 v/v). 100 µl of each sample was added to a 96 well 
plate.  
 
2.9.1.2 Liver tissue 
The liver organic phase samples for DI-MS were reconstituted in 500 µl methanol:THF 
(2:1 v/v). 50 µl of each sample was aliquoted into a 96 well plate where the samples were 
diluted by the addition of a further 150 µl methanol:THF (2:1 v/v).  
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2.9.1.2 White adipose tissue 
The white adipose tissue organic phase samples for DI-MS were reconstituted in 1 ml 
methanol:THF (2:1 v/v). 60 µl of each sample was aliquoted into a 96 well plate where 
the samples were diluted by the addition of a further 600 µl methanol:THF (2:1 v/v). 
 
2.9.2. Direct Infusion and Mass Spectrometry Parameters 
The infusion solvent (methanol-THF, 2:1 v/v) was initially pumped at 50 µl/min.  The 
sample (10 µl) was introduced via infusion and the flow rate maintained at 50 µl/min for 
1.2 min.  Flow rate was then increased to 300 µl/min for 0.8 min and returned to 50 
µl/min prior to the next injection.  Infused sample was introduced to, and ionised in, a 
standard electrospray source with sheath gas flow of 12 units, auxiliary gas flow of 1 unit 
and sweep gas flow of 1 unit, capillary temperature of 290 °C, and spray voltage of 5 kV. 
The capillary and tube lens voltages for positive mode analysis were set to 40 and 80 V, 
respectively. In negative mode the capillary voltage was -50 V; the tube lens voltage was 
set to -200 V. The scan range was set at 100-1100 m/z in profile mode.  To ensure 
analytical reproducibility samples were analyzed either in triplicate or duplicate using 
both positive and negative ionisation modes, a pooled sample and a blank sample were 
also analysed every 6 injections. 
 
2.9.3. Processing of Direct Infusion Mass Spectrometry Data 
DI-MS chromatograms were processed using Xcaliber (version 2.0; Thermo Electron).  
The mass data was averaged from the chromatogram for the period of sample injection 
and the “exact masses” were exported; the data points summed between M and M+1, to 
give variables which corresponded to individual peaks, normalised to total spectral area 
and integrated.   
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2.9.4. MS/MS Method 
MS/MS data was utilised for lipid identification.  MS/MS data was collected by infusing 
a pooled sample by syringe pump at a flow rate of 15 µl/min.  Centroid mode was used 
with a scan width of 100 m/z to 1000 m/z and a parent mass step value of 1 m/z.  The 
isolation width was 1.5 m/z and the collision energy was 35 eV; all other parameters were 
as outlined in section 2.9.2. 
 
2.10 Transcriptomic Analysis 
2.10.1. RNA Extraction 
Cells were grown, treated with PPARδ agonist or PPARγ agonist and collected as has 
already been described in sections 2.1.1, 2.1.3, 2.1.4 and 2.1.6.  An RNeasy RNA 
extraction and purification kit was used to extract total RNA from 3T3-L1 adipocytes 
(Qiagen GmbH, Hilden, Germany).  Approximately 5mg of cells was used per sample for 
RNA isolation.  Procedures were carried out according to the manufacturer’s instructions.  
Extracted RNA was quantified using a Nanodrop ND-1000 Spectrometer (Nanodrop 
Technologies Inc., Wilmington, USA) to measure the absorbance at 260 nm.  Sample 
purity was assessed using the A260/A280 ratio.  Samples with an A260/A280 ratio above 1.8 
were considered sufficiently pure.   
 
2.10.2. Microarray Analysis 
Transcriptomic analysis was conducted by Cambridge Genomic Centre for Microarray 
Resources (Cambridge Genomic Services, Department of Pathology, University of 
Cambridge).  An automated Illumina Infinium Gene Expression BeadArray (Illumina Inc, 
San Diego, CA) was used to perform mRNA transcriptional profiling.  A mouse WG6 
array platform was used with 45281 probes. 
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2.10.3. Processing Microarray Data 
Quality control was carried out using the arrayQualityMetrics R package and no samples 
failed or were identified as outliers to their replicates. Statistical selection was performed 
using the detection p-value provided by Illumina. This value represents the confidence 
that a given transcript is expressed above the background defined by the negative control 
probe.  The R package lumi was used for this analysis 191.  The detection p-value 
threshold was set to 0.01.  Probes were required to be successfully detected (p-value<0.01 
in Lumi) in at least one sample to pass the selection. The data is transformed using 
variance stabilisation and then normalised using quantile normalisation192. Gene 
expression was compared between PPARδ agonist treated, PPARγ agonist treated and 
control 3T3-L1 cells using the R package limma193. The threshold utilised in this analysis 
was the 5% confidence interval.  The selected and normalised data was then analysed 
using the multivariate statistics in the Simca-P+ package as is described in section 2.11.  
The 6% of transcripts most responsible for separation in the multivariate models were 
then examined (3% most increased and 3% most decreased in PPARδ agonist treated 
cells as identified in the multivariate models). 
 
The Reactome Skypainter tool (www.reactome.org) was used to determine which 
biological pathways were statistically significant in the 3% of genes most increased and 
most decreased in transcription in PPAR agonist treated cells. From a given set of genes 
known to participate in a pathway, the total genes for mus musculus and the submitted 
list of genes (the genes increased or decreased in expression in PPAR activated cells) of 
which N genes participate in the given pathway, the probability of observing at least N 
genes from a pathway if that pathway is not overrepresented in the submitted list of genes 
is calculated using the one-tailed version of Fisher's exact test. Therefore a p-value 
smaller than or equal to the significance level suggests that the pathway is statistically 
significant in the submitted list of genes. 
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2.11 Data Handling for Metabolomics 
2.11.1. Pretreatment of Metabolomic Data for Multivariate Analysis 
Pretreatment is often applied to metabolomic data preceding multivariate analysis.  The 
pretreatment of the data usually takes the form of mean centring and scaling.  Mean 
centring involves the calculation of the mean of each variable, which is then subtracted 
from the variable values for each observation; centring all variables to a mean value of 0.  
The manipulation is employed in the majority of chemometrics to centre data in scores 
plots.   
 
Scaling ensures models are not excessively influenced by variables with large ranges as 
these typically have larger degrees of variance relative to variables possessing smaller 
ranges and functions by multiplying the data by a specific scaling weighting.  The scaling 
weighting utilised is dependent upon the nature of the data being analysed.   
 
Pareto scaling is used when there is some knowledge of the relative importance of 
variables within a dataset, for example when analytical noise has been included in a data 
set and lower weighting needs to be given to these variables; a scaling weight of 1/(Sk)
1/2, 
Sk being the standard deviation of the variable k, is used in this instance and therefore 
scales each variable k to the variable’s standard deviation.  Within metabolomic studies 
Pareto scaling increases the importance of low concentration metabolites without greatly 
magnifying the contribution of noise in the subsequent multivariate model. 
 
Univariant scaling is used in the case of data where little is known about the importance 
of the variables within the data; the variance of each variable is standardised to 1 by 
multiplying each variable by the scaling weight 1/Sk.  Thus, the influence of any one 
variable is limited by the scaling and in metabolomic study prevents a single metabolite 
dominating a data set. 
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The multivariate analysis in this thesis was conducted by importing the normalised data 
generated from the analytical platforms into SIMCA-P+ version 11 (Umetrics, Umeå, 
Sweden). Data was mean centred and scaled.  GC-MS data in this thesis was scaled 
utilising unit variance, ensuring all peaks contribute to the multivariate models generated, 
as only identified peaks were incorporated into the data sets.  Since the bucketing routine 
used in the processing of NMR data incorporates baseline noise in the data set, Pareto 
scaling was used for the analysis of 1-dimensional 1H-NMR data; this assigns a lesser 
weighting to the noise variables.  Pareto scaling was also employed for the analysis of 
LC-MS and DI-MS data. 
 
2.11.2. Multivariate Statistical Analysis: Principal Component Analysis 
PCA is a multivariate projection method and an unsupervised technique where a single 
covariance matrix contains the values for all the variables measured.   PCA reduces the 
dimensionality of multidimensional data sets while the characteristics of the data that are 
most responsible for variance are retained; via a transformation a data set of dimension N 
is reduced to dimension M.  In PCA correlated variables are transformed into 
uncorrelated variables called principal components (PCs).  Each observation is plotted in 
k-dimensional space, each dimension corresponding to an individual variable.  Each 
principal component represents a vector within k-dimensional space.  PC 1 would 
represent the greatest variance in the dataset, PC 2 the second most variance, and so forth.  
The principal components must intercept the origin and have the minimal square of the 
distance between each observation and itself.  The observations are projected onto the 
principal components to generate a coordinate; this value is the score, t1, for PC 1 or t2 for 
PC 2.  PC 1 and PC 2 are orthogonal and so define a plane in the data (Figure 2.1).  
Clustering of observations can be seen when their scores are plotted.   
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Figure 2.1: A. Mean centered observations in the data matrix are plotted in the 
variable (k-dimensional) space. B. The first principal component, PC1, 
represents the maximum variance direction in the data.  Each observation 
is projected onto the PC to obtain a co-ordinate.  The co-ordinate value is 
the score. C. A second principal co-ordinate, PC2 is oriented through the 
average point and orthogonal to PC1 to represent the second largest 
variation in the data set. D. Two PCs generate a plane in the variable 
space. By projecting each observation onto the plane the scores can be 
visualised graphically in a scores plot. 
 
Clustering of data is shown in the scores plots but in order to examine which variables 
generate the differences in clustered groups a loadings plot is needed.  Loadings are 
Eigenvectors generated from an Eigen transformation of the variables in the original 
covariance matrix.  Loadings describe the orientation of the PCs in the multidimensional 
space, and thus the contribution of a variable to the separation of clusters depends on its 
distance from the origin of the loadings plot. Directionality of PC can therefore be 
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explained by the cosine of the angle between PC 1 and each variable and loadings 
coefficients can be generated for each PC (Figure 2.2). An alternative means of viewing 
loadings is with coefficient column plots in which the contribution of each variable to a 
model is represented by the size of the bar and error bars indicate the significance of 
changes to a set confidence limit.  
 
 
Figure 2.2: PC loadings express the orientation of the model plane in k-dimensional 
space.  The cosine of the angles α1, α2, and α3 gives the direction of PC1 in 
relation to the original variables.  These values demonstrate how the 
variables X1, X2 and X3 contribute to PC1.  An additional set of loading 
coefficients express the direction of PC2 in relation to the original 
variables.  Therefore, six loading values (cosine of angles) describe the 
model planes orientation in the k-dimensional space. 
 
2.11.3 Multivariate Statistical Analysis:  Projection to Latent Structures by Partial 
Least Squares 
PLS constitutes a regression analysis of PCA, modelling the covariance of a relationship 
between two sets of variables termed X and Y.  Each observation corresponds to a point 
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in X-space and a point in Y-space.  A PLS component represents a line in the X-space 
which describes maximum variance while concurrently correlating with the Y-vector.  
The scores in the X-space are attained by projection onto the PLS components; for PLS 
component 1 the vector t1 is generated, for PLS component 2 the vector t2 is generated.  
The scores are latent variables used to explain the Y variable. 
 
During metabolomics studies it is important to establish which variables, and therefore 
metabolites, are most significantly contributing to the model; this is achieved by cross-
examining both the X-variable weight vectors, known as w* , which describe how x-
variables are linearly combined forming the X score vectors and the Y-variable weight 
vectors, c. 
 
Traditionally the contribution of a variable to a PLS model is summarised using two 
methods.  The variable influence on projection (VIP) parameter is a weighted sum of 
squares of PLS weights (w*), taking account of the residual variation in Y, per 
dimension.  The second method involves plotting the regression coefficients, indicating 
how the X variables influence Y.  A variable with a coefficient that has a confidence limit 
above 95% is statistically significant in explaining Y.   
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Figure 2.3: PLS analysis. A. Observations are plotted in x-dimensional space B. The 
observations are simultaneously plotted in y-dimensional space, which is 
reduced to a 1-dimensional y-vector. C. PLS component 1 is calculated, 
modelling the distribution of the observations in the x-dimensional space 
whilst providing correlation with the y-vector.  When observations are 
projected onto the PLS component they receive a t-score; the t-scores 
taken together give the score vector t1 D. Multiplying t1 by the weight of 
the y vector, c1 gives an estimate of y.  The difference in the y values and 
the estimated y values can be modelled by employing additional PLS 
components.   
 
2.11.4 Multivariate Statistical Analysis: Partial Least Squares-Discriminant 
Analysis 
PLS-DA is a supervised extension of PCA which uses prior knowledge of class 
membership and regression trends to augment the separation between groups.  Class 
membership is assigned using an artificial Y matrix with N columns, where N is the 
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number of classes. The column corresponding to a particular class contains ones whilst 
all other columns contain zeros for observations that belong to that specific class.  PLS-
DA components represent projections in the X-space that optimise separation between the 
projected observations based on class.  Metabolomic investigation establishes which 
metabolites contribute most significantly to separation in the models by concurrently 
investigating the corresponding weights for the X-matrix (w*) and Y matrix (c). 
 
2.11.5 Validation of Multivariate Models 
Validation of multivariate models requires examination of the model dimensionality.  
This is calculated by the degree of variation described by a model, and by the accuracy 
with which a model can predict the X data. 
 
For both PLS-DA and PCA the variation in the model given by a component is known as 
R2.  The term R2 is defined as R2=1-RSS/SXXtot.corr. where RSS is the residual sum of 
squares of the data from the component and SXX tot.corr. is the total variation in the X 
matrix post mean centring.  If the R2 was 1 that would indicate the total variation in the 
data matrix had been explained by the model.   
 
Validation of PLS models generates two R2 values defined as R2X and R2Y, describing 
the variation the model explains in the X matrix and the Y matrix.  By increasing the 
components in a model, the R2 can be increased though this risks over-fitting the model 
making it statistically insignificant; this can be avoided by cross validating the model.  
 
The term Q2, defined as Q2=1-PRESS/SXXtot.corr., where PRESS is the sum of the squared 
differences between the predicted and real values (predictive residual sum of squares) is 
used as an indicator of the predictive nature of the model.  For every successive 
component built for a model the cross validation is calculated up to the point where 
generation of new components no longer improves the model’s predictive power.  
Significantly predictive models are considered to have Q2 values greater than 0.4. 
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Outliers are readily identified in multivariate analysis; significantly deviant observations 
will be obvious in scores plots as the plots contain an ellipse which indicates the 95% 
confidence interval established using a multivariate generalisation of the Student’s t-test 
known a Hotelling’s T2.  The outliers can also be identified using the distance to model in 
X space defined as DModX; this equals the residual standard deviation of an observation.  
When DModX is larger than the Dcrit (>95%) then the observation is a moderate outlier. 
 
2.11.6 Multivariate Statistical Analysis Methodology 
PCA models within this thesis were generated in SIMCA-P+11.0 (Umetrics AB, Umeå, 
Sweden) to indentify the major trends and outliers in the datasets.  The supervised 
techniques PLS-DA and, where appropriate, PLS were utilised to examine differences 
between specific groups and probe the metabolic changes producing the separation 
between groups.  Metabolites identified in the VIP/coefficients plots were deemed to 
have changed globally if they contributed to separation in the models with a confidence 
limit of 95% or greater as determined by a jack-knifing routine within the SIMCA 
package.  To assess the variation explained by each model the R2 values were used.  In 
order to assess the robustness of the predictive nature of the models, Q2 values were used.  
The SIMCA-P+ validation function was also employed to monitor that PLS-DA and PLS 
models were not over fitted.   
 
2.11.7 Univariate Statistical Analysis Methodology 
Gas Chromatography-Mass Spectrometry 13C labelled substrate, clinical chemistry data 
and selected microarray transcriptomic data was analysed by univariate techniques.  
Univariate analysis was performed using an unpaired Student’s t-test with a significance 
level set to p<0.05.  An F-test was also utilised to compare the variance of two 
distributions. All univariate analysis was conducted in the GraphPad Prism package 
(version 4). 
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Chapter 3 
 
Metabolic Phenotyping of a Model of Adipocyte Differentiation 
 
3.1 Introduction 
 
The 3T3-L1 murine cell line was developed by Green and co-workers and is a derivative 
of the 3T3 mouse fibroblast cell line194, 195.  It was found that, if 3T3-L1 cells were 
allowed to reach a resting condition in a confluent state the cells develop an adipocyte 
phenotype.  This cell-line has become a well established and widely used model for the 
study of the biochemical processes undergone during mammalian adipogenesis.  In the 
preconfluent state 3T3-L1 cells morphologically and biochemically resemble 
fibroblasts196, 197. However, once the cells reach 100% confluency they can be 
differentiated into mature adipocytes by initial treatment with insulin, which activates the 
IGF-1 receptor, dexamethasone, a synthetic glucocorticoid, and 1-methyl-3-
isobutylxanthine a cyclic nucleotide phosphodiesterase inhibitor increasing cAMP and 
cGMP, activating cyclic nucleotide dependent protein kinases198.  The process is robust 
and relatively uniform with 70-90% of cells differentiating and mirroring reactions to 
lipogenic/lytic hormones, morphological changes and metabolic processes observed 
during mammalian adipocyte development199.  The cells accumulate TAG, acquire the 
rounded morphology of adipocytes and lose the ability to revert to a growth state. 
 
A recent resurgence in the use of the 3T3-L1 adipose tissue differentiation model has 
accompanied expansion of research into the developing global obesity crisis.  The 
adipocyte is not merely a lipid depository, as it was once viewed, but a key metabolic
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regulator responsible for the production of cytokines, metabolic substrates and 
adipokines; wielding influence over metabolism both locally and on a systemic level.  
Adipocytes function as a secure fatty acid storage depot, capable of accumulating 
extensive lipid concentrations without toxic side effects to the cell itself or on the level of 
the whole organism.  The adipocyte is now regarded as a key player in the aetiology of 
insulin resistance and the resultant metabolic syndrome.  Once the fatty acid storage 
capacity of white adipose tissue is exceeded, as occurs in the obese state and certain 
lipodystrophies, lipid can accumulate in peripheral tissues, including the muscle and 
liver; a phenomenon highly correlated with lipotoxicity and insulin resistance200.  
Therefore, research has concentrated on the deregulation of metabolism within adipose 
tissue, which may contribute to the wider effects of TIIDM, the metabolic syndrome and 
obesity201, 202, 203.  
 
The differentiation of preadipocyte cells into mature adipocytes requires a complex 
interaction of metabolic pathways that as yet remain to be fully defined.  A diverse range 
of pathways have been implicated as vital to the differentiation process including 
polyamine biosynthesis204, essential fatty acid pathways205, eicosanoid biosynthesis206, 
fatty acid desaturation207  as well as fatty acid synthesis208 and the TCA cycle209.  Many 
of these pathways may be critical to differentiation at specific points during the process, 
either being perturbed by a process associated with differentiation or alternatively 
providing metabolic cues to induce other processes.   
 
Chapter 3 
 
 
79 
3.2 Aims and Objectives 
 
In this study, the metabolic changes associated with adipocyte differentiation of the 3T3-
L1 cell line have been studied using combined GC-MS, 1H-NMR spectroscopy, LC-MS, 
DI-MS and 13C substrate labelling detected by HSQC NMR and GC-MS in conjunction 
with multivariate statistics.  The metabolic changes identified were then compared and 
contrasted to the metabolic differences between pre- and post-differentiation primary 
adipocytes observed using GC-MS and LC-MS.  The changes in metabolite 
concentrations at distinct periods during differentiation have been defined including 
alterations in the TCA cycle, glycolysis, the production of odd chain fatty acids by α-
oxidation, fatty acid synthesis, fatty acid desaturation, polyamine biosynthesis and trans-
esterification to produce complex lipids.  These metabolic alterations reflect the changing 
role of the 3T3-L1 cells during differentiation, as well as possibly providing metabolic 
triggers to stimulate the processes which occur during differentiation.  Defining the 
metabolic phenotype of differentiating 3T3-L1 preadipocytes, as they mature into 
adipocyte cells and comparing this to differentiating murine primary cells using 
metabolomics has generated a metabolically phenotyped in vitro model of adipose tissue. 
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3.3 Materials and Methods 
3.3.1. 3T3-L1 Adipocyte Cell Culture 
3T3-L1 preadipocytes were grown and differentiated as described in Chapter 2 
Materials and Methods (section 2.1.1 3T3-L1 cell culture and adipocyte 
differentiation).  The T75 flasks were assigned to groups of 3 flasks each corresponding 
to 0 h, 2 h, 4 h, 8 h, 16 h, 24 h, 72 h, 120 h and 216 h time points during the 
differentiation process.   
 
3.3.2. Primary Adipocyte Cell Isolation and Differentiation 
Primary preadipocytes were isolated from the gonadal fat pad of mice and differentiated 
as described in Chapter 2 Materials and Methods (section 2.1.2 Primary adipocyte cell 
isolation and differentiation).  One mouse was used per 28 cm2 well. Five wells were 
collected as undifferentiated preadipocytes. Three wells were fully differentiated up to 
day 7. 
 
3.3.3. Oil Red O Staining and Intracytoplasmic Lipid Accumulation 
Three additional T75 flasks of 3T3-L1 adipocytes were grown per 0 h, 2 h, 4 h, 8 h, 16 h, 
24 h, 72 h, 120 h and 216 h time point group (as in section 3.3.1).  The cells were stained 
and the intracytoplasmic lipid accumulation assessed as in Chapter 2 Materials and 
Methods (section 2.1.5 Oil Red O staining and intracytoplasmic lipid accumulation). 
 
3.3.4. 3T3-L1 and Primary Adipocyte Cell Collection and Metabolite Extraction 
3T3-L1 cells were collected at 0 h, 2 h, 4 h, 8 h, 16 h, 24 h, 72 h, 120 h and 216 h time 
points following the initiation of differentiation.  Primary cells were collected at 0 h and 
168 h. 5 mg 3T3-L1 cell pellets and 1 mg primary cell pellets were used for the extraction 
process.  The cells were collected and their metabolites extracted as described in Chapter 
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2 Materials and Methods (sections 2.1.6 and 2.3 Adipocyte cell collection and 3T3-L1 
cell, primary adipocyte and tissue metabolite extraction).  
 
3.3.5. 
1
H-NMR Spectroscopy Analysis 
All samples were analysed using a Bruker AVANCE II+ spectrometer operating at 
500.13 MHz for the 1H frequency using a 5 mm Broadband TXI Inverse ATMA probe.  
All procedures are as depicted in Chapter 2 Materials and Methods (sections 2.6.1. 
Spectrometer, 2.6.2. Sample preparation, 2.6.3. 1-dimensional 1H-Nuclear Magnetic 
Resonance experimental method and 2.6.4. Processing 1-dimensional 1H-Nuclear 
Magnetic Resonance data). 
 
3.3.6. GC-MS Analysis 
The aqueous phase of extracts were derivatised as described in Chapter 2 Materials and 
Methods (section 2.7.1). 
 
The organic phase of extracts were derivatised as described in Chapter 2 Materials and 
Methods (section 2.7.2).   
 
GC-MS analyses were made using a Trace GC Ultra coupled to a Trace DSQ II single-
quadrupole mass spectrometer.  Parameters for the GC-MS analysis of aqueous phase 
metabolites and organic phase metabolites were as described in Chapter 2 Materials 
and Methods (sections 2.7.3.1 Gas Chromatography-Mass Spectrometry methods for 
aqueous phase samples and 2.7.3.2 Gas Chromatography-Mass Spectrometry methods 
for organic phase samples).  Derivatised aqueous phase samples were injected splitless 
and organic phase samples were injected with a split ratio of 25.  
 
GC-MS chromatograms were processed using Xcaliber (version 2.0; Thermo Electron) as 
outlined in Chapter 2 Materials and Methods (2.7.5. Processing Gas Chromatography-
Mass Spectrometry data). 
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3.3.7. UPLC-MS Analysis 
Chromatography was performed using an ACQUITY UPLC® system equipped with an 
Acquity UPLC 1.7 µm BEH C8 column (2.1×100 mm) coupled to a Micromass QTof-
Ultima with a Z-spray electrospray source.  All chromatography and mass spectrometric 
parameters were as outlined in Chapter 2 Materials and Methods (section 2.8.1. 
Chromatography and mass Spectrometry parameters) 
 
The organic phase of the extracts were reconstituted in methanol-chloroform (2:1, 1 ml).  
Aliquots of diluted organic phase sample (5 µl) were injected onto the C8 column.  The 
column mobile phase was held at 50% solvent B for 0.5 min followed by an increase 
from 50%-100% solvent B over 0.5-6.5 min.  The mobile phase was then held at 100% B 
for 3.5 min.  Between 10 and 10.25 min the mobile phase was returned to 50% B and 
held for 3.75 min to re-equilibrate the column.  The total UPLC cycle was 14 min.  The 
eluent flow rate was 600 µl/min. 
 
Tandem mass spectrometry procedures were as described in Chapter 2 Materials and 
Methods (2.8.3 Tandem mass spectrometry method). 
 
Data was processed using Micromass MarkerLynx Applications Manager as depicted in 
Chapter 2 Materials and Methods (2.8.4. Processing Liquid Chromatography-Mass 
Spectrometry data). 
 
3.3.8. Direct Infusion Mass Spectrometry 
Direct infusion mass spectrometric analysis was performed using a Thermo Finnigan 
LTQ equipped with a Finnigan Surveyor pump and Finnigan Micro AS Autosampler. 
 
The organic phase samples for DI-MS were reconstituted in 500 µl methanol:THF (2:1 
v/v). 100 µl of each sample was added to a 96 well plate. Samples were analyzed in 
duplicate using both positive and negative mode.  All other direct infusion and mass 
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spectrometric parameters were as described in Chapter 2 Materials and Methods 
(section 2.9.2. Direct infusion and mass spectrometry parameters). 
  
 DI-MS chromatograms were processed using Xcaliber as outlined in Chapter 2 
Materials and Methods (2.9.3. Processing of direct infusion mass spectrometry data). 
 
3.3.9. Multivariate Analysis 
Multivariate data analysis was performed using SIMCA-P+ 11.0 (Umetrics AB, Umeå, 
Sweden).  NMR, DI-MS and UPLC-MS data sets were mean-centered and Pareto-scaled 
prior to analysis.  GC-MS data sets were scaled to UV. Data sets were analyzed using 
PCA, PLS and PLS-DA. Further details are summarised in Chapter 2 Materials and 
Methods (section 2.11.6 Multivariate Statistical Analysis Methodology). 
 
3.3.10. 
13
C-glucose Substrate Labelling Study 
At 2 days post differentiation media was removed from the T75 flasks and replaced with 
DMEM (10% (v/v) FBS, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 
4.5 g/l 12C unlabelled glucose (n=6) or 4.5 g/l 1-13C-glucose (n=7). 
 
After 2 days cells were collected and metabolites extracted as previously described in 
Chapter 2 Materials and Methods (sections 2.1.6 and 2.3 Adipocyte cell collection and 
3T3-L1 cell, primary adipocyte and tissue metabolite extraction).  Two-dimensional 
HSQC 13C-Nuclear Magnetic Resonance spectroscopy was performed on the samples 
using the methodology in Chapter 2 Materials and Methods (2.6.5. 2-dimensional 
Heteronuclear Single-Quantum Coherence 
13
C-Nuclear Magnetic Resonance 
experimental method). 
 
GC-MS analysis of organic and aqueous phases, processing and analysis was also carried 
out as previously described in Chapter 2 Materials and Methods (section 2.7.4. Gas 
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Chromatography-Mass Spectrometry analysis, processing and data handling for 3T3-L1 
adipocyte 13C labelled substrate studies). 
 
3.3.11. 
13
C-palmitate Substrate Labelling Study 
13C labelled and unlabelled palmitate solutions were prepared as is summarised in 
Chapter 2 Materials and Methods (section 2.4.3. Preparation of 13C and 12C palmitate 
solution). 
 
At 2 days post-differentiation media was removed from the T75 flasks and replaced with 
DMEM (serum free, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 70 µM  
unenriched palmitate (n=6) or 70 µM U-13C labelled palmitate (n=6). 
 
After 2 days cells were collected and metabolites extracted as previously described in 
Chapter 2 Materials and Methods (sections 2.1.6 and 2.3 Adipocyte cell collection and 
3T3-L1 cell, primary adipocyte and tissue metabolite extraction).   
 
GC-MS analysis of organic and aqueous phases was also carried out as previously 
described in Chapter 2 Materials and Methods (section 2.7.4. Gas Chromatography-
Mass Spectrometry analysis, processing and data handling for 3T3-L1 adipocyte 13C 
labelled substrate studies). 
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3.4 Results 
3.4.1. 3T3-L1 Adipocytes 
High resolution 1H-NMR spectroscopy, GC-MS, LC-MS and DI-MS analysis, combined 
with multivariate pattern recognition were used to profile metabolism within 
differentiating 3T3-L1 murine cells.  The combination of these analytical tools was used 
in order to maximise the coverage of the metabolome within the cells. High resolution 
1H-NMR spectroscopy detected 25 identifiable metabolites.  GC-MS detected 100-150 
defined peaks from aqueous phase samples and 60-70 defined peaks from organic phase 
samples.  Matching the mass spectra detected with those held in the NIST/ EPA/ NIH 
mass spectral library identified 60% of metabolites for aqueous extracts and 65% for 
lipids. Of the species detected using DI-MS negative mode ionisation that contribute to 
separation in the multivariate models 40% (~150) were identified both in terms of lipid 
class and their fatty acyl moieties.  Of the species detected using LC-MS that contribute 
to separation in the multivariate models 60% were identified using MS/MS.   
 
Across all multivariate models used to examine the individual spectra/chromatograms a 
similar trend in the separation of time points was detected where by the earliest time 
points showed only subtle variation before diverging steadily up to 24 h.  This trend for 
the first 24 h was along PC 2 which represents the second most amount of correlated 
variation detected in the dataset. Significant separation then occurs for the latter time 
points (24-120 h) along PC 1, which represents the most amount of correlated variation 
detected in the dataset. By 216 h clustering along component 2 has returned to a position 
similar to the earliest time points; however separation along component 1 remained 
altered (Figure 3.1).  
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Figure 3.1:  A. PLS scores plot showing clustering of aqueous phase metabolites 
analyzed by GC-MS extracted from 3T3-L1 cells at 0 h, 2 h, 4 h, 8 h, 16 h, 
24 h, 72 h, 120 h and 216 h time points during the differentiation process. 
(R2=0.63, Q2=0.97). The PLS model was formed by cross correlating the 
metabolic profile (X variables) against the time of differentiation (Y 
variable).  B. PLS scores plot showing clustering of aqueous phase 
metabolites analyzed by 1H-NMR extracted from 3T3-L1 cells at 0 h, 2 h, 
4 h, 8 h, 16 h, 24 h, 72 h, 120 h and 216 h time points during the 
differentiation process. (R2=0.99, Q2=0.97). The PLS model was formed 
by regressing against time.  C. PLS scores plot showing clustering of 
organic phase metabolites analyzed by GC-MS extracted from 3T3-L1 
cells at 0 h, 2 h, 4 h, 8 h, 16 h, 24 h, 72 h, 120 h and 216 h time points 
during the differentiation process. (R2=0.99, Q2=0.98). The PLS model 
was formed by regressing against time.  D. PCA scores plot showing 
clustering of metabolites analyzed by LC-MS extracted from 3T3-L1 cells 
at 0 h, 2 h, 4 h, 8 h, 16 h, 24 h, 72 h, 120 h and 216 h time points during 
the differentiation process. (R2=0.73, Q2=0.61). 
 
3.4.1.1 3T3-L1 preadipocyte differentiation and intracytoplasmic lipid accumulation   
Oil red O stained images of the differentiating cells demonstrated that the cells 
maintained a fibroblastic like morphology for the early time points.  By 16 h a number of 
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cells had altered their morphology to a more rounded phenotype.  By 120 h the cells were 
beginning to resemble adipocytes and accumulate lipid as indicated by the stain. The 
staining for the final time point showed mature 3T3-L1 cells with a rounded morphology 
and lipid containing vesicles; 75 percent of the total number of cells differentiated 
(Figure 3.2).  Spectrophotometric measurement at 510 nm of the eluted Oil Red O from 
the stained cells confirmed that the cells had begun to accumulate lipid by 120 h and had 
significantly differentiated by 216 h (Figure 3.3). 
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Figure 3.2: A. Oil Red O stained images of differentiating 3T3-L1 adipocytes at time 
points 0-216 h. B. Graph showing cell counts and the percentage of 
differentiating cells at time points 0-216 h.  
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Figure 3.3: Spectrophotometric measurement at 510 nm of Oil Red O eluted from the 
stained cells at 0-216 h. 
 
 
3.4.1.2 Total fatty acid metabolism   
To establish the fatty acid content of the cell differentiation media prior to addition to the 
cell cultures the media was extracted and the organic phase fatty acids derivatised and 
analysed using GCMS (Figure 3.4). The media was found to contain relatively high 
concentrations of palmitate and stearate, however the concentrations of other even chain 
fatty acids was relatively low. The concentrations of odd chain fatty acids were low with 
only pentadecanoate and heptadecanoate detectable. Also low in concentration were the 
∆9 desaturated fatty acids with only C16:1 and C18:1 detected. The media was also 
established as a source of the essential fatty acid linoleic acid.   
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Figure 3.4: A typical GC-MS total ion chromatogram (TIC) from the analysis of methyl 
esterification-derivatised organic extracts from fresh media.  Metabolites are 
identified from exact retention times and comparison of corresponding mass 
spectrum with the NIST database and a FAME standard mix. 
  
The total fatty acid concentrations in 3T3-L1 cells were measured using GC-MS analysis 
of their methyl esterified derivatives from the organic phase of the cell extracts.  Between 
24-72 h, the even chained fatty acids (C8:0, 10:0, 12:0, 14:0) and the ∆9 desaturase 
products C14:1, C16:1 and C18:1 increased in concentration as detected by their 
contribution to PC 2 of the PCA model used to analyze the fatty acid methyl ester dataset.  
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In addition pantothenate, a key constituent of Co-Enzyme A, was detected at 72 h 
(Figure 3.5 A.) and was accompanied by a decrease in the concentration of acetate which 
is in part produced from the β-oxidation product acetyl-CoA.  Also increased in 
concentration was carnitine, a key metabolite involved in fatty acid transport across the 
membrane of several cellular organelles.  Accumulation of even chained fatty acids 
continued 72-120 h (C8:0, C10:0, C14:0) as detected in the loading coefficients for PC 1. 
In addition this increase was accompanied by an increase in odd chain fatty acids (C9:0, 
C11:0, C13:0, C15:0, C17:0) (Figure 3.5 B).  The increase in the concentration of these 
odd chain fatty acids also pre-empted an increase in the concentration of their 
desaturation products (C11:1, C15:1, C17:1, C19:1) (Figure 3.5 C).  Pantothenate and 
carnitine concentrations continued to increase up to 216 h whilst acetate concentrations 
decreased by 120 h.  At 216 h a decrease in the concentration of all omega-6 fatty acid 
pathway intermediates and a decrease in the end products of the omega-3 pathway 
(5,8,11,14,17-20:5 and 4,7,10,13,16,19-22:6) were detected.  At this time point there was 
also a continued increase in the even chain fatty acids (C8:0, 10:0, 12:0 14:0), their 
monounsaturated products and palmitoleate, accompanied by continued increases in odd 
chain fatty acids (C9:0, 11:0, 13:0, 15:0 and 17:0) and monounsaturated odd chain fatty 
acids (C11:1, 15:1, 17:1).  The concentration of larger chain fatty acids decreased (20:0, 
24:0, 24:1) across the time course.  The concentration of palmitate increases between 16-
24 h before decreasing, alongside stearate for the remainder of the differentiation process 
(Figure 3.5 D and 3.5 E).  Accompanying the changes observed in the concentrations of 
the essential fatty acid pathway intermediates, the concentration of arachidonic acid 
esterified to phospholipids increased at 24 h and again at the 216 h time point. 
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Figure 3.5: A. Bar graph showing the average integrated area of the pantothenate peak 
at 24 h, 72 h, 120 h and 216 h time points as measured by 1H-NMR 
spectroscopy. Standard error bars are shown. .* P < 0.05 calculated 
between adjacent time points. B. Graph showing the average integrated 
area of the pentadecanoate peak (C15:0) peak at 24 h, 72 h, 120 h and 216 
h time points as measured by GC-MS of fatty acid methyl esters. Standard 
error bars are shown.  * P < 0.05 calculated between adjacent time points.  
C. Bar graph showing the average integrated area of the cis-10-
heptadecanoate peak at 24 h, 72 h, 120 h and 216 h time points. Standard 
error bars are shown. * P < 0.05 calculated between adjacent time points. 
D. A typical GC-MS total ion chromatogram (TIC) from the analysis of 
methyl esterification-derivatised 3T3-L1 cell organic extracts from the 0 h 
time point.  Metabolites are identified from exact retention times and 
comparison of corresponding mass spectrum with the NIST database and a 
FAME standard mix. E. A typical GC-MS total ion chromatogram (TIC) 
from the analysis of methyl esterification-derivatised 3T3-L1 cell organic 
extracts from the 216 h time point.  Metabolites are identified from exact 
retention times and comparison of corresponding mass spectrum with the 
NIST database and a FAME standard mix. 
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3.4.1.3 Carbohydrate metabolism  
Concentrations of glycolytic and TCA cycle intermediates were measured using 1H-NMR 
and GC-MS analysis of their methoximated and silylated derivatives from the aqueous 
phase of the cell metabolite extraction.  During the first 4 h of differentiation a number of 
TCA cycle intermediates increased in concentration including succinate, fumarate and 
malate. For the first 2 h of the differentiation process this was also accompanied by an 
increase in glycolysis as indicated by increases in lactate and pyruvate and a decrease in 
glucose-6-phosphate. Both changes were accompanied by an increase in the 
concentration of ATP.  Between 8 h and 16 h the concentrations of the latter 
intermediates (succinate, fumarate and malate) in the TCA cycle decreased as the 
concentrations of the early intermediates isocitrate and citrate increased indicating the 
change in steady state for the two halves of the cycle. At the same time the concentrations 
of glucose and galactose increased and lactate decreased suggestive of a decrease in 
glycolytic flux consistent with greater coupling between glycolytic flux and the TCA 
cycle.  By 72 h, corresponding to the identified initiation of lipid accumulation, the 
concentration of the TCA cycle intermediates fumarate, malate, isocitrate and citrate 
increased; a corresponding increase in ATP concentrations suggests that the flux of the 
TCA cycle was also increased. The concentration of glucose was also reduced at this time 
point. The TCA cycle intermediates continued to increase at 120 h, with the 
concentrations of succinate, fumarate, malate and citrate all increasing across this time 
period.  Accompanying upregulation of glycolytic flux was established with observed 
decreases in the concentrations of glucose, fructose and galactose and increases in 
pyruvate and lactate between 24 h and 120 h.  At 216 h TCA cycle and glycolytic 
intermediates were decreased in concentration as the cells reached terminal 
differentiation – at this time point the concentrations of glucose, galactose and fructose 
were increased and those of pyruvate, lactate, succinate, fumarate, malate, isocitrate and 
citrate were decreased compared to 120 h.  
 
3.4.1.4 Amino acid metabolism   
Concentrations of amino acids and polyamine biosynthesis intermediates were measured 
using 1H-NMR spectroscopy and GC-MS analysis.  The concentration of glutamine 
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increased after 4 h and again after 16 h with a concomitant decrease in the concentration 
of glutamate. Polyamine metabolism was also altered during differentiation with an 
increase in the concentration of the putrescine precursors aspartate and ornithine detected 
prior to an increase in the concentration of putrescine detected after 24 h. The levels of 
the polyamine pathway metabolites, including putrescine, then decreased by 216 h.   
 
3.4.1.5 Complex lipids and free fatty acids   
Concentrations of FFAs and glycerophospholipids were measured using DI-MS (Figure 
3.6).  LC-MS was used to measure the concentrations of glycerophospholipids and 
TAGs.  
 
 
Figure 3.6:  Direct infusion of 3T3-L1 cell lipid extraction in negative mode using an 
LTQ ion trap. A. Direct infusion mass spectrum of 3T3-L1 cell lipid 
extraction fraction. B. MS/MS spectrum of an ion at 701 m/z. Daughter 
ions are labelled. 
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At 24 h an increase in even chain saturated and unsaturated FFAs was detected as was an 
increase in the intermediates and end products of the omega-3 and omega-6 fatty acid 
pathways. By 72 h there was an increase in the concentrations of even chain unsaturated 
fatty acids accompanied by an increase in the concentrations of odd chain saturated and 
unsaturated fatty acids which continued to the 216 h time point. The concentrations of the 
longer chain unsaturated even chain fatty acids were decreased by 120 h as were the 
concentrations of the omega-6 fatty acid pathway intermediates.  At the conclusion of the 
study there was a detected increase in the concentration of α-linolenic acid and 
concomitant decrease in the essential fatty acid pathway intermediates and end products. 
A continued decrease in the longer, even chain fatty acids was also detected at 216 h.  
The composition of TAGs was also altered with an increase in the incorporation of odd 
chain saturated and unsaturated fatty acids and a concomitant decrease in the 
concentration of even chain fatty acids at 72 h.  Accumulation of odd chain fatty acids 
continued at 120 h with a concomitant decrease in even long chain fatty acids.  By 216 h 
the concentration of TAGs esterified with odd chain fatty acids continued to increase 
while an associated decrease in the concentration of TAGs incorporating C16:0 and 
C18:0 was detected (Table 3.1). 
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Table 3.1: The changes in TAG concentrations during the differentiation of 3T3-L1 
preadipocytes into mature adipocytes at the 72 h, 120 h and 216 h time 
points. TAGs were detected by LC-MS and identified using MS/MS.    
 
3.4.2. 3T3-L1 Adipocyte 
13
C-labelled Substrate Study  
To investigate the mechanisms generating the changes in the steady state concentrations 
of metabolites identified in the metabolomic studies 13C stable isotope labelled substrate 
studies were conducted.  Given that the most significant changes were found to occur in 
the lipid composition of the differentiating cells and especially considering the unusual 
concentration of odd chain fatty acids we elected to investigate synthesis and metabolic 
processing of fatty acids directly using stable isotope techniques. 
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3.4.2.1 
13
C-glucose labelling study  
 
13C enrichment of a number of key metabolites was measured using HSQC NMR 
analysis of the organic phase metabolites and GC-MS analysis of the organic and 
aqueous phases.  When using 1-13C-glucose as a substrate lactate, succinate and 
glutamate were all found to be enriched when analysed by GC-MS (Figure 3.7), as were 
the lipid resonances in HSQC spectra corresponding to ω 1-3 resonances, allylic carbons, 
terminal lipid resonances (CH3 resonances), the methylene envelope and esterified and 
non-esterified glycerol (Figure 3.8). Further investigation, by GC-MS, of the enrichment 
of individual fatty acid species demonstrated that both C14:0 and C16:0 had clearly 
incorporated 13C from glucose (Figure 3.9 A,B).    
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Figure 3.7:  A. Graph showing GC-MS M+1/M ion ratio for lactate when using 1-13C-
glucose and unlabelled glucose.  Enrichment of lactate is shown. B. Graph 
showing GC-MS M+1/M ion ratio for succinate when using 1-13C-glucose 
and unlabelled glucose, showing enrichment of succinate. C. Graph 
showing GC-MS M+1/M ion ratio for glutamate when using 1-13C-
glucose and unlabelled glucose, showing enrichment of glutamate.  *P < 
0.05, **P < 0.01, ***P < 0.005. 12C is unenriched glucose, 13C is 1-13C 
enriched glucose. Parent ions were used to calculate ion ratio. 
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Figure 3.8: HSQC NMR spectra of organic extraction phase of 3T3-L1 cells exposed 
to unlabelled (A) or 1-13C-glucose (B). Key: ω 1-3 Carbon signals, allylic 
carbons, C1-3 signals, the methylene envelope and esterified and non-
esterified glycerol 13C cross peaks are labelled. 
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3.4.2.2 
13
C-palmitate labelling study 
13C enrichment of a range of metabolites was identified using GC-MS analysis of the 
organic and aqueous phases (the possibility remains that there were small amounts of 
13C labelled fatty acid impurities in the 13C labelled palmitate).  Pentadecanoate was 
found to be enriched confirming the observed increase in odd chain fatty acid abundance 
detected by analysis of the total pool of FFAs (Figure 3.9 C). The palmitate desaturation 
product palmitoleate was also found to be enriched with 13C in accordance with the 
observed activity of the ∆9 desaturase from the metabolomic studies (Figure 3.9 D). 
 
 
Figure 3.9:  A. Graph showing GC-MS M+1/M ion ratio for myristate when using 1-
13C-glucose and unlabelled glucose. Enrichment of myristate is shown. B. 
Graph showing GC-MS M+1/M ion ratio for palmitate when using 1-13C-
glucose and unlabelled glucose, showing enrichment of palmitate. C. 
Graph showing GC-MS M+1/M ion ratio for pentadecanoate when using 
U-13C-palmitate and unlabelled palmitate, showing enrichment of 
pentadecanoate. D. Graph showing GC-MS M+1/M ion ratio for 
palmitoleate when using U-13C-palmitate and unlabelled palmitate, 
showing enrichment of palmitoleate. *P < 0.05, ***P < 0.005. 
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3.4.3. Primary Adipocytes  
To examine the relevance of the 3T3-L1 adipocyte model to mature adipocytes and to 
investigate how the 3T3-L1 cells recapitulate metabolic changes that occur in adipocytes, 
the differentiation of primary adipocytes was investigated.  As less primary cell material 
was available for analysis when compared with that available for the 3T3-L1 cells, the 
decision was taken to focus the investigation on the lipid changes occurring within the 
primary adipocytes during differentiation.  Therefore GC-MS and LC-MS, combined 
with multivariate pattern recognition were used to compare metabolic differences 
between primary preadipocytes and differentiated primary adipocytes (Figure 3.10).  
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Figure 3.10:  A. PLS-DA scores plot showing clustering of organic phase metabolites 
analyzed by GC-MS extracted from ■ primary preadipocytes and ● 
differentiated primary adipocytes. (R2=0.76, Q2=0.97) B. PLS-DA scores 
plot showing clustering of aqueous phase metabolites analyzed by GC-MS 
extracted from ■ primary preadipocytes and ● differentiated primary 
adipocytes. (R2=0.71, Q2=0.96) C. PLS-DA scores plot showing clustering 
of organic phase metabolites analyzed by LC-MS extracted from ■ 
primary preadipocytes and ● differentiated primary adipocytes. (R2=0.443, 
Q2=0.99). Two technical replicates were analysed. 
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3.4.3.1 Total fatty acid metabolism   
The total fatty acid concentrations were measured using GC-MS analysis of their methyl 
esterified derivatives from the organic phase of the cell extracts.  An increase in the 
concentrations of the shorter chain fatty acids (C12:0 and C14:0) and concomitant 
decrease in the concentrations of the longer chain fatty acids (C16:0, C18:0, C20:0, C 
22:0 and C24:0) were observed in the differentiated primary adipocytes when compared 
to the primary preadipocytes.  The odd chain length fatty acids (C13:0 and C15:0) and the 
∆9 desaturase products (C14:1, C16:1, C18:1, C19:1, C20:1 and C24:1) were also 
identified as increased in concentration in the differentiated primary adipocytes.  
 
3.4.3.2 Carbohydrate metabolism   
Concentrations of glycolytic and TCA cycle intermediates were measured using GC-MS 
analysis of their methoximated and silylated derivatives from the aqueous phase of the 
cell metabolite extraction.  The concentrations of glucose-6-phosphate, lactate, fumarate 
and malate were all found to be increased in the differentiated primary adipocytes 
compared to the primary preadipocytes.  This was a comparable result to the changes 
identified in the 3T3-L1 cell line.  
 
3.4.3.1 Triacylglycerols   
The composition of TAGs was altered during differentiation of the primary adipocytes. 
There was an increase in the accumulation of odd chain length fatty acids into TAGs. In 
addition the concentration of desaturated fatty acid constituents of the TAGs was 
increased (Table 3.2).  
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Table 3.2: The TAG species increased in concentration during the differentiation of 
primary preadipocytes into primary adipocytes. TAGs were detected by 
LC-MS.   
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3.5 Discussion 
 
During 3T3-L1 adipocyte development the commitment to differentiate occurs between 
24-48 h and is followed by the process of lipid accumulation210.  In the study described in 
this chapter these processes are reflected in the multivariate models of the various 
analytical assays. One of the earliest changes in the process of differentiation was 
associated with upregulation of the TCA cycle, as represented by an increase in the pool 
sizes of a number of the intermediates, possibly to increase ATP for the differentiation 
process. By 72 h, corresponding to the identified initiation of lipid accumulation, the 
intermediates of the TCA cycle again increase in concentration, but at this time point it is 
dominated by increases in citrate and isocitrate as fatty acid synthesis increases, with 
citrate being used to supply cytosolic acetyl-CoA, a key intermediate of fatty acid 
synthesis. Finally at 216 h the metabolite concentrations of the glycolytic pathway and 
the TCA cycle are such that it would suggest decreased need for these pathways, possibly 
as the energy demand of the cell decreases following differentiation. Alternatively, it 
could be viewed that now the dominant pathways involve fatty acid metabolism rather 
than pathways involving glucose (Figure 3.11). 
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Figure 3.11: Glycolysis and TCA cycle metabolic pathways altered during the initiation 
phase of 3T3-L1 adipocyte differentiation (0-48 h). Metabolites increased 
in concentration are marked Red; metabolites decreased in concentration 
are marked with Blue. 
 
The increase in the concentration of glutamine detected during differentiation has 
previously been observed and is caused by induction of glutamine synthase as a result of 
glucocorticoid stimulation during the commitment to differentiate211. Furthermore, the 
detected changes in polyamine biosynthesis are known to be essential for differentiation 
of 3T3-L1 cells into adipocytes204.  The observed increase in concentration again 
corresponds to the induction of lipid accumulation and commitment to differentiate and a 
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reduction in polyamine biosynthesis intermediates at 216 h also suggest the cells return to 
a resting state at this time point; an observation which correlates with changes in 
transcription of ornithine decarboxylase during adipocyte differentiation, with this 
enzyme producing putrescine from ornithine212.  
 
From 72 h onwards there is a significant increase in the majority of fatty acids as the 
process of lipid accumulation occurs following the preadipocytes commitment to 
differentiate.  Accompanying the increase in fatty acids there was also an increase in 
desaturation and especially of the monounsaturated forms of fatty acids.  Stearoyl-CoA 
desaturase 2 has recently been identified as essential for differentiation. Considering there 
is a predominance of saturated fatty acids in the growth media and the transcription of the 
enzyme is upregulated during differentiation213, it is likely the desaturation observed is 
carried out by this enzyme207.  Sequential peroxisomal fatty acid α-oxidation and ∆-9 
desaturation of fatty acids has been shown to occur in differentiating 3T3-L1 adipocytes, 
explaining the detected increase in odd chain fatty acids, their desaturation and 
accumulation into complex lipids214.  Analysis of the media eliminated this as the source 
of the odd chain fatty acids; the highest concentration fatty acids present in the media 
were palmitate and stearate, and odd chain fatty acids were only detected at low levels.  A 
concomitant increase in the concentration of the CoA constituent pantothenate was 
detected alongside the lipid changes. CoA is necessary for fatty acid synthesis, transport 
of fatty acids into peroxisomes and both α and β fatty acid oxidation.  Therefore, it 
appears CoA is increased in response to demand for fatty acid synthesis and α-oxidation.  
The increase in the concentration of the fatty acid transport molecule carnitine at 72 h, 
continuing to 216 h, may indicate the requirement for export of odd chain fatty acids 
from peroxisomes following α-oxidation, since peroxisomes contain short- and medium-
chain carnitine acyltransferases functioning to esterify carnitine to fatty acids in order to 
cross the peroxisomal membrane215.  The transcription of propionyl CoA carboxylase, an 
enzyme involved in fatty acid α-oxidation, and the enzyme carnitine acyl transferase 
have previously been reported as upregulated during 3T3-L1 differentiation213.  
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Furthermore the utilisation of glucose to generate fatty acids during 3T3-L1 metabolism 
has been confirmed through the use of 13C-labelled glucose to monitor the metabolic flux 
through glycolysis, the TCA cycle and into fatty acid synthesis. Once the fatty acids are 
synthesised they are subjected to desaturation by the ∆9 desaturase or to α-oxidation, 
forming odd chain fatty acids as indicated by the metabolomic data and confirmed 
through the use of U-13C labelled palmitate.   
 
The observed decrease in the end products of the omega-3 essential fatty acid pathway, 
5,8,11,14,17-eicosapentaenoic acid and 4,7,10,13,16,19-docosahexaenoic acid, may be 
necessary for the regulation of differentiation in the 3T3-L1 cell line.  Docosahexaenoic 
acid has been shown to inhibit differentiation and promote lipolysis in the adipocytes216.   
 
The concentration of arachidonic acid acyl groups in phospholipids appears to increase 
from 24 h with a decrease in its concentration as a FFA detected by 120 h.  
Glucocorticoids block release of arachidonic acid from intracellular phospholipid 
pools217.  Given arachidonic acid is the initial substrate for the omega-6 essential fatty 
acid pathway this will lead to the decrease in the intermediates and products of this 
pathway, as observed in this study.  The control of flux through this pathway is vital to 
differentiation since arachidonic acid as a substrate for cyclooxygenase-2, strongly 
inhibits adipocyte differentiation via a prostaglandin synthesis pathway218.  In addition 
eicosapentaenoic acid represses the expression of peroxisome proliferator-activated 
receptor-γ, a nuclear receptor vital to adipocyte differentiation205 (Figure 3.12).  
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Figure 3.12:  A. Metabolic pathways altered during the lipid accumulation phase of 
3T3-L1 adipocyte differentiation (72-120 h). Metabolites increased in 
concentration are marked in Red; metabolites decreased in concentration 
are marked in Blue. B. Metabolic pathways altered at terminal 
differentiation of 3T3-L1 adipocytes (216 h). Metabolites increased in 
concentration are marked in Red; metabolites decreased in concentration 
are marked with Blue. 
 
Metabolomic analysis of the differentiation of primary adipocytes was conducted to 
allow comparison of the metabolic changes that occur during differentiation of the 
primary cells with those identified in the differentiation of the 3T3-L1 adipocyte model, 
from which the relevance of applying metabolomic investigation to the 3T3-L1 cell line 
for the study of adipocytes could be assessed.  Primary adipocyte metabolomic 
investigation focused on the lipid changes occurring within the primary adipocytes during 
differentiation as the composition of this metabolite class was found to be most 
significantly altered during the differentiation of the 3T3-L1 cells.  The availability of 
primary adipocyte material was also limited. 
 
The changes observed in the total fatty acid composition of the primary adipocytes as the 
cells differentiated was comparable with those seen in the 3T3-L1 cells.  In both cell 
types there was an increase in the concentration of the short and mid chain fatty acids, 
odd chain fatty acids and the monounsaturated products of the ∆9 desaturase.  As with the 
3T3-L1 cells an increase in the incorporation of odd chain and monounsaturated fatty 
acids into TAGs was also detected    An increase in the concentration of glycolytic and 
TCA cycle intermediates, analogous to the metabolic changes observed in the 3T3-L1 
cells during differentiation, was also observed in differentiated primary adipocytes and 
may correspond to the utilisation of glucose to generate fatty acids as was confirmed in 
the 3T3-L1 cells using 13C-labelled glucose. 
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3.6 Conclusions 
 
Although the 3T3-L1 cell line is a robust and extensively used tool for the investigation 
of adipocyte biology it is worthy of note that, as with all immortalised cell lines, they do 
not behave identically to their primary cell line counterparts.  However, the metabolic 
differences found between primary preadipocytes and primary differentiated adipocytes 
matched many of the findings observed in the 3T3-L1 cell line. Therefore it is hoped the 
current study will provide invaluable cues for research conducted in the 3T3-L1 cell line, 
primary cell lines and even white adipose tissue when following the changes in 
metabolism associated with differentiation.    
 
In conclusion, global metabolic profiling has been used to study the changes in 
metabolism required to bring about differentiation of fibroblastic like cells into mature 
adipocytes.  A diverse number of interacting metabolic pathways essential to 
differentiation have been highlighted as altered at key points in this process.  The changes 
in metabolite concentrations during commitment to differentiate, lipid accumulation and 
the return to a resting state have been studied and the TCA cycle, glycolysis, fatty acid α-
oxidation, synthesis and desaturation, polyamine biosynthesis and esterification of acyl 
groups to complex lipids have been identified as implicit to 3T3-L1 maturation.  
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Chapter 4 
 
PPARδ Activation in White Adipose Tissue: Burning Fat by 
Upregulation of the TCA Cycle 
 
 
4.1 Introduction 
 
The WHO estimates over 180 million people worldwide suffer from TIIDM.  The 
incidence of obesity, a major risk factor for the development of TIIDM, is also increasing 
globally.  While a number of anti-diabetic treatments have been produced they rarely 
address the related obese state and consequently fail to confront this underlying risk 
factor.  Therefore it becomes imperative that new treatment approaches with both anti-
diabetic and anti-obesity properties are found. 
 
The PPARs have already yielded viable targets for the treatment of TIIDM and 
dyslipidaemia; TZDs, PPARγ agonists, are currently used in the clinic for the treatment 
of TIIDM and fibrates, PPARα agonists, are routinely used to treat dyslipidaemia.  
Treatment with TZDs results in the recruitment of new metabolically active adipocytes 
causing an increase in lipid storage capacity and normalisation of adipocytokine levels219; 
whereas activation of PPARα by fibrates results in an increase in fatty acid catabolism in 
the heart and liver and decreases low-density lipoprotein-cholesterol concentrations128. 
 
A pharmacological agonist for PPARδ is yet to make it into the clinic, the receptor 
remains to be functionally defined and the physiological ligand for PPARδ is still to be 
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described.  Nevertheless, the receptor has been shown to be activated by several 14 to 18 
carbon containing polyunsaturated fatty acids, including eicosanoids such as 
prostaglandin A1, iloprost and carbaprostacyclin, in the micromolar range
132.  The 
development of a number of high affinity synthetic ligands for PPARδ has shown the 
receptor holds considerable promise for the treatment of TIIDM, the metabolic syndrome, 
dyslipidaemia and obesity.  Insulin resistant obese rhesus monkeys treated with the 
selective PPARδ agonist GW501516 demonstrated significant increases in HDL-
cholesterol with concomitant decreases in TAGs and LDL-cholesterol170.  PPARδ 
activation has also shown efficacy in reducing adiposity by decreasing intracellular TAG 
accumulation in mouse brown adipose tissue and liver169 . 
 
Investigation into the function of PPARδ in white adipose tissue has, thus far, 
demonstrated that the receptor has an important role in the regulation of metabolism and 
energy homeostasis.  In vitro investigation has shown that expression of PPARδ is 
induced early in the differentiation of the 3T3-L1 murine adipocyte cell line172 and during 
early brown adipogenesis173.  PPARδ is also implicated in the stimulation of adipogenesis 
via the induction of PPARγ expression and mitotic clonal expansion174, 175. Tissue 
specific over-expression of PPARδ in the white adipose tissue of transgenic mice resulted 
in decreases in body weight, adipocyte TAG accumulation, circulating FFAs and 
circulating TAG169.  The same transgenic mice were also protected against weight gain, 
adipocyte hypertrophy, hypertriglyceridaemia, and steatosis.  PPARδ activation also 
leads to elevated expression of Uncoupling protein-1 in white adipose tissue169. 
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4.2 Aims and Objectives 
 
In order to deconvolute the effect of PPARδ activation on the control of metabolism in 
white adipose tissue we have performed a metabolomics study using both in vivo analysis 
in the ob/ob mouse and in vitro analysis using the murine 3T3-L1 adipocyte cell line.  A 
synthetic, high affinity pharmacological agonist, GW610742, was used to activate 
PPARδ in both the mice and the adipocyte cell line (GW610742 EC50 for murine PPARδ 
is 28 nM compared to 8,900 nM for PPARα and >10,000 nM for PPARγ)185.  A 
combined GC-MS, 1H-NMR, LC-MS and DI-MS approach was used in conjunction with 
multivariate statistics to probe the metabolic phenotype resulting from PPARδ activation.  
To unambiguously define the mechanisms by which PPARδ alters the metabolism of 
adipose tissue we then carried out 13C-stable isotope substrate labelling studies using 1-
13C glucose and U-13C palmitate, respirometric analysis using a Clark-type oxygen 
electrode and transcriptomic microarray analysis. 
 
It was found that PPARδ activation was not only characterised by increased fatty acid 
oxidative metabolism as previously observed but also by glucose oxidation. This 
implicates PPARδ as a control for global oxidative energy metabolism and suggests a 
mechanism by which activation of the nuclear receptor, in part, brings about its anti-
diabetic and anti-obesity properties by simultaneously reducing the quantity of TAGs and 
glucose in white adipose tissue.   
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4.3 Materials and Methods 
 
4.3.1 Ob/Ob Mouse Study Tissue Collection and Extraction 
Animals were kept as is outlined in Chapter 2 Materials and Methods (section 2.2.1. 
Animal handling).  Briefly, the ob/ob mice were dosed orally daily at 8 am with 0.5% 
Hydroxypropylmethylcellulose/0.1% Tween80 vehicle control (n=8) or a PPARδ agonist, 
GW610742 (n=8 at 30 mg/kg).  Injection volume was adjusted daily according to body 
weight at 10 ml/kg.  White adipose tissue was collected as summarised in Chapter 2 
Materials and Methods (section 2.2.4. Tissue handling). 
 
4.3.2 3T3-L1 Cell Culture 
3T3-L1 preadipocytes were grown and differentiated as described in Chapter 2 
Materials and Methods (section 2.1.1 3T3-L1 cell culture and adipocyte 
differentiation).   
 
4.3.3 3T3-L1 PPARδ Activation 
3T3-L1 adipocytes were treated with the selective PPARδ agonist GW610742 as is 
outlined in Chapter 2 Materials and Methods (2.1.3. Activation of PPARδ in 3T3-L1 
adipocytes). Briefly, adipocytes were treated with either DMSO (control n=6 T75 flasks) 
or GW610742 PPARδ selective agonist (n=6 T75 flasks at 100 nM and 1 µM) for 2 days. 
 
4.3.4. Oil Red O Staining and Intracytoplasmic Lipid Accumulation 
Six additional T75 flasks of 3T3-L1 adipocytes were grown per control, 100 nM and 1 
µM treatment groups. Three flasks per group were stained prior to PPARδ agonist 
treatment to assess levels of differentiation; three flasks per groups were stained post 
PPARδ agonist treatment to assess the effects of PPARδ activation on the concentration 
of neutral lipid stored within the adipocytes.  The cells were stained and the 
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intracytoplasmic lipid accumulation assessed as in Chapter 2 Materials and Methods 
(section 2.1.5 Oil Red O staining and intracytoplasmic lipid accumulation). 
 
4.3.5 3T3-L1 Cell Collection  
The cells were collected and their metabolites extracted as described in Chapter 2 
Materials and Methods (sections 2.1.6 and 2.3 Adipocyte cell collection).  
 
4.3.6 Tissue and 3T3-L1 Metabolite Extraction  
Metabolites were extracted from white adipose tissue and 3T3-L1 cells using the 
modified Bligh and Dyer method187.  The details are as in Chapter 2 Materials and 
Methods (section 2.3 3T3-L1 Cell, Primary Adipocyte and Tissue Metabolite 
Extraction). 
 
4.3.7 
1
H-NMR Spectroscopy 
All samples were analysed using a Bruker AVANCE II+ spectrometer operating at 
500.13 MHz for the 1H frequency using a 5 mm Broadband TXI Inverse ATMA probe.  
All procedures are as depicted in Chapter 2 Materials and Methods (sections 2.6.1. 
Spectrometer, 2.6.2. Sample preparation, 2.6.3. 1-dimensional 1H-Nuclear Magnetic 
Resonance experimental method and 2.6.4. Processing 1-dimensional 1H-Nuclear 
Magnetic Resonance data). 
 
4.3.8 GC-MS Analysis 
The aqueous phase of extracts was derivatised as described in Chapter 2 Materials and 
Methods (section 2.7.1 Derivatisation of aqueous phase metabolites). 
 
The organic phase of extracts was derivatised as described in Chapter 2 Materials and 
Methods (section 2.7.2 Derivatisation of organic phase metabolites).   
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GC-MS analyses were made using a Trace GC Ultra coupled to a Trace DSQ II single-
quadrupole mass spectrometer.  Parameters for the GC-MS analysis of aqueous phase 
metabolites and organic phase metabolites were as outlined in Chapter 2 Materials and 
Methods (sections 2.7.3.1 Gas Chromatography-Mass Spectrometry methods for 
aqueous phase samples and 2.7.3.2 Gas Chromatography-Mass Spectrometry methods 
for organic phase samples).  Derivatised organic samples were injected with a split ratio 
of 60 for white adipose tissue and 8 for 3T3-L1 cells. 
 
GC-MS chromatograms were processed using Xcaliber (version 2.0; Thermo Electron) as 
outlined in Chapter 2 Materials and Methods (2.7.5. Processing Gas Chromatography-
Mass Spectrometry data). 
 
4.3.9 UPLC-MS Analysis 
Chromatography was performed using an ACQUITY UPLC® system equipped with an 
Acquity UPLC 1.7 µm BEH C8 column (2.1×100 mm) coupled to a Micromass QTof-
Ultima with a Z-spray electrospray source.  All chromatography and mass spectrometric 
parameters were as outlined in Chapter 2 Materials and Methods (section 2.8.1. 
Chromatography and mass Spectrometry parameters) 
 
The organic phase of adipose tissue extracts was reconstituted in methanol-chloroform 
(2:1, 500 µl).  This was further diluted 10-fold prior to injection onto the C8 column (5 
µl).  The column mobile phase was held at 85% solvent B for 0.5 min followed by an 
increase from 85%-100% solvent B over 0.5-8 min.  The mobile phase was then held at 
100% B for 4 min.  Between 12 and 12.25 min the mobile phase was returned to 85% B 
and held for 1.75 min to re-equilibrate the column. 
 
3T3-L1 Cell Organic phase metabolites were reconstituted in methanol-chloroform (2:1, 
1 ml).  Aliquots of diluted organic phase sample (5 µl) were injected onto the C8 column.  
The column mobile phase was held at 50% solvent B for 0.5 min followed by an increase 
from 50%-100% solvent B over 0.5-6.5 min.  The mobile phase was then held at 100% B 
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for 3.5 min.  Between 10 and 10.25 min the mobile phase was returned to 50% B and 
held for 3.75 min to re-equilibrate the column.    The total UPLC cycle was 14 min and 
the eluent flow rate was 600 µl/min for both methods.    
 
Tandem mass spectrometry procedures were as described in Chapter 2 Materials and 
Methods (2.8.3 Tandem mass spectrometry method). 
 
Data was processed using Micromass MarkerLynx Applications Manager as depicted in 
Chapter 2 Materials and Methods (2.8.4. Processing Liquid Chromatography-Mass 
Spectrometry data). 
 
4.3.10 DI-MS Analysis 
Mass spectrometric analysis was performed using a Thermo Finnigan LTQ equipped with 
a Finnigan Surveyor pump and Finnigan Micro AS Autosampler. 
 
The white adipose tissue organic phase samples for DI-MS were reconstituted in 1 ml 
methanol:THF (2:1 v/v). 60 µl of each sample was aliquoted into a 96 well plate where 
the samples were diluted by the addition of a further 600 µl methanol:THF (2:1 v/v). 
 
The 3T3-L1 organic phase samples for DI-MS were reconstituted in 500 µl 
methanol:THF (2:1 v/v). 100 µl of each sample was added to a 96 well plate. Samples 
were analyzed in triplicate using both positive and negative mode.   
 
All other direct infusion and mass spectrometric parameters were as described in 
Chapter 2 Materials and Methods (section 2.9.2. Direct infusion and mass 
spectrometry parameters). 
 
DI-MS chromatograms were processed using Xcaliber as outlined in Chapter 2 
Materials and Methods (2.9.3. Processing of direct infusion mass spectrometry data). 
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4.3.11 
13
C-glucose Substrate Labelling Study  
At 2 days post differentiation media was removed from the T75 flasks and replaced with 
DMEM (10% (v/v) FBS, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 
4.5 g/l unlabelled glucose with DMSO control (n=6) or with 1µM GW610742 PPARδ 
selective agonist (n=7) or 4.5 g/l 1-13C-glucose with DMSO control (n=7) or with 1 µM 
GW610742 PPARδ selective agonist (n=7).  After 2 days cells were collected and 
metabolites extracted as described in Chapter 2 Materials and Methods (sections 2.1.6 
and 2.3 Adipocyte cell collection).  
 
4.3.12 
13
C-palmitate Substrate Labelling Study 
Preparation of 13C labelled and unenriched palmitate solution is defined in Chapter 2 
Materials and Methods (2.4.3. Preparation of 13C and 12C palmitate solution). 
  
At 2 days post-differentiation media was removed from the T75 flasks and replaced with 
DMEM (serum free, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 70 µM 
unlabelled palmitate (n=6) with DMSO control (n=6) or with 1 µM GW610742 PPARδ 
selective agonist (n=7)  or 70 µM U-13C labelled palmitate (n=7) with DMSO control 
(n=6) or with 1 µM GW610742 PPARδ selective agonist (n=7). After 2 days cells were 
collected and metabolites extracted as previously described in Chapter 2 Materials and 
Methods (sections 2.1.6 Adipocyte cell collection and 2.3 Adipocyte cell collection). 
 
4.3.13 
13
C-HSQC NMR Spectroscopy 
Dried organic phase extracts were dissolved in 600 µl of deuterated chloroform. Samples 
were analyzed using a DRX Avance II+ spectrometer interfaced to a 5-mm TXI ATMA 
probe.  All procedures are as depicted in Chapter 2 Materials and Methods (sections 
2.6.5. 2-dimensional Heteronuclear Single-Quantum Coherence 13C-Nuclear Magnetic 
Resonance experimental method and 2.6.6. Processing 2-dimensional Heteronuclear 
Single-Quantum Coherence
 13
C-Nuclear Magnetic Resonance data). 
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4.3.14 
13
C-labelled Substrate GC-MS Analysis  
Analysis of organic and aqueous phases was carried out as previously described in 
Chapter 2 Materials and Methods (section 2.7.1 Derivatisation of aqueous phase 
metabolites, 2.7.2. Derivatisation of organic phase metabolites, 2.7.3.1 Gas 
Chromatography-Mass Spectrometry methods for aqueous phase samples and 2.7.3.2 
Gas Chromatography-Mass Spectrometry methods for organic phase samples). 
 
Enrichment of metabolites was identified by calculating isotope ratios of the M and M+1 
ions for the parent ion of the fragmentation pattern in the case of 13C-glucose metabolism 
analysis and TCA cycle intermediates originating from 13C-palmitate oxidation.  For fatty 
acid synthesis and desaturation products from 13C-labelled palmitate an ion ratio of 
M+16/M was used and for fatty acids originating from oxidation of U-13C-labelled 
palmitate an ion ratio of M+n/M, where n = the carbon chain length of the fatty acid was 
used.  Statistical analysis was performed using a univariate t-test. 
 
4.3.15 Multivariate Analysis 
Multivariate data analysis was performed using SIMCA-P+ 11.0 (Umetrics AB, Umeå, 
Sweden).  NMR, DI-MS and UPLC-MS data sets were mean-centered and Pareto-scaled 
prior to analysis.  GC-MS data sets were scaled to UV. Data sets were analyzed using 
PCA, PLS and PLS-DA. Further details are summarised in Chapter 2 Materials and 
Methods (section 2.11.6 Multivariate Statistical Analysis Methodology). 
 
4.3.16 Respirometric Analysis of PPARδ Agonist Treated 3T3-L1 Cells  
Cells were grown, treated with PPARδ agonist and collected as is outlined in Chapter 2 
Materials and Methods (section 2.1.1 3T3-L1 cell culture and adipocyte differentiation, 
2.1.3. Activation of PPARδ in 3T3-L1 adipocytes, 2.1.6 and 2.3 Adipocyte cell collection)   
with the exception that they were collected into respiration medium (100 mM KCl, 
50 mM MOPS, 1.0 mM KH2PO4, 1.0 mg/ml defatted BSA, pH 7.4). Respiratory rates of 
in situ permeabilised control and PPARδ agonist treated 3T3-L1 cells were measured 
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using a Clark-type oxygen electrode (Strathkelvin Instruments Ltd, Glasgow, UK) with 
methods developed by Kuznetsov et al188. Respiration rates were recorded and quantified 
using 782 Oxygen System v3.0 software (Strathkelvin Instruments). Procedures are 
defined in Chapter 2 Materials and Methods (section 2.5 Respirometric analysis of 
PPARδ agonist treated 3T3-L1 cells). 
  
4.3.17 Microarray Analysis of PPARδ Agonist Treated 3T3-L1 Cells  
Cells were grown, treated with PPARδ agonist and collected as is outlined in Chapter 2 
Materials and Methods (section 2.1.1 3T3-L1 cell culture and adipocyte differentiation, 
2.1.3. Activation of PPARδ in 3T3-L1 adipocytes, 2.1.6 and 2.3 Adipocyte cell collection)     
An RNeasy RNA extraction and purification kit was used to extract total RNA from 3T3-
L1 adipocytes (Qiagen GmbH, Hilden, Germany). RNA extraction procedures were 
carried out according to the methods outlined in Chapter 2 Materials and Methods 
(section 2.10.1. RNA extraction). 
 
Transcriptomic analysis was conducted by Cambridge Genomic Centre for Microarray 
Resources (Cambridge Genomic Services, Department of Pathology, University of 
Cambridge). An automated Illumina Infinium Gene Expression BeadArray (Illumina Inc, 
San Diego, CA) was used to perform mRNA transcriptional profiling.  A mouse WG6 
array platform was used with 45281 probes.  
 
Quality control was carried out using the arrayQualityMetrics R package and no samples 
failed or were identified as outliers to their replicates. Statistical selection was performed 
using the detection p-value provided by Illumina. This value represents the confidence 
that a given transcript is expressed above the background defined by the negative control 
probe.  The R package lumi was used for this analysis191 .  The detection p-value 
threshold was set to 0.01.  Probes were required to be successfully detected (p-value<0.01 
in lumi) in at least one sample to pass the selection. The data is transformed using 
variance stabilisation and then normalised using quantile normalisation192. Gene 
expression was compared between PPARδ agonist treated and control 3T3-L1 cells using 
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the R package limma193. The threshold utilised in this analysis was the 5% confidence 
interval with false discovery rate.  The selected and normalised data was then analysed 
using the multivariate statistics in the Simca-P+ package as has been described.  The 6% 
of transcripts most responsible for separation in the multivariate models were then 
examined (3% most increased and 3% most decreased in PPARδ agonist treated cells as 
identified in the multivariate models). 
 
The Reactome Skypainter tool (www.reactome.org) was used to determine which 
pathways were statistically significant in the 3% of genes most increased and most 
decreased in transcription in PPARδ agonist treated cells.  From a given set of genes 
known to participate in a pathway, the total genes for mus musculus and the submitted list 
of genes (the genes increased or decreased in expression in PPARδ activated cells) of 
which N genes participate in the given pathway, the probability of observing at least N 
genes from a pathway if that pathway is not overrepresented in the submitted list of genes 
is calculated using the one-tailed version of Fisher's exact test. Therefore a p-value 
smaller than or equal to the significance level suggests that the pathway is statistically 
significant in the submitted list of genes. 
 
4.3.18 Univariate Statistical Analysis Methodology 
Selected microarray transcriptomic data was analysed by univariate techniques.  
Univariate analysis was performed using an unpaired Student’s t-test with a significance 
level set to p<0.05.  An F-test was also utilised to compare the variance of two 
distributions. All univariate analysis was conducted in the GraphPad Prism package 
(version 4). 
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4.4 Results 
4.4.1 Metabolomic Analysis 
1H-NMR spectroscopy, GC-MS, LC-MS and DI-MS analysis, combined with 
multivariate pattern recognition were used to profile metabolism within the white adipose 
tissue of ob/ob mice and 3T3-L1 murine cultured adipocytes treated with a PPARδ 
agonist.  The different analytical techniques had varying sensitivities. High resolution 1H-
NMR spectroscopy detected ~15 metabolites in white adipose tissue and 25 identifiable 
metabolites in 3T3-L1 cells. GC-MS detected 100-150 defined peaks from aqueous phase 
samples in both cultured cells and tissue and 30-40 defined peaks from tissue organic 
phase samples and 60-70 metabolites from 3T3-L1 cells.  Matching the mass spectra 
detected with those held in the NIST library identified 40-60% metabolites for aqueous 
extracts and ~70% for lipids.  Phospholipid targeted UPLC-MS detected ~600 unique 
metabolite species in positive mode.  Identification of metabolite species was performed 
using MS/MS. 
 
To assess metabolic changes in the dataset a common processing strategy was adopted 
throughout the analysis. To investigate metabolite perturbations common to PPARδ 
activation PCA and PLS-DA models were built for both the white adipose tissue and the 
3T3-L1 adipocytes.  PCA and PLS-DA models were generated for the white adipose 
tissue and the cultured cells, comparing the control group with the PPARδ agonist treated 
groups.  Metabolites identified in the VIP/coefficients plots as significantly contributing 
to separation in the models were then considered to have changed globally.  The 
metabolite changes in the white adipose tissue and 3T3-L1 adipocytes are considered 
below. 
 
4.4.1.1 White adipose tissue  
The most robust multivariate model generated from the profiling of white adipose tissue 
was from the analysis of GC-MS FAME data (Figure 4.1A) where significant changes in 
fatty acid metabolism were detected.  The concentration of longer chain fatty acids 
(pentadecanoic acid and palmitic acid) was decreased with a concomitant increase in the 
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concentration of the shorter chain fatty acids (caprylic acid C8:0, capric acid C10:0, 
lauric acid C12:0 and myristic Acid C14:0).  Analysis of DI-MS negative mode 
ionisation data of the organic phase metabolites also generated robust multivariate 
models (Figure 4.1B), which indicated that the composition of the FFAs in the white 
adipose tissue of the ob/ob mice was altered upon PPARδ activation.  A decrease in the 
concentration of the saturated long chain fatty acids (nonadecanoic acid C19:0, arachidic 
acid C20:0, henicosanoic acid C21:0 and behenic acid C22:0) was detected alongside an 
increase in the concentrations of the ω-6 fatty acid pathway intermediates (γ-linolenic 
acid C18:3, dihomo-γ-linolenic acid C20:3 and arachidonic acid C20:4). The 
concentration of free stearic acid and palmitic acid also increased, as did the desaturation 
products C18:1 and C18:2. One problem with investigating metabolic changes in whole 
animals is that changes in tissue metabolism are also influenced by alterations in systemic 
metabolism across the animal. This is particularly true for a PPARδ agonist which will 
profoundly influence a number of tissues. Hence, to address these metabolic changes 
were investigated in a tissue specific cell culture system. 
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Figure 4.1: A. PLS-DA scores plot showing the clustering of GC-MS chromatograms 
from the organic fraction of the white adipose tissue from ob/ob mice 
treated with a PPARδ agonist compared with the control group. ●, PPARδ 
agonist treated, ■, control (R2=0.321, Q2=0.685). B. PLS-DA scores plot 
showing the clustering of DI-MS negative ionisation mode chromatograms 
from the organic phase of white adipose tissue extracts from ob/ob mice 
treated with a PPARδ agonist compared with control animals ●, PPARδ 
agonist treated, ■, control (R2=0.724, Q2=0.584). Two technical replicates 
were analysed. 
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4.4.1.2 3T3-L1 adipocytes  
Investigation of the effects of PPARδ activation on the metabolism of the 3T3-L1 
adipocyte tissue specific cell line within a cell culture system was conducted to generate 
an in vitro model of adipose tissue specific PPARδ activation.  Oil red O staining for 
neutral lipids in the differentiated cells prior to treatment with the PPARδ agonist 
demonstrated that there were comparable levels of differentiation in the treatment groups 
(Figure 4.2A).  Spectrophotometric measurement at 510 nm of eluted Oil Red O from 
stained cells post PPARδ agonist treatment determined that activation of PPARδ 
decreased the concentration of neutral lipid accumulated in the 3T3-L1 adipocytes 
(Figure 4.2B). 
 
Figure 4.2: A. Graph showing cell counts and the percentage of differentiating cells 
prior to treatment with PPARδ agonist. B. Spectrophotometric 
measurement at 510 nm of Oil Red O eluted from stained 3T3-L1 cells 
treated with DMSO control, 100 nM and 1 µM GW610742 PPARδ 
agonist. 
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Global analysis of the 3T3-L1 metabolic response to PPARδ activation using the 
analytical platforms of GC-MS, LC-MS, DI-MS and 1H-NMR spectroscopy and 
multivariate pattern recognition implicated a number of key pathways as being altered 
(Figure 4.3).  A decrease in the concentration of a range of sugars including galactose, 
maltose and glucose and polyol pathway intermediates, glucitol and fructose was detected 
alongside an increase in the concentration of the TCA cycle intermediate isocitrate and 
glutamate, which is readily converted to 2-oxoglutarate. Also increased were the 
concentrations of the glucuronate and pentose interconversion pathway intermediates D-
glucuronate-1-phosphate, myo-inositol and arabitol. 
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Figure 4.3: A. PLS-DA scores plot showing the clustering of GC-MS chromatograms 
from the organic fraction of 3T3-L1 adipocytes treated with 1 µM PPARδ 
agonist GW610742 compared with the control group. ◊, 1 µM PPARδ 
agonist dose, ■, control (R2=0.82, Q2=0.815). B. PLS-DA scores plot 
showing the clustering of GC-MS chromatograms from the aqueous 
fraction of 3T3-L1 adipocytes treated with 100 nM and 1 µM PPARδ 
agonist GW610742 compared with the control group. ◊, 1 µM PPARδ 
agonist dose,  ●, 100 nM PPARδ agonist dose, ■, control (R2=0.771, 
Q2=0.746). C. PLS-DA scores plot showing the clustering of 1H-NMR 
spectra from the aqueous fraction of 3T3-L1 adipocytes treated with 1 µM 
PPARδ agonist GW610742 compared with the control group. ◊, 1 µM 
PPARδ agonist dose, ■, control (R2=0.871, Q2=0.845). D. PLS-DA scores 
plot showing the clustering of DI-MS negative mode ionisation 
chromatograms from the organic fraction of 3T3-L1 adipocytes treated 
with 100 nM and 1 µM PPARδ agonist GW610742 compared with the 
control group. ◊, 1 µM PPARδ agonist dose, ●, 100 nM PPARδ agonist 
dose, ■, control (R2=0.696, Q2=0.853). Three technical replicates were 
analysed for DI-MS.  
 
The high energy phosphate buffering capacity of the adipocytes was altered by PPARδ 
activation with a detected increase in the concentrations of both creatine and creatinine.  
Chapter 4 
 
 129 
The essential fatty acid metabolism of the 3T3-L1 adipocytes was significantly affected 
by PPARδ activation.  The concentration of the ω-6 fatty acid pathway intermediates and 
end products (dihomo-γ-linoleic acid C20:3, arachidonic acid C20:4 and docosatetraenoic 
acid C22:4) were increased as were the intermediates and end products of the ω-3 fatty 
acid pathway (eicosapentaenoic acid C20:5, docosapentaenoic acid C22:5 and 
docosahexaenoic acid C22:6).   
 
The fatty acid oxidation/synthesis pathways were also altered by PPARδ activation.  A 
range of fatty acids (undecanoic acid C11:0, tridecanoic acid C13:0, myristic acid C14:0, 
myristoleaic acid C14:1, 12-methyl myristic acid 12-methyl C14:0, pentadecanoic acid 
C15:0, pentadecenoic acid C15:1, palmitic acid C16:0, 14-methyl palmitic acid 14-
methyl C16:0, palmitoleic acid C16:1, ethyl-9-palmitoleic acid ethyl-9-C16:1, margaric 
acid C17:0, heptadecenoic acid C17:1 and Oleate C18:1) were all identified as decreased 
in concentration with a concomitant increase in the concentration of the peroxisomal 
oxidation product, adipic acid.  
 
Changes in the composition of complex lipids was observed in the PPARδ activated 3T3-
L1 adipocytes.  An increase in the concentration of a number of glycerophosphocholine 
(GPCho) species was ascertained (C34:1 GPCho, C32:0 16:0/16:0 GPCho, C36:1 
GPCho, C34:1 GPCho, C36:2 GPCho, C36:3 GPCho, C35:5 GPCho, C34:0 GPCho). 
There was also a decrease in the concentration of specific TAGs (TAG 
C18:3/C17:0/C19:0), TAG C18:1/C17:1/C19:1, TAG C20:1/C17:1/C17:1, TAG 
C20:1/C15:0:C19:2, TAG C20:1/C15:1/C19:1, TAG C52:1, TAG C53:2, TAG C52:5, 
TAG C52:6). 
 
4.4.2 
13
C-labelled Substrate Studies 
In order to identify the metabolic mechanisms associated with PPARδ activation in 3T3-
L1 adipocytes the 13C-labelled substrates 1-13C glucose and U-13C-palmitate were used to 
monitor flux through glycolytic and fatty acid oxidative pathways. 
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4.4.2.1 1-
13
C-glucose  
Analysis by HSQC-NMR spectroscopy of the organic fraction of control and PPARδ 
agonist treated adipocytes incubated in media containing 1-13C glucose showed that 
glycerol and esterified glycerol from PPARδ treated cells had reduced enrichment 
compared with the control group (Figure 4.4).  Examination of the aqueous phase by 
GC-MS revealed that lactate, glutamate (readily labelled from the TCA cycle from 
labelled 2-oxoglutarate) and succinate from PPARδ agonist treated cells were enriched 
with 13C when compared to control (Figure 4.5).  GC-MS investigation of the organic 
fraction showed that palmitic acid from control adipocytes incubated in 1-13C glucose had 
a greater concentration of 13C enrichment than that of PPARδ agonist treated cells. 
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Figure 4.4: A. A graph of the average integrated area of the 2D-HSQC-NMR organic 
fraction glycerol peak (13C Chemical shift 62.04) from control and 1 µM 
PPARδ agonist treated 3T3-L1 adipocytes incubated in 1-13C-glucose. B. 
A graph of the average integrated area of the 2D-HSQC-NMR organic 
fraction glycerol peak (13C Chemical shift 62.17) from control and 1 µM 
PPARδ agonist treated 3T3-L1 adipocytes incubated in 1-13C-glucose. C. 
A graph of the average integrated area of the 2D-HSQC-NMR organic 
fraction esterified glycerol peak from control and 1 µM PPARδ agonist 
treated 3T3-L1 adipocytes incubated in 1-13C-glucose. *P < 0.05, ***P < 
0.005. Parent ions were used to calculate ion ratio. 
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Figure 4.5: A. Graphs showing the M+1/M isotope ratio 13C enrichment of lactate, 
glutamate and succinate analysed by GC-MS of the aqueous fraction from 
control and PPARδ agonist dosed 3T3-L1 cells incubated with 1-13C-
glucose. *P < 0.05, **P < 0.01. The metabolites have been mapped to the 
glycolysis and TCA cycle metabolic pathways. ↑ indicates a metabolite 
increased in 13C enrichment by PPARδ activation. B. Graph showing the 
M+1/M isotope ratio 13C enrichment of palmitic acid analysed by GC-MS 
of the organic fraction from control and PPARδ agonist dosed 3T3-L1 
cells incubated with 1-13C-glucose. *P < 0.05. Parent ions were used to 
calculate ion ratio. 
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4.4.2.2 U-
13
C-palmitate   
Assessment of the aqueous phase by GC-MS indicated that the TCA cycle intermediates 
malate, fumarate, succinate and glutamate from PPARδ agonist treated adipocytes were 
enriched compared to control cells (Figure 4.6A).  Investigation of the organic phase by 
GC-MS demonstrated that the fatty acids downstream of palmitic acid in the β-oxidation 
pathway, myristic acid and lauric acid, showed greater 13C enrichment in PPARδ agonist 
treated cells; as did palmitoleic acid, the ∆-9 desaturation product of palmitic acid.  
Simultaneously the enrichment of stearic acid and arachidic acid, which are upstream of 
palmitic acid in the fatty acid synthesis pathway, was reduced in PPARδ agonist treated 
cells (Figure 4.6B). 
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Figure 4.6: A. Graphs showing the M+1/M isotope ratio 13C enrichment of malate, 
glutamate, fumarate and succinate analysed by GC-MS of the aqueous 
fraction from control and PPARδ agonist dosed 3T3-L1 cells incubated 
with U-13C-palmitate. *P < 0.05, **P < 0.01,***P < 0.005. The 
metabolites have been mapped to the TCA cycle metabolic pathway. ↑ 
indicates a metabolite increased in 13C enrichment by PPARδ activation. 
B. Graphs showing the isotope ratio 13C enrichment of arachidic acid, 
stearic acid, palmitoleic acid, myristic acid and lauric acid analysed by 
GC-MS of the organic fraction from control and PPARδ agonist dosed 
3T3-L1 cells incubated with U-13C-palmitate. *P < 0.05, **P < 0.01. The 
metabolites have been mapped to the fatty acid synthesis/β-oxidation 
pathway. ↑ indicates a metabolite increased, and ↓ indicates a metabolite 
decreased in 13C enrichment by PPARδ activation. Parent ions were used 
to calculate ion ratio. 
Chapter 4 
 
 135 
4.4.3 Respirometric Analysis  
Following the identification of increased flux through the glycolytic, TCA cycle and β-
oxidation metabolic pathways in 3T3-L1 adipocytes treated with PPARδ agonist, 
respirometric analysis was conducted to investigate the influence of PPARδ activation on 
the rate of oxygen consumption of the cells.  The oxygen consumption of PPARδ agonist 
treated and control 3T3-L1 cells was measured both when using fatty acid as substrate 
and isolated electron transport chain complex IV oxidation using in situ studies in a 
Clarke type oxygen electrode.  Both complex IV and fatty acid oxidation were 
significantly increased in the adipocytes exposed to the PPARδ agonist when compared 
to control adipocytes (Figure 4.7A and Figure 4.7B). 
 
Figure 4.7: A. Graph showing the respiratory rates of in situ permeabilised control and 
PPARδ agonist treated 3T3-L1 cells performing β-oxidation using 
palmitoyl-carnitine measured using a Clark-type oxygen electrode. *P = 
0.05. B. Graph showing the respiratory rates of the electron transport chain 
complex IV of in situ permeabilised control and PPARδ agonist treated 
3T3-L1 cells measured using a Clark-type oxygen electrode. *P < 0.05. 
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4.4.4 Microarray Transcriptomic Analysis   
The combination of steady state metabolomic changes in adipose tissue and adipocytes 
and isotope labelling studies indicated a profound upregulation of β-oxidation following 
PPARδ activation. These changes were investigated in further detail by scrutinising the 
transcriptome using microarray analysis of PPARδ activation in adipocytes. Of the 45281 
probes utilised 13718 were expressed above the background defined by the negative 
control probe.  From these 2349 were determined to be differentially expressed (P < 0.05) 
between PPARδ agonist treated and control 3T3-L1 adipocytes, with 117 estimated false 
positives using a threshold of 5% of differentially expressed probes.  Multivariate models 
were built using the normalised data from the 13718 transcripts measured (Figure 4.8).   
 
Figure 4.8:  PLS-DA scores plot showing the clustering of gene transcription in control 
and PPARδ agonist treated 3T3-L1 adipocytes as measured with 
microarray analysis. ●, PPARδ agonist treated, ■, control (R2=0.35, 
Q2=0.9). 
 
The 6% of transcripts most responsible for separation in the multivariate models were 
then examined (3% most increased and 3% most decreased in PPARδ agonist treated 
cells as identified in the multivariate models).  The multivariate analysis indicated that 
the mRNA of genes involved in a number of key metabolic pathways was altered 
following PPARδ activation.  The reactome skypainter tool was then utilised to 
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determine which pathways and reactions were statistically overrepresented by the 3% 
most increased (Table 4.1) and 3% most decreased transcripts in PPARδ agonist treated 
cells identified in the multivariate models. 
P-value Pathway 
Transcripts increased in PPARδ agonist treated cells 
mapping to the pathway 
6.3e-08 Glucose regulation of insulin secretion 
Cycs, Etfa, Mdh2, Aldoa, Dld, Ndufb10, Ndufb9, Atp5a1, Ndufb5, Gpi1, 
Tpi1, Pgk1, mt-Co2, Sdhb, Sdhd, mt-Atp6, Cox7b, Ndufb2 
1.3e-06 Integration of energy metabolism 
Cycs, Etfa, Mdh2, Aldoa, Dld, Ndufb10, Ndufb9, Atp5a1, Cpt2, Ndufb5, 
Gpi1, Tpi1, Pgk1, mt-Co2, Sdhb, Sdhd, mt-Atp6, Cox7b, Ndufb2 
1.3e-06 Diabetes pathways 
Hspa8, Cycs, Wdr89, Etfa, Mdh2, Aldoa, Dld, Ndufb10, Myo5a, Ndufb9, 
Atp5a1, Rps21, Rps3a, Sec11c, Ndufb5, Gpi1, Tpi1, Pgk1, Sdhb, mt-Co2, 
Dnajb9, Sdhd, mt-Atp6, Cox7b, 2900062L11Rik, Ndufb2 
8.5e-06 Electron transport chain 
Cycs, Ndufb5, Etfa, mt-Co2, Ndufb10, Sdhb, Sdhd, Ndufb9, Cox7b, 
Ndufb2 
3.4e-05 
H2AX in recruitment of repair factors for DNA 
damage and double strand breaks  
Hist1h2ah, Hist2h2ac, Hist1h2ao, Hist1h2af 
7.1e-04 Citric acid cycle (TCA cycle) Dld, Sdhb, Sdhd, Mdh2 
1.4e-03 
Mitochondrial fatty acid β-oxidation of 
saturated and unsaturated fatty acids 
Hadhb, Acadl, Acadvl 
1.6e-03 Glycolysis Aldoa, Tpi1, Pgk1, Gpi1 
1.7e-03 G1/S DNA damage checkpoints Cdc25a, Rfwd2, Psmd12, Cdk2, Psmd14, Psmd11 
2.1e-03 Gluconeogenesis Aldoa, Tpi1, Pgk1, Mdh2, Gpi1 
3.2e-03 
Transfer of electrons through the succinate 
dehydrogenase complex 
Sdhb, Sdhd 
4.3e-03 Glucose metabolism Pgm2, Aldoa, Tpi1, Pgk1, Dld, Mdh2, Gpi1 
4.5e-03 Metabolism of lipids and lipoproteins 
Agpat3, Hadhb, Ppp1cc, Slc27a1, Lass2, Angptl4, Cpt2, Akr1b3, Abcd3, 
Acadl, Sgpl1, Acaa2, Acadvl, Mod1, Hmgcs2, Adfp 
5.3e-03 Metabolism of carbohydrates Prps2, Mdh2, Gpi1, Aldoa, Pgm2, Pgk1, Tpi1, Dld 
7.8e-03 
Cdc25A mediated dephosphorylation of Cyclin 
A:phospho-Cdk2 
Cdc25a, Cdk2 
7.8e-03 Cleavage of the signal peptide of preproghrelin Sec11c, 2900062L11Rik 
7.8e-03 Notch 1 traffic and signalling Notch1, Fbn1 
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7.8e-03 
PEX-19 docks ABCD1/ABCD3 to peroximal 
membrane 
Abcd3, Pex19 
7.8e-03 
Formation of acetoacetic acid in synthesis of 
ketone bodies 
Hmgcs2, Acaa2 
1.1e-02 
Dephosphorylation of Cyclin:phospho-Cdc 
complexes in cell cycle regulation 
Cdc25a, Cdk2 
1.5e-02 
Activation of the mRNA upon binding of the 
cap-binding complex and eIFs, and subsequent 
binding to 43S 
Rps3a, Eif4b, Pabpc1, Eif4ebp1, Rps21 
1.8e-02 
Cyclin:Cdk-associated events at G1/S phase 
DNA damage checkpoint transition in the cell 
cycle 
Cdc25a, Psmd12, Cdk2, Psmd14, Psmd11 
2.0e-02 Proteasome mediated degradation of COP1 Rfwd2, Psmd12, Psmd14, Psmd11 
2.0e-02 DARPP-32 events Ppp1cc, Cdk2, Pde1b 
2.2e-02 
Synthesis of deoxyribonucleoside 5'-
diphosphates from ribonucleoside 5'-
diphosphates 
Glrx2, Txn1 
3.2e-02 Additional cell cycle checkpoints Cdc25a, Cdc20, Rfwd2, Psmd12, Cdk2, Psmd14, Psmd11 
Table 4.1: Table of the pathways and reactions statistically significant in the 3% most 
increased transcripts in PPARδ agonist treated cells identified in the 
multivariate models. From a given set of genes known to participate in a 
pathway, the total genes for mus musculus and the submitted list of genes 
(the genes increased in PPARδ activated cells) of which N genes 
participate in the given pathway, the probability of observing at least N 
genes from a pathway if that pathway is not overrepresented in the 
submitted list of genes is calculated using the one-tailed version of Fisher's 
exact test.  A p-value smaller than or equal to the significance level 
suggests that the pathway is significantly represented.  The genes 
increased in expression and contributing to each pathway are shown. 
 
Key pathways of homeostatic regulation identified as statistically affected from the 
transcripts increased in expression by PPARδ activation as can be seen in table 1 include 
regulation of insulin secretion, integration of energy metabolism and pathways implicated 
in diabetes.  Specific metabolic pathways and reactions were also influenced by PPARδ 
activation. 
 
The expression of genes coding proteins involved in the mitochondrial β-oxidation 
pathway was increased.  Transcription of several of the core enzymes including carnitine 
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palmitoyltransferase II, very long chain acyl-Coenzyme A dehydrogenase, long chain 
acyl-Coenzyme A dehydrogenase, hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-Coenzyme A hydratase trifunctional enzyme and acetyl-CoA 
acyltransferases 2 were increased in PPARδ agonist treated cells.  An increase in the 
expression of a number of genes functioning in peroxisomal fatty acid β-oxidation was 
also detected and includes peroxisomal D3,D2-enoyl-CoA isomerase, peroxisomal enoyl 
Coenzyme A hydratase 1 and ATP-binding cassette, sub-family D, member 3.  Alongside 
these changes were an increase in the transcription of genes involved in both 
mitochondrial and peroxisomal biogenesis and maintenance (mitochondrial specific 
Single stranded DNA binding protein 1, mitochondrial ribosomal proteins S6 and S12 
and peroxisomal biogenesis factors 14 and 19). 
 
The transcription of several genes whose products play a role in the glycolytic metabolic 
pathway was also upregulated in PPARδ agonist treated cells. Affected transcripts 
include those for phosphoglucomutase 2, glucose phosphate isomerise 1, aldolase A, 
fructose-bisphosphate and phosphoglycerate kinase 1.  The expression of genes encoding 
enzymes responsible for the catalysis of the reactions of the TCA cycle, malate 
dehydrogenase, components of the succinate dehydrogenase complex and 
dihydrolipoamide dehydrogenase, was also upregulated.   
 
There was a detected increase in the expressed mRNA concentrations of components of 
the electron transport chain. Amongst the increased transcripts were NADH 
dehydrogenase and several of its accessory subunits, cytochrome c, cytochrome c oxidase 
II and ATP synthase. 
 
The metabolomic data indicated that the ∆-9 desaturation of fatty acids was a key point in 
the PPARδ regulated processing of fatty acids.  However, the transcripts coding for the 
fatty acid desaturase 3 and the stearoyl-CoA desaturase, enzymes responsible for the 
desaturation of fatty acids were not found in the 3% most increased transcripts from 
PPARδ agonist treated cells.  Therefore the normalised data for these transcripts was 
selected for univariate statistical analysis.  Using an unpaired Student’s t-test with a 
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significance level set to p<0.05 and an F-test, utilised to compare the variance of two 
distributions, the transcription of both fatty acid desaturase 3 and stearoyl-CoA 
desaturase was found to be significantly increased in PPARδ agonist treated adipocytes 
(Figure 4.9). 
 
Figure 4.9 Graphs of the microarray normalised data for the transcripts of A. fatty 
acid desaturase 3 and B. stearoyl-CoA desaturase 2 in control and PPARδ 
agonist treated 3T3-L1 adipocytes analysed using an unpaired Student’s t-
test. The transcription of both fatty acid desaturase 3 and stearoyl-CoA 
desaturase was found to be significantly increased in PPARδ agonist 
treated adipocytes. *P < 0.05, **P < 0.01. 
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4.5 Discussion 
 
A comprehensive array of analytical techniques were used in a metabolomic investigation 
to study the metabolic changes occurring in white adipose tissue from ob/ob mice 
following PPARδ activation and to understand the role of PPARδ in treating the 
combined effects of type II diabetes and obesity.  Experimentation was then progressed 
into a tissue specific cell line (3T3-L1 adipocytes) within a cell culture system to generate 
an in vitro model of PPARδ activation in adipose tissue, and in particular to investigate 
the upregulation of fatty acid oxidation in isolation from changes induced by PPARδ 
activation in other tissues, and systemic metabolism as a whole.  However, steady state 
metabolite concentrations cannot fully define changes in flux. To elucidate the metabolic 
mechanisms responsible for the observed changes in metabolite concentrations, within 
adipose tissue, a 13C stable isotope substrate labelling study, respirometric study and 
transcriptomic microarray study were employed. 
 
PPARδ activation in white adipose tissue generated changes in the fatty acid composition 
whereby there was a decrease in the concentration of the longer chain fatty acids and a 
concomitant increase in the shorter chain fatty acids.  The detected alterations in the 
constituent fatty acids were indicative of an increase in fatty acid β-oxidation resulting 
from PPARδ activation.  When examining PPARδ activation in the 3T3-L1 adipocyte 
cell line it was again found that there was a decrease in the concentration of a range of 
fatty acids alongside an increase in the concentration of TCA cycle intermediates and 
adipic acid, the main end product of peroxisomal β-oxidation220.   
 
The mechanism by which PPARδ activation brought about the alterations in fatty acid 
composition was confirmed using U-13C-palmitate and 1-13C-glucose.  The U-13C-
palmitate labelling study established that PPARδ activation resulted in an increase in flux 
through the β-oxidation pathway, as 13C-enrichment was increased in shorter chain fatty 
acids from PPARδ treated adipocytes, found downstream of palmitate in the β-oxidation 
pathway, relative to the control group.  The 13C-enrichment of TCA cycle intermediates 
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was increased in adipocytes incubated in U-13C-palmitate and treated with the PPARδ 
agonist relative to the enrichment in the control adipocytes, confirming increased 
oxidative breakdown of fatty acids.  Concomitantly the fatty acid synthesis pathway was 
confirmed as downregulated; longer chain fatty acids found upstream in the synthesis 
pathway showed decreased 13C-enrichment in 3T3-L1 adipocytes incubated in labelled 
palmitate and treated with the PPARδ agonist compared with the control group. A result 
reciprocated by the decreased 13C-enrichment detected in palmitate from cells incubated 
with 1-13C-glucose and treated with the PPAR agonist when compared to control 
adipocytes.  This conclusion was supported by the respirometric data which confirmed 
that adipocytes treated with PPARδ had a higher oxidative rate when using fatty acids as 
a fuel source.  Transcriptomic analysis supported the findings from the metabolic studies 
with identified increases in the transcription of genes involved in fatty acid mitochondrial 
and peroxisomal β-oxidation including carnitine palmitoyltransferase II, very long chain 
acyl-Coenzyme A dehydrogenase, long chain acyl-Coenzyme A dehydrogenase, 
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase trifunctional enzyme, acetyl-CoA acyltransferases 2, D3,D2-
enoyl-CoA isomerase, peroxisomal enoyl Coenzyme A hydratase 1 and ATP-binding 
cassette, sub-family D, member 3).   
 
A further key finding was that PPARδ activation lead to an increase in the oxidation of 
glucose. The metabolomic studies demonstrated that upon PPARδ activation the steady 
state concentration of several sugars, including glucose was decreased and accompanied 
by an increase in several TCA cycle intermediates.  An increase in the catabolism of 
glucose resulting from PPARδ activation was confirmed using 1-13C-glucose with the 
observation that the enrichment of lactate, succinate and glutamate in cells treated with 
PPARδ agonist was greater than that of control adipocytes. Transcriptomic analysis 
substantiated this finding with the identification that the expression of genes with roles in 
glycolysis and the TCA cycle was significantly increased upon PPARδ activation.  Genes 
affected include those for phosphoglucomutase 2, glucose phosphate isomerise 1, 
aldolase A, fructose-bisphosphate, phosphoglycerate kinase 1, malate dehydrogenase, 
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components of the succinate dehydrogenase complex and dihydrolipoamide 
dehydrogenase.   
 
Additional evidence for an increase in global oxidative metabolism, over a view of 
exclusive fatty acid oxidation, comes from the respirometric studies, in which it was 
ascertained that independently of fatty acid oxidation the oxidative rate of electron 
transport chain complex IV was increased with PPARδ activation.  An increase in global 
oxidation resulting from PPARδ activation is supported by transcriptomic analysis which 
shows that the receptor is responsible for increases in mitochondrial biogenesis and 
expression of key electron transport chain components such as cytochrome c, cytochrome 
c oxidase, complex II and ATP synthase. 
 
Supporting the evidence for increased global oxidative metabolism is the finding that 
PPARδ activation increased the concentration of creatine and creatinine within the 3T3-
L1 adipocytes and so altered the high energy phosphate buffering capacity of the cells.  
These findings are consistent with previously reported observations in skeletal muscle.  A 
decrease in the intramyocellular lipid-to-total creatine ratio in the soleus and tibialis 
anterior muscles from Sprague-Dawley rats treated with selective PPARδ agonist 
GW610742 has been discerned using in vivo 1H-MRS221.  In addition an increase in the 
concentration of creatine and phosphocreatine was detected in the gastrocnemius of ob/ob 
mice following pharmacological activation of PPARδ222.    
 
The ω-6 essential fatty pathway and both the ω-3 and ω-6 essential fatty acid pathways 
were upregulated in PPARδ agonist treated ob/ob mice white adipose tissue and 3T3-L1 
adipocytes, respectively.  The ∆ 6-desaturase is integral to both pathways; the enzyme 
introduces the initial double bond to linoleate forming γ-linolenate in the  ω-6 pathway 
and introduces the double bond to linolenate forming stearidonic acid.  The ∆ 6-
desaturase gene is known to contain a PPRE and is under PPAR transcriptional control223 
and therefore appears to be the point of PPARδ transcriptional control within the 
essential fatty acid pathways. 
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Using U-13C-palmitate it was shown that when PPARδ is activated in 3T3-L1 adipocytes 
the enrichment of palmitoleate is increased relative to control and therefore desaturation 
of palmitate to palmitoleate is increased.  Stearoyl-CoA desaturase, the enzyme 
responsible for the ∆-9 desaturation of saturated fatty acids to the monounsaturated form, 
is known to be under PPAR expressional control224. Univariate analysis of the normalised 
microarray data for stearoyl-CoA desaturase and fatty acid desaturase 3, an additional 
enzyme responsible for the ∆-9 desaturation of fatty acids, demonstrated that the 
expression of these enzymes was increased in the PPARδ agonist treated adipocytes. 
 
A decrease in the concentration of a number of TAGs was observed in the 3T3-L1 
adipocytes. Within white adipose tissue a number of FFAs, such as palmitic acid, were 
increased in concentration despite their total concentration within the tissue decreasing.  
These metabolic alterations are complicit with previously observed changes indicating 
that PPARδ activation in white adipose tissue results in an increase in lipolysis in the 
tissue225.  The results are corroborated by our observation, made using HSQC-NMR, that 
there was a decrease in the enrichment of glycerol in adipocytes incubated with 1-13C-
glucose and treated with PPARδ agonist when compared to control cells; indicating 
reduced synthesis of glycerol from glucose on activation of PPARδ. This, in part, could 
also explain the decrease in the concentration of TAGs due to reduced synthesis.  It is 
reasonable to conclude that PPARδ activation leads to a mobilisation of lipid stores and 
concomitant decrease in the synthesis of the complex lipids such as TAGs required for 
fatty acid storage.       
 
It is worthy of note that the concentrations of several metabolites in the polyol pathway 
were decreased in concentration following PPARδ activation; a finding likely to be more 
attributable to increased glucose catabolism than direct control of the pathway by the 
receptor.  However, given the role that the polyol pathway and aldose reductase have in 
the formation of toxic advance glycation end-products and resultant diabetic 
complications such as neuropathy, nephropathy and retinopathy, a decrease in the activity 
of this pathway may prove a significant anti-diabetic effect of PPARδ activation226. 
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The increased concentrations of the glucuronate and pentose phosphate pathway 
intermediates can be explained by previous studies which demonstrate that PPARδ 
increases glucose flux through the pentose phosphate pathway contributing to the nuclear 
receptors ability to ameliorate hyperglycaemia; it has been suggested that the 
glyceraldehyde-3-phosphate, formed from the 5-carbon sugar phosphates during the 
pentose phosphate shunt, can then enter glycolysis227. 
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4.6 Conclusions 
 
To summarise, it has been shown that the anti-diabetic and anti-obesity effects of PPARδ 
activation are brought about, in part, by a decrease in fatty acid synthesis and fat storage 
within synthesised TAG depots and a concomitant mobilisation of complex lipid fat 
stores.  The mobilisation of lipid energy stores is accompanied by upregulation of not 
only fatty acid oxidation but also by carbohydrate oxidative metabolism in white adipose 
tissue, a tissue not traditionally thought of as being energetic and oxidative.  Essential to 
this process is the integration and co-ordination of the energy metabolism pathways, 
which PPARδ accomplishes by upregulating the transcription of a series of genes 
involved in glycolysis, the TCA cycle, the electron transport chain and fatty acyl β-
oxidation (Figure 4.10) (Table 4.1).  
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Figure 4.10: Diagram showing the effect of PPARδ activation on the integration of the 
energy metabolism pathways of 3T3-L1 adipocytes based on the 
combination of results from the metabolomic, transcriptomic and stable 
isotope labelling studies.  Red indicates an increase in concentration or 
expression in cells treated with the GW610742 PPARδ selective agonist. 
Blue indicates a decrease in concentration in cells treated with the 
GW610742 PPARδ selective agonist. 
 
In conclusion PPARδ activation in white adipose tissue does not exclusively stimulate 
either fatty acid oxidation or carbohydrate oxidation but rather global oxidative 
metabolism; activation of the nuclear receptor burns fatty acids by stoking the 
carbohydrate fire. 
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Tissue Specific PPARγ Activation Sequesters Glucose and 
Lipid into the White Adipose Tissue Storage Depot 
 
 
5.1 Introduction 
 
PPARγ is a ligand activated transcription factor belonging to the PPAR nuclear receptor 
family.  Upon binding its ligand the receptor heterodimerises with the RXR and binds to 
specific sequences in target genes known as PPRE135.  Once bound to ligand the PPARs 
undergo a conformational change, facilitating the release of corepressors and allowing the 
binding of transcriptional coactivators228.   The receptor exists in two distinct protein 
isoforms, PPARγ1 and PPARγ2, which exhibit specific tissue expression patterns
229.  
PPARγ1 is found almost ubiquitously whereas the PPARγ2 isoform is definitively 
expressed in adipose tissue230. 
 
White adipose tissue is vital to the control of energy metabolism and global lipid 
homeostasis.  PPARγ plays an essential role within adipose tissue, where it is the master 
regulator of adipogenesis and key to mature adipocyte survival158, 159.  The receptor is 
also a crucial regulator of lipid metabolism in mature adipocytes.  Activation of PPARγ 
regulates expression of several lipid metabolism genes including oxidized LDL receptor 
1, lipoprotein lipase, the glycerol transporter aquaporin 7, phosphoenolpyruvate 
carboxykinase and fatty-acid transport protein231, 232, 233, 234.  Upregulation of these genes 
results in an increase in the uptake of circulating fatty acids and consequentially an 
enhancement of adipocyte lipid storage.  PPARγ activation also inhibits lipolysis235, 
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upregulates the expression of GLUT4 glucose transporter mRNA levels and increases 
glucose uptake in adipocytes236. 
 
Despite its role in adipose tissue formation, PPARγ is also a target for insulin sensitising 
drugs for the treatment of TIIDM164.  The TZD class of compounds are PPARγ ligands 
currently available in the clinic that bring about insulin sensitisation163.  Nevertheless, the 
use of TZDs for the treatment of TIIDM has not been without controversy.  In 2007 
meta-analyses of two TZDs, rosiglitazone and pioglitazone were published, suggesting 
that both drugs were associated with increased risk of heart failure (rosiglitazone 109% 
increase P < 0.001, pioglitazone 41% increase P = 0.02)237, 238.   Although rosiglitazone 
was not found to increase cardiovascular mortality and pioglitazone was shown to reduce 
the risk of myocardial infarction, stroke and death in TIIDM patients.  The world wide 
sales for the TZDs were significantly affected by these findings with the revenue 
generated by rosiglitazone dropping from $3.2 billion in 2006 to $1.49 billion in 2008.  
Pioglitazone sales were more stable and in 2008 generated $2.4 billion world wide. In 
spite of the contention over the use of TZDs they continue to share a substantial amount 
of the anti-diabetic drug market.     
 
The insulin sensitising mode of action of PPARγ activation is thought to be a result of the 
fatty acid sequestration into TAGs and storage in adipocytes; lowering plasma FFA 
concentrations239 and partitioning the lipids away from other peripheral tissues, such as 
skeletal muscle, where their accumulation is deleterious and may cause lipotoxicity240.  
However, other plasma lipid concentration lowering drugs do not share this insulin 
sensitising effect, suggesting additional mechanisms are at play. 
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5.2 Aims and Objectives 
 
With the aim of identifying metabolic effects of PPARγ activation in adipose tissue that 
may be contributing to the nuclear receptor’s anti-diabetic potential a metabolomics study 
using both in vivo analysis in the ob/ob mouse and in vitro analysis using the murine 3T3-
L1 adipocyte cell line has been performed.  A synthetic, high affinity, non-TZD, PPARγ 
agonist, GW347845, was used to activate the nuclear receptor in both the mice and the 
adipocyte cell line.  To increase the coverage of the metabolome a combination of 
multiple analytical techniques was used.  GC-MS, 1H-NMR, LC-MS and DI-MS in 
conjunction with multivariate statistics were employed to probe the metabolic phenotype 
of PPARγ activated adipose tissue.  Mechanistic analysis was then performed with 13C-
stable isotope substrate labelling studies, using 1-13C-glucose and U-13C-palmitate, and 
transcriptomic microarray analysis to explicitly define the pathways, as identified in the 
metabolomic analysis, by which PPARγ activation alters the metabolism of adipose 
tissue. 
 
It was discovered that PPARγ activation in white adipose tissue not only resulted in the 
increased uptake, elongation and sequestration of circulating fatty acids into TAG pools 
and a decrease in fatty acid breakdown by β-oxidation but also an increase in de novo 
fatty acid synthesis directly from glucose.  In addition PPARγ activation is implicated in 
the augmentation of calcium cellular signalling; a signalling pathway associated with 
insulin signalling and downstream metabolic effects.  Providing additional mechanisms 
for the observed normalisation of blood glucose and dyslipidaemia in both human 
patients and murine subjects with the metabolic syndrome and TIIDM when treated with 
PPARγ agonists.  
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5.3 Materials and Methods 
 
5.3.1 Ob/Ob Mouse Study Tissue Collection and Extraction 
Animals were kept as is outlined in Chapter 2 Materials and Methods (section 2.2.1. 
Animal handling).  Briefly, the ob/ob mice were dosed orally daily at 8 am with 0.5% 
Hydroxypropylmethylcellulose/0.1% Tween80 vehicle control (n=8) or a PPARγ agonist, 
GW347845 (n=8 at 5 mg/kg).  Injection volume was adjusted daily according to body 
weight at 10 ml/kg.  White adipose tissue was collected as summarised in Chapter 2 
Materials and Methods (section 2.2.4. Tissue handling). 
 
5.3.2 3T3-L1 Cell Culture 
3T3-L1 preadipocytes were grown and differentiated as described in Chapter 2 
Materials and Methods (section 2.1.1 3T3-L1 cell culture and adipocyte 
differentiation).   
 
5.3.3 3T3-L1 PPARγ Activation 
3T3-L1 adipocytes were treated with the selective PPARγ agonist GW347845 as is 
outlined in Chapter 2 Materials and Methods (2.1.4. Activation of PPARγ in 3T3-L1 
adipocytes). Briefly, adipocytes were treated with either DMSO (control n=6; T75 flasks) 
or GW347845 PPARγ selective agonist (n=6; T75 flasks at 10 nM and 100 nM) for 2 
days. 
 
5.3.4. Oil Red O Staining and Intracytoplasmic Lipid Accumulation 
Three additional T75 flasks of 3T3-L1 adipocytes were grown per control, 10 nM and 
100 nM treatment groups. Three flasks per group were stained prior to PPARγ agonist 
treatment to assess levels of differentiation.  The cells were stained and the 
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intracytoplasmic lipid accumulation assessed as in Chapter 2 Materials and Methods 
(section 2.1.5 Oil Red O staining and intracytoplasmic lipid accumulation). 
 
5.3.5 3T3-L1 Cell Collection  
The cells were collected and their metabolites extracted as described in Chapter 2 
Materials and Methods (sections 2.1.6 and 2.3 Adipocyte cell collection).  
 
5.3.6 Tissue and 3T3-L1 Metabolite Extraction  
Metabolites were extracted from white adipose tissue and 3T3-L1 cells using the 
modified Bligh and Dyer method187.  The details are as in Chapter 2 Materials and 
Methods (section 2.3 3T3-L1 Cell, Primary Adipocyte and Tissue Metabolite Extraction). 
 
5.3.7 
1
H-NMR Spectroscopy  
All samples were analysed using a Bruker AVANCE II+ spectrometer operating at 
500.13 MHz for the 1H frequency using a 5 mm Broadband TXI Inverse ATMA probe.  
All procedures are as depicted in Chapter 2 Materials and Methods (sections 2.6.1. 
Spectrometer, 2.6.2. Sample preparation, 2.6.3. 1-dimensional 1H-Nuclear Magnetic 
Resonance experimental method and 2.6.4. Processing 1-dimensional 1H-Nuclear 
Magnetic Resonance data). 
 
5.3.8 GC-MS Analysis 
The aqueous phase of extracts was derivatised as described in Chapter 2 Materials and 
Methods (section 2.7.1 Derivatisation of aqueous phase metabolites). 
 
The organic phase of extracts was derivatised as described in Chapter 2 Materials and 
Methods (section 2.7.2 Derivatisation of organic phase metabolites).   
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GC-MS analyses were made using a Trace GC Ultra coupled to a Trace DSQ II single-
quadrupole mass spectrometer.  Parameters for the GC-MS analysis of aqueous phase 
metabolites and organic phase metabolites were as outlined in Chapter 2 Materials and 
Methods (sections 2.7.3.1 Gas Chromatography-Mass Spectrometry methods for 
aqueous phase samples and 2.7.3.2 Gas Chromatography-Mass Spectrometry methods 
for organic phase samples).  Derivatised organic samples were injected with a split ratio 
of 60 for white adipose tissue and 8 for 3T3-L1 cells. 
 
GC-MS chromatograms were processed using Xcaliber (version 2.0; Thermo Electron) as 
outlined in Chapter 2 Materials and Methods (2.7.5. Processing Gas Chromatography-
Mass Spectrometry data). 
 
5.3.9 UPLC-MS Analysis 
Chromatography was performed using an ACQUITY UPLC® system equipped with an 
Acquity UPLC 1.7 µm BEH C8 column (2.1×100 mm) coupled to a Micromass QTof-
Ultima with a Z-spray electrospray source.  All chromatography and mass spectrometric 
parameters were as outlined in Chapter 2 Materials and Methods (section 2.8.1. 
Chromatography and mass Spectrometry parameters) 
 
The organic phase of adipose tissue extracts was reconstituted in methanol-chloroform 
(2:1, 500 µl).  This was further diluted 10-fold prior to injection onto the C8 column (5 
µl).  The column mobile phase was held at 85% solvent B for 0.5 min followed by an 
increase from 85%-100% solvent B over 0.5-8 min.  The mobile phase was then held at 
100% B for 4 min.  Between 12 and 12.25 min the mobile phase was returned to 85% B 
and held for 1.75 min to re-equilibrate the column. 
 
3T3-L1 Cell Organic phase metabolites were reconstituted in methanol-chloroform (2:1, 
1 ml).  Aliquots of diluted organic phase sample (5 µl) were injected onto the C8 column.  
The column mobile phase was held at 50% solvent B for 0.5 min followed by an increase 
from 50%-100% solvent B over 0.5-6.5 min.  The mobile phase was then held at 100% B 
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for 3.5 min.  Between 10 and 10.25 min the mobile phase was returned to 50% B and 
held for 3.75 min to re-equilibrate the column.    The total UPLC cycle was 14 min and 
the eluent flow rate was 600 µl/min for both methods.    
 
Tandem mass spectrometry procedures were as described in Chapter 2 Materials and 
Methods (2.8.3 Tandem mass spectrometry method). 
 
Data was processed using Micromass MarkerLynx Applications Manager as depicted in 
Chapter 2 Materials and Methods (2.8.4. Processing Liquid Chromatography-Mass 
Spectrometry data). 
 
5.3.10 DI-MS Analysis 
Mass spectrometric analysis was performed using a Thermo Finnigan LTQ equipped with 
a Finnigan Surveyor pump and Finnigan Micro AS Autosampler. 
 
The white adipose tissue organic phase samples for DI-MS were reconstituted in 1 ml 
methanol:THF (2:1 v/v). 60 µl of each sample was aliquoted into a 96 well plate where 
the samples were diluted by the addition of a further 600 µl methanol:THF (2:1 v/v). 
 
The 3T3-L1 organic phase samples for DI-MS were reconstituted in 500 µl 
methanol:THF (2:1 v/v). 100 µl of each sample was added to a 96 well plate. Samples 
were analyzed in triplicate for negative mode and duplicate for positive mode ionisation.   
 
All other direct infusion and mass spectrometric parameters were as described in 
Chapter 2 Materials and Methods (section 2.9.2. Direct infusion and mass 
spectrometry parameters). 
 
DI-MS chromatograms were processed using Xcaliber as outlined in Chapter 2 
Materials and Methods (2.9.3. Processing of direct infusion mass spectrometry data). 
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5.3.11 
13
C-glucose Substrate Labelling Study  
At 2 days post differentiation media was removed from the T75 flasks and replaced with 
DMEM (10% (v/v) FBS, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 
4.5 g/l unlabelled glucose with DMSO control (n=6) or with 1 µM GW347845 PPARγ 
selective agonist (n=7) or 4.5 g/l 1-13C-glucose with DMSO control (n=7) or with 1 µM 
GW347845 PPARγ selective agonist (n=7).  After 2 days cells were collected and 
metabolites extracted as described in Chapter 2 Materials and Methods (sections 2.1.6 
and 2.3 Adipocyte cell collection).  
 
5.3.12 
13
C-palmitate Substrate Labelling Study 
Preparation of 13C labelled and unenriched palmitate solution is defined in Chapter 2 
Materials and Methods (2.4.3. Preparation of 13C and 12C palmitate solution). 
 
At 2 days post-differentiation media was removed from the T75 flasks and replaced with 
DMEM (serum free, 50 units/ml penicillin, and 50 µg/ml streptomycin) and either 70 µM 
unlabelled palmitate (n=6) with DMSO control (n=6) or with 1 µM GW347845 PPARγ 
selective agonist (n=7)  or 70 µM U-13C labelled palmitate (n=7) with DMSO control 
(n=6) or with 1 µM GW347845 PPARγ selective agonist (n=7). After 2 days cells were 
collected and metabolites extracted as previously described in Chapter 2 Materials and 
Methods (sections 2.1.6 Adipocyte cell collection and 2.3 Adipocyte cell collection). 
 
5.3.13 
13
C-labelled Substrate GC-MS Analysis  
Analysis of organic and aqueous phases was carried out as previously described in 
Chapter 2 Materials and Methods (section 2.7.1 Derivatisation of aqueous phase 
metabolites, 2.7.2. Derivatisation of organic phase metabolites, 2.7.3.1 Gas 
Chromatography-Mass Spectrometry methods for aqueous phase samples and 2.7.3.2 
Gas Chromatography-Mass Spectrometry methods for organic phase samples). 
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Enrichment of metabolites was identified by calculating isotope ratios of the M and M+1 
ions for the parent ion of the fragmentation pattern in the case of 13C-glucose metabolism 
analysis and TCA cycle intermediates originating from 13C-palmitate oxidation.  For fatty 
acid synthesis and desaturation products from 13C-labelled palmitate an ion ratio of 
M+16/M was used and for fatty acids originating from oxidation of 13C-labelled 
palmitate an ion ratio of M+n/M, where n = the carbon chain length of the fatty acid was 
used.  Statistical analysis was performed using a univariate t-test. 
 
5.3.14 Multivariate Analysis 
Multivariate data analysis was performed using SIMCA-P+ 11.0 (Umetrics AB, Umeå, 
Sweden).  NMR, DI-MS and UPLC-MS data sets were mean-centered and Pareto-scaled 
prior to analysis.  GC-MS data sets were scaled to UV. Data sets were analyzed using 
PCA, PLS and PLS-DA. Further details are summarised in Chapter 2 Materials and 
Methods (section 2.11.6 Multivariate Statistical Analysis Methodology). 
 
5.3.15 Microarray Analysis of PPARγ Agonist Treated 3T3-L1 Cells  
Cells were grown, treated with PPARγ agonist and collected as is outlined in Chapter 2 
Materials and Methods (section 2.1.1 3T3-L1 cell culture and adipocyte differentiation, 
2.1.4 Activation of PPARγ in 3T3-L1 adipocytes, 2.1.6 and 2.3 Adipocyte cell collection)     
An RNeasy RNA extraction and purification kit was used to extract total RNA from 3T3-
L1 adipocytes (Qiagen GmbH, Hilden, Germany). RNA extraction procedures were 
carried out according to the methods outlined in Chapter 2 Materials and Methods 
(section 2.10.1. RNA extraction). 
 
Transcriptomic analysis was conducted by Cambridge Genomic Centre for Microarray 
Resources (Cambridge Genomic Services, Department of Pathology, University of 
Cambridge). An automated Illumina Infinium Gene Expression BeadArray (Illumina Inc, 
San Diego, CA) was used to perform mRNA transcriptional profiling.  A mouse WG6 
array platform was used with 45281 probes.  
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Quality control was carried out using the arrayQualityMetrics R package and no samples 
failed or were identified as outliers to their replicates. Statistical selection was performed 
using the detection p-value provided by Illumina. This value represents the confidence 
that a given transcript is expressed above the background defined by the negative control 
probe.  The R package lumi was used for this analysis191.  The detection p-value 
threshold was set to 0.01.  Probes were required to be successfully detected (p-value<0.01 
in lumi) in at least one sample to pass the selection. The data is transformed using 
variance stabilisation and then normalised using quantile normalisation192. Gene 
expression was compared between PPARγ agonist treated and control 3T3-L1 cells using 
the R package limma193. The threshold utilised in this analysis was the 5% confidence 
interval.  The selected and normalised data was then analysed using the multivariate 
statistics in the Simca-P+ package as has been described.  The 6% of transcripts most 
responsible for separation in the multivariate models were then examined (3% most 
increased and 3% most decreased in PPARδ agonist treated cells as identified in the 
multivariate models). 
 
The Reactome Skypainter tool (www.reactome.org) was used to determine which 
pathways were statistically significant in the 3% of genes most increased and most 
decreased in transcription in PPARγ agonist treated cells. From a given set of genes 
known to participate in a pathway, the total genes for mus musculus and the submitted list 
of genes (the genes increased or decreased in expression in PPARγ activated cells) of 
which N genes participate in the given pathway, the probability of observing at least N 
genes from a pathway if that pathway is not overrepresented in the submitted list of genes 
is calculated using the one-tailed version of Fisher's exact test. Therefore a p-value 
smaller than or equal to the significance level suggests that the pathway is statistically 
significant in the submitted list of genes. 
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5.4 Results 
5.4.1 Metabolomic Analysis 
1H-NMR spectroscopy, GC-MS, LC-MS and DI-MS analysis, combined with 
multivariate pattern recognition were used to examine metabolism within the white 
adipose tissue of ob/ob mice and 3T3-L1 murine cultured adipocytes treated with a 
PPARγ agonist. To assess metabolic changes in the dataset a common processing strategy 
was adopted throughout the analysis. To investigate metabolite perturbations mutual to 
PPARγ activation PCA and PLS-DA models were built for both the white adipose tissue 
and the 3T3-L1 adipocytes.  PCA and PLS-DA models were generated for the white 
adipose tissue and the cultured cells, comparing the control group with the PPARγ 
agonist treated groups.  Metabolites identified in the VIP/coefficients plots as 
significantly contributing to separation in the models were then considered to have 
changed globally.  The metabolite changes in the white adipose tissue and 3T3-L1 
adipocytes are considered below. 
 
5.4.1.1 White adipose tissue  
Robust multivariate models were generated to describe the metabolic influence of PPARγ 
activation in the white adipose tissue of ob/ob mice from data collected by DI-MS 
analysis of the organic extracts and GC-MS analysis of both the aqueous and organic 
metabolite extracts (Figure 5.1). 
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Figure 5.1: A. PLS-DA scores plot showing the clustering of DI-MS positive 
ionisation mode chromatograms from the organic phase of white adipose 
tissue extracts from ob/ob mice treated with a PPARγ agonist compared 
with control animals ◊, PPARγ agonist treated, ■, control (R2=0.887, 
Q2=0.949). Two technical replicates were analysed.  B. PLS-DA scores plot 
showing the clustering of DI-MS negative ionisation mode chromatograms 
from the organic phase of white adipose tissue extracts from ob/ob mice 
treated with a PPARγ agonist compared with control animals ◊, PPARγ 
agonist treated, ■, control (R2=0.926, Q2=0.949). Two technical replicates 
were analysed. C. PLS-DA scores plot showing the clustering of GC-MS 
chromatograms from the aqueous fraction of white adipose tissue extracts 
from ob/ob mice treated with a PPARγ agonist compared with control 
animals ◊, PPARγ agonist treated, ■, control (R2=0.499, Q2=0.786). D. 
PLS-DA scores plot showing the clustering of GC-MS chromatograms 
from the organic fraction of white adipose extracts from ob/ob mice treated 
with a PPARγ agonist compared with control animals ◊, PPARγ agonist 
treated, ■, control (R2=0.305, Q2=0.738). 
 
Activation of PPARγ in the white adipose tissue of ob/ob mice resulted in a decrease in 
the concentration of several carbohydrate and sugar species including galactose and 
glucose. Concomitantly acetic acid concentrations were observed to decrease. These 
changes in the glycolytic pathway are accompanied by a change in the steady state 
equilibrium of the TCA cycle and oxidative metabolism. The concentration of the early 
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TCA cycle intermediates isocitrate and succinate were increased whilst latter 
intermediates fumarate and malate were decreased in concentration.  
 
Amino acid metabolism in the white adipose tissue was modified by the activation of 
PPARγ; the concentrations of threonine, glycine, serine, isoleucine, phenylalanine, 
valine, alanine, aspartate and proline were increased, whilst the concentration of β-
alanine was decreased. 
 
The fatty acid metabolic pathways of the adipose tissue were also modified by activation 
of the nuclear receptor.  There was a detected increase in the concentrations of the ∆-9 
desaturation products, myristoleate C14:1, cis-10-pentadecanoate C15:1, and palmitoleate 
C16:1. Also increased in concentration were the fatty acid myristate C14:0 and the long 
chain fatty acid arachidate C20:0.  
 
DI-MS detected increases in the concentrations of free arachidonic acid C20:4 and 
docosahexaenoic acid 22:6, respectively, the ω-6 and ω-3 essential fatty acid pathway 
products. 
 
The complex lipid metabolic pathways were altered upon PPARγ activation; the 
concentrations of a number of glycerophosphoinositols were decreased as was the 
concentration of their constituent, myo-inositol.  Cholesterol ester concentrations were 
also increased in the white adipose tissue of PPARγ agonist treated animals. 
 
5.4.1.2 3T3-L1 adipocytes 
Investigation of the effects of PPARγ activation on the metabolism of the 3T3-L1 
adipocyte tissue specific cell line within a cell culture system was conducted to generate 
an in vitro model of adipose tissue specific PPARγ activation.  Oil red O staining for 
neutral lipids in the differentiated cells prior to treatment with the PPARγ agonist 
demonstrated that there were comparable levels of differentiation in the treatment groups 
(Figure 5.2). 
Chapter 5 
 
 162 
 
Figure 5.2:  Graph showing cell counts and the percentage of differentiating cells prior 
to treatment with PPARγ agonist. 
 
The metabolic effect of activation of PPARγ in 3T3-L1 adipocytes was investigated using 
a range of analytical platforms, including GC-MS, DI-MS, LC-MS and 1H-NMR 
spectroscopy enabling extensive coverage of the metabolome; the data obtained from 
analysis was used in chemometric processing to create multivariate statistical models 
designating the metabolites that were altered upon stimulation of the nuclear receptor 
(Figure 5.3). 
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Figure 5.3:  A. PLS-DA scores plot showing the clustering of GC-MS chromatograms 
from the aqueous fraction of 3T3-L1 adipocytes treated with 10 nM 
PPARγ agonist GW347845 and 100 nM PPARγ agonist GW347845 
compared with the control group., 10 nM PPARγ agonist dose ◊, 100 
nM PPARγ agonist dose, ■, control (R2=0.765, Q2=0.735). B. PLS-DA 
scores plot showing the clustering of GC-MS chromatograms from the 
organic fraction of 3T3-L1 adipocytes treated with 10 nM PPARγ agonist 
GW347845 and 100 nM PPARγ agonist GW347845 compared with the 
control group., 10 nM PPARγ agonist dose ◊, 100 nM PPARγ agonist 
dose, ■, control (R2=0.87, Q2=0.895). C. PLS-DA scores plot showing the 
clustering of LC-MS chromatograms from the organic fraction of 3T3-L1 
adipocytes treated with 10 nM PPARγ agonist GW347845 and 100 nM 
PPARγ agonist GW347845 compared with the control group., 10 nM 
PPARγ agonist dose ◊, 100 nM PPARγ agonist dose, ■, control (R2=0.778, 
Q2=0.564).  D. PLS-DA scores plot showing the clustering of DI-MS 
positive mode ionisation chromatograms from the organic fraction of 3T3-
L1 adipocytes treated with 10 nM PPARγ agonist GW347845 and 100 nM 
PPARγ agonist GW347845 compared with the control group., 10 nM 
PPARγ agonist dose ◊, 100 nM PPARγ agonist dose, ■, control (R2=0.781, 
Q2=0.873). Two technical replicates were analysed. E. PLS-DA scores 
plot showing the clustering of DI-MS negative mode ionisation 
chromatograms from the organic fraction of 3T3-L1 adipocytes treated 
with 10 nM PPARγ agonist GW347845 and 100 nM PPARγ agonist 
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GW347845 compared with the control group., 10 nM PPARγ agonist 
dose ◊, 100 nM PPARγ agonist dose, ■, control (R2=0.856, Q2=0.882). 
Three technical replicates were analysed. F. PLS-DA scores plot showing 
the clustering of 1H-NMR spectra from the aqueous fraction of 3T3-L1 
adipocytes treated with 100 nM PPARγ agonist GW347845 compared 
with the control group. ◊, 100 nM PPARγ agonist dose, ■, control 
(R2=0.819, Q2=0.978). 
 
The 3T3-L1 adipocytes exposed to the PPARγ agonist were found to have reduced 
concentrations of glycolytic pathway intermediates including glucose, gluconic acid, 
pyruvate and lactate. 
 
The polyol pathway is also profoundly affected by the activation of the ligand-gated 
receptor; the steady state concentrations of both glucitol and fructose were observed to be 
increased in the adipocytes treated with the PPARγ agonist. 
 
Steady state concentrations of a number of TCA cycle intermediates, glutamate (a 
surrogate for α-ketoglutarate), succinate, fumarate and malate were decreased in PPARγ 
activated adipocytes indicating a role in oxidative metabolic control for the nuclear 
receptor. 
 
The cells treated with PPARγ agonist also displayed altered amino acid metabolism with 
detected decreases in the concentration of aspartate, asparagine, glutamine, threonine and 
β-alanine.  
 
Activation of PPARγ altered the metabolism of the fatty acid synthesis and oxidation 
pathways within the 3T3-L1 adipocytes; there was an observed decrease in the shorter 
chain fatty acids (tridecanoate C13:0, myristate C14:0, isomyristate, 12-methyl 
tetradecanoate, pentadecanoate C15:0, 10-pentadecanoate C15:1, palmitoleate C16:1, 
margaric acid C17:0, cis-10-heptadecenoic acid C17:1, isostearate and elaidate and oleate 
C18:1) and a concomitant increase in the steady state concentrations of the long chain 
fatty acids, arachidate C20:0 and behenic acid C22:0.  The concentration of carnitine was 
also decreased in adipocytes treated with the PPARγ agonist.  The ω-6 essential fatty acid 
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pathway was also perturbed as a consequence of PPARγ stimulation; the steady state 
concentration of γ-linolenate was decreased, concurrently the concentration of the 
consecutive pathway intermediate, dihomo-γ-linolenate was increased, again implicating 
the fatty acid elongase.   
 
The concentrations of FFAs altered by PPARγ activation closely matched the detected 
changes in the total fatty acid population.  Longer chain FFAs were increased in 
concentration (C22:0, C20:0, C22:6, C22:5, C22:3, C22:7, C22:4) whilst the 
concentration of shorter chain FFAs was observed to decrease (C15:0, C17:0, C18:0, 
C16:1, C18:1, C17:1, C19:1, C19:3, C18:2). 
 
The substituent complex lipids of the 3T3-L1 adipocytes were also modified by 
activation of PPARγ.  The TAG pool was restructured as a consequence of stimulation of 
the nuclear receptor; there was a detected increase in the desaturation and length of the 
acyl chains esterified to the TAGs (Table 5.1).  The glycerophospholipids were observed 
to have changed upon stimulation of the ligand activated transcription factor; a decrease 
in the concentration of a number of phospholipid species including 
glycerophosphocholines, glycerophosphoethanolamines and glycerophosphoinositols 
were accompanied by a decrease in their constituents, α-glycerophosphoric acid and 
myo-inositol phosphate.  In addition, 3T3-L1 adipocytes incubated with the PPARγ 
agonist had elevated concentrations of a number of cholesterol ester species.      
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Table 5.1:  TAG species altered in concentration in 3T3-L1 adipocytes treated with 
GW347845 PPARγ agonist.  TAGs were detected using LC-MS.  Lipids 
identified in the VIP/coefficients plots as significantly contributing to 
separation in the PCA and PLS-DA models built for the LC-MS analysis 
of the organic metabolite fraction. The control group was compared with 
the PPARγ agonist treated group. 
 
5.4.2 
13
C-labelled Substrate Studies 
The metabolic mechanisms of PPARγ activation in 3T3-L1 adipocytes were elucidated 
using the 13C-labelled substrates 1-13C glucose and U-13C-palmitate to monitor flux 
through glycolytic, oxidative and fatty acid synthesis pathways.   
 
5.4.2.1 1-13C-glucose 
Analysis by GC-MS of the aqueous fraction of control and PPARγ agonist treated 
adipocytes incubated in media containing 1-13C glucose revealed that when treated with 
the PPARγ agonist, the glycolytic pathway product, lactate had reduced 13C enrichment 
(Figure 5.4A.). The enrichment of the TCA cycle intermediates succinate and glutamate 
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was also decreased in adipocytes with activated PPARγ (Figure 5.4B.C.). In addition, the 
polyol pathway intermediate, glucitol, was increased in 13C-enrichment when the 
adipocytes were treated with the PPARγ agonist.  Investigation, by GC-MS, of the 
organic fraction from control and PPARγ agonist treated adipocytes incubated in 1-13C 
glucose demonstrated that the long chain fatty acid arachidate had a greater concentration 
of 13C enrichment in PPARγ agonist treated cells (Figure 5.4D.). 
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Figure 5.4:  Graphs showing the M+1/M isotope ratio 13C enrichment of A. lactate, B. 
succinate and C. glutamate analysed by GC-MS of the aqueous fraction 
from control and PPARγ agonist dosed 3T3-L1 cells incubated with 1-13C-
glucose. D. Graph showing the M+1/M isotope ratio 13C enrichment of 
arachidate analysed by GC-MS of the organic fraction from control and 
PPARγ agonist dosed 3T3-L1 cells incubated with 1-13C-glucose.  *P < 
0.05. The metabolites have been mapped to the glycolysis, TCA cycle and 
fatty acid synthesis metabolic pathways. ↑ indicates a metabolite increased 
in 13C enrichment by PPARγ activation. ↓ indicates a metabolite decreased 
in 13C enrichment by PPARγ activation. Parent ions were used to calculate 
ion ratio. 
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5.4.2.2 U-
13
C-palmitate    
GC-MS analysis of the aqueous phase of cells incubated in U-13C-palmitate indicated that 
the early TCA cycle intermediates glutamate and isocitrate exhibited decreased 13C 
enrichment in PPARγ agonist treated adipocytes when compared to control adipocytes 
(Figure 5.5A.B.). Assessment of the organic phase by GC-MS indicated that the 13C-
enrichment of the long chain fatty acid arachidate was increased in the PPARγ agonist 
treated cells when compared to control (Figure 5.5C.).  Concurrently the 13C-enrichment 
of the shorter chain fatty acid, myristate was detected by GC-MS to have decreased in the 
adipocytes treated with PPARγ agonist in comparison to control 3T3-L1 cells (Figure 
5.5D.).  An increase in the 13C enrichment of palmitate in cells treated with PPARγ 
agonist, when compared to control adipocytes was also observed. (Figure 5.5E.). 
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Figure 5.5: Graphs showing the M+1/M isotope ratio 13C enrichment of A. glutamate 
and B. isocitrate analysed by GC-MS of the aqueous fraction from control 
and PPARγ agonist dosed 3T3-L1 cells incubated with 13C-U-palmitate. 
Graphs showing the isotope ratio 13C enrichment of C. myristate, D. 
arachidate and E. palmitate analysed by GC-MS of the organic fraction 
from control and PPARγ agonist dosed 3T3-L1 cells incubated with 13C-
U-palmitate. The metabolites have been mapped to the TCA cycle and 
fatty acid β-oxidation/synthesis metabolic pathways. Red indicates a 
metabolite increased in 13C enrichment by PPARγ activation. Blue 
indicates a metabolite decreased in 13C enrichment by PPARγ activation. 
*P < 0.05, **P < 0.01,***P < 0.005. Parent ions were used to calculate ion 
ratio. 
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5.4.3 Microarray Transcriptomic Analysis 
The results from the steady state metabolomic experiments in adipose tissue and 
adipocytes and isotope labelling studies suggest PPARγ activation has a pronounced 
effect on glucose utilisation and fatty acid metabolism in adipocytes. To define these 
changes the focus of investigation was moved to the transcriptome using microarray 
analysis of PPARγ activation in adipocytes.  Of the 45281 probes utilised 13755 were 
expressed above the background defined by the negative control probe.  From these 3282 
were determined to be differentially expressed (P < 0.05) with 164 estimated false 
positives using a threshold of 5% of differentially expressed probes. Multivariate models 
were built using the normalised data from the 13755 transcripts measured (Figure 5.6).  
 
Figure 5.6:  PLS-DA scores plot showing the clustering of gene transcription in control 
and PPARγ agonist treated 3T3-L1 adipocytes as measured with 
microarray analysis. ●, PPARγ agonist treated, ■, control (R2=0.42, 
Q2=0.84). 
 
The 6% of transcripts most responsible for separation in the multivariate models were 
then examined (3% most increased and 3% most decreased in PPARγ agonist treated 
cells as identified in the multivariate models).  The multivariate analysis indicated that 
the mRNA of genes involved in a number of key metabolic pathways was altered 
following PPARγ activation.  The reactome skypainter tool was then utilised to determine 
which pathways and reactions were statistically overrepresented by the 3% most 
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increased (Table 5.2) and 3% most decreased transcripts in PPARγ agonist treated cells 
identified in the multivariate models. 
P-value Pathway 
Transcripts increased in PPARγ 
agonist treated cells mapping to the 
pathway 
6.4e-05 Glycolysis Aldoa, Pgam1, Pfkl, Gapdh, Gpi1 
1.1e-03 Gluconeogenesis Aldoa, Slc25a11, Pgam1, Gapdh, Gpi1 
1.2e-03 
Ca2+ signalling via IP3 binding to the IP3 receptor, opening the 
endoplasmic reticulum Ca2+ channel 
Itpr2, Itpr1 
1.2e-03 Sar1p activation and membrane binding Preb, Sar1b 
1.8e-03 PLC mediated signalling events Prkaca, Itpr2, Itpr1, Adcy6, Pde1b 
2.5e-03 
Hormone-sensitive lipase (HSL)-mediated triacylglycerol 
hydrolysis 
Prkaca, Abhd5, Ppp1ca 
2.6e-03 Metabolism of lipids and lipoproteins 
Prkaca, Abhd5, Abcd3, Ppp1ca, Ncor1, 
Chd9, Slc27a1, Hsd17b4, Acaa2, Sin3b, 
Scd2, Hmgcl, Fads3, Csnk1g2, Angptl4 
3.2e-03 Regulation of insulin secretion 
Prkaca, Dlst, Ndufb6, Itpr1, Gpi1, Aldoa, 
Ndufs6, Pgam1, Itpr2, Pfkl, Gapdh 
5.8e-03 Formation of acetoacetic acid in the synthesis of ketone bodies  Hmgcl, Acaa2 
8.2e-03 Additional metabolism of carbohydrates 
Aldoa, Slc25a11, Pgam1, Pfkl, Gapdh, 
Gpi1, G6pdx 
1.1e-02 PKA mediated events Prkaca, Pde1b 
1.1e-02 
Regulation of lipid metabolism by peroxisome proliferator-
activated receptor alpha (PPARalpha) 
Sin3b, Scd2, Fads3, Ncor1, Chd9, Slc27a1, 
Angptl4 
1.4e-02 DARPP-32 events Prkaca, Ppp1ca, Pde1b 
1.7e-02 STAT signalling Stat5a, Stat6 
1.7e-02 Integration of energy metabolism 
Prkaca, Dlst, Ndufb6, Gpi1, Aldoa, Ndufs6, 
Pgam1, Pfkl, Adcy6, Gapdh 
2.0e-02 β-oxidation of very long chain fatty acids Abcd3, Hsd17b4 
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2.4e-02 Adenylate cyclise mediated CREB phosphorylation Prkaca, Adcy6 
2.6e-02 Signalling by NGF/TRKA 
Prkaca, Itpr1, Gbl, Arhgef11, Pde1b, 
Bcl2l11, Foxo1, Itpr2, Adcy6, Araf 
3.1e-02 Peroxisomal lipid metabolism Abcd3, Slc27a1, Hsd17b4 
Table 5.2: The pathways statistically significant in the 3% most increased transcripts 
in PPARγ agonist treated cells identified in the multivariate models. From 
a given set of genes participating in a pathway, the total genes for mus 
musculus and the submitted genes (genes increased in PPARγ activated 
cells) of which N genes participate in a pathway, the probability of 
observing at least N genes from a pathway if that pathway is not 
overrepresented in the submitted list of genes is calculated using Fisher's 
exact test.  A p-value smaller than the significance level suggests the 
pathway is significantly represented.   
 
A number of primary cellular signalling pathways were identified as statistically affected 
from the transcripts increased in expression by PPARγ activation including inositol 
triphosphate, calcium, calmodulin and G-protein signalling.  PPARγ activation also 
affected the expression of genes involved in specific metabolic energy pathways and 
reactions as well as the integration of energy metabolism. 
 
The expression of genes encoding proteins involved in the glycolytic metabolic pathway 
was also upregulated in PPARγ agonist treated cells.  Transcription of several of the key 
enzymes including glucose phosphate isomerise, phosphofructokinase, aldolase A 
fructose-bisphosphate, phosphoglycerate mutase 1 and glyceraldehyde-3-phosphate 
dehydrogenase was upregulated.  Consistent with the metabolic changes observed in the 
polyol pathway the expression of sorbitol dehydrogenase, which catalyses the conversion 
of glucitol to fructose, was increased in PPARγ agonist treated 3T3-L1 cells.  In addition, 
the expression of the gene encoding the TCA cycle enzyme isocitrate dehydrogenase was 
identified as decreased.  
 
PPARγ activation was also discerned to significantly affect the transcription of genes 
responsible for the remodelling and metabolism of lipids.  The fatty acid desaturases 
stearoyl-CoA desaturase 2 and fatty acid desaturase 3, a possible ∆-9 fatty acid 
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desaturase, were increased in expression following PPARγ activation (P < 0.005 for both 
stearoyl-CoA desaturase 2 and fatty acid desaturase 3).  The transcripts of a number of 
genes that favour conditions of fatty acid synthesis are also increased in concentration in 
the adipocytes following treatment with the PPARγ agonist; these genes include sterol 
regulatory element binding transcription factor 2, a transcription factor required for lipid 
homeostasis that regulates the LDL receptor gene as well as the cholesterol and fatty acid 
synthesis pathways241, holocarboxylase synthetase, which activates acetyl-CoA-
carboxylase (and pyruvate carboxylase) by conjugating biotin to these enzymes242, NAD 
kinase, which transfers a phosphate group of ATP to NAD generating NADP for use as 
an electron donor in biosynthetic reactions including fatty acid synthesis and malonyl 
CoA:ACP acyltransferase which catalyses the transfer of a malonyl moiety from 
malonyl-CoA to the phosphopantethenate moiety of the acyl carrier peptide in the first 
step of fatty acid synthesis.  Concomitantly the expression of acyl-CoA thioesterase 7 and 
nudix-type motif 19 Coenzyme A diphosphatase, enzymes which catalyse the hydrolysis 
of medium and long chain acyl-CoAs to FFA and CoA243, was upregulated in the treated 
adipocytes. In addition the transcription of solute carrier family 27a1 mRNA was 
increased in PPARγ agonist treated cells; this protein is an insulin responsive fatty acid 
transporter responsible for the import of long chain fatty acids into adipose tissue 
undergoing high levels of TAG synthesis244. 
 
Genes involved in the restructuring and remodelling of complex lipids were also affected 
by PPARγ activation. Lysophosphatidylcholine acyltransferases 3 acyltransferase 
expression was increased in adipocytes treated with PPARγ; this enzyme catalyses the 
conversion of lysophosphocholines, lysophosphoserines and lysophosphoethanolamines 
into phosphocholines, phosphoserines and phosphoethanolamines, respectively and 
favours polyunsaturated fatty acyl-CoAs as acyl donors245.  Transcription of the platelet 
activating factor acetylhydrolase 2 lipase was also increased in the PPARγ activated 
adipocytes.  Expression of angiopoietin-related protein 4, a protein regulating 
extracellular lipolysis through lipoprotein lipase, was increased in the agonist treated 
3T3-L1 cells246.    
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PPARγ activation also increased the expression of nuclear receptor corepressor 1 in the 
3T3-L1 adipocytes. Nuclear receptor corepressor 1 is a transcriptional repressor 
responsible for the downregulation of gluconeogenesis, lipolysis and fatty acid β-
oxidation247. Additionally transcription of the PPAR transcriptional coactivator, 
Chromodomain-helicase-DNA-binding protein 9, was upregulated in the PPARγ agonist 
treated adipocytes.     
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5.5 Discussion 
 
A comprehensive metabolomics investigation was performed using a diverse range of 
analytical and chemometric techniques.  The primary aim of this study was to probe the 
metabolic effects of PPARγ activation within the white adipose tissue of ob/ob mice to 
elucidate the metabolic influence stimulus of this receptor has on a tissue perceived to be 
the primary target for synthetic PPARγ ligands in their use as anti-diabetic agents.  A 
3T3-L1 adipocyte cell culture system was then employed to generate an in vitro model of 
PPARγ activation in adipose tissue, which was subsequently analysed using metabolomic 
methods.  The metabolomic data was then complemented with investigations in 3T3-L1 
adipocytes using 13C-labelled substrates to monitor flux through glycolytic, oxidative and 
fatty acid synthesis pathways and RNA microarray analysis to explain alterations in gene 
transcription; these additional techniques were utilised to explicate the mechanisms by 
which PPARγ activation generates its metabolic properties. 
 
Transcriptomic analysis highlighted the significant upregulation in the expression of 
genes involved in calcium and calmodulin signalling within adipocytes treated with the 
PPARγ agonist, GW347845.  The calcium signalling pathway is implicated in the insulin 
responsive signalling pathway and influences many metabolic targets248, 249.  Calcium 
signalling increases GLUT4 translocation to the plasma membrane, possibly through a 
phosphatidic acid lipid signalling mechanism mediated by phospholipase D250, and 
increases glucose transportation into adipocytes251. PPARγ activation has previously been 
linked to an increase in glucose uptake and glycolysis in white adipose tissue236, 252.  A 
consistent observation from both the white adipose tissue and 3T3-L1 adipocytes exposed 
to PPARγ agonist was a decrease in the concentration of glucose and other carbohydrate 
species.  Transcriptomic analysis indicated that expression of a number of key enzymes 
catalysing the events of glycolysis was increased in PPARγ activated adipocytes.  The 
glycolytic enzymes affected were glucose phosphate isomerase, phosphofructokinase, 
aldolase A fructose-bisphosphate, phosphoglycerate mutase 1 and glyceraldehyde-3-
phosphate dehydrogenase.  It would appear however that the utilisation of the 
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carbohydrates is not limited to glycolysis. The concentration of the end products of 
glycolysis, acetic acid in white adipose tissue and pyruvate and lactate in the 3T3-L1 
cells decreased when PPARγ was activated.  The decrease in 13C-labelling of lactate from 
1-13C-glucose confirms this observation.  Further to this, calcium signalling is known to 
activate pyruvate dehydrogenase253, leading to examination of the TCA cycle, the 
consecutive step in oxidative breakdown of carbohydrate.   
 
TCA cycle metabolism in both white adipose tissue and cultured adipocytes is modified 
by PPARγ activation to favour a reduction in oxidation of carbohydrates and an increase 
in fatty acid synthesis.  In white adipose tissue the equilibrium of the cycle is altered in 
favour of the earlier intermediates (oxidation substrates), at the expense of the latter 
intermediates (oxidation products) and appears to occur at the electron transport chain 
complex II intersect with increases in the concentrations of isocitrate and succinate while 
the concentrations of fumarate and malate were decreased . The effect in adipocytes is 
even more pronounced with a decrease in the concentration of a range of latter 
intermediates. Analysis with 13C-labelled glucose showed a reduction in 13C-enrichment 
of TCA cycle intermediates and substantiated the reduction in oxidative metabolism.  
Augmenting these findings were the results of the transcriptomic analysis which 
identified a decrease in the concentration of the mRNA of the gene coding for the TCA 
cycle enzyme isocitrate dehydrogenase, which catalyses the oxidative decarboxylation of 
isocitrate to 2-oxoglutarate.   
 
Alternative pathways of carbohydrate metabolism were also observed to be altered by 
activation of PPARγ.  Intermediates of the polyol pathway, glucitol and fructose, were 
identified as increased in concentration in the 3T3-L1 adipocytes analysed by 
metabolomics.  Further investigation using 1-13C-glucose established increased flux 
through this pathway.  Corroborating findings were detected in the transcriptomic 
analysis which verified an increase in the expression of sorbitol dehydrogenase, a polyol 
pathway enzyme that catalyses the conversion of glucitol to fructose.  The polyol 
pathway has been implicated in the formation of advanced glycation end-products 
(AGEs)254.  AGEs are formed by a reaction between carbohydrates and the free amino 
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groups of proteins, lipids and DNA.  These glycation products are often found in excess 
with pathologies such as diabetes, where they are thought to contribute to macro- and 
micro-vascular complications via several deleterious mechanisms including the 
accumulation in circulatory vessel walls, the in situ glycation of substrates and direct 
binding to cellular receptors255.  Therefore the implication that PPARγ activation 
increases activity of the polyol pathway in adipocytes potentially complicates the use of 
TZDs and other PPARγ agonists in the treatment of diabetes and the metabolic syndrome.  
 
The activation of PPARγ in both the white adipose tissue and cultured cells generated 
changes in the composition of the cellular fatty acid pool.  The effect of PPARγ 
activation on fatty acid metabolism, although more distinct in cultured cells, where there 
was a defined decrease in the concentrations of shorter chain fatty acids and an increase 
in the concentration of longer chain fatty acids as opposed to white adipose tissue where 
there was an increase in the long chain fatty acid arachidate, was indicative of fatty acid 
synthesis and elongation.  The increased 13C-enrichment of arachidate in adipocytes 
incubated in 1-13C-glucose and treated with the PPARγ agonist verified an increase in 
fatty acid synthesis as a result of PPARγ activation; a finding further corroborated by the 
observed increase in 13C-enrichment of arachidate in PPARγ activated adipocytes 
incubated in U-13C -palmitate.  Activation of PPARγ in white adipose tissue is known to 
upregulate the expression of a number of genes involved in fatty acid lipogenesis and 
elongation 233, 256, together with the results of the microarray analysis which show an 
increase in the concentration of mRNA for genes that promote fatty acid synthesis there 
is an indication of a switch to a lipogenic metabolic state upon receptor activation.  An 
upregulation of transcription, in response to PPARγ activation, affected sterol regulatory 
element binding transcription factor 2, a transcription factor required for lipid 
homeostasis that regulates the LDL receptor gene as well as the cholesterol and fatty acid 
synthesis pathways241, holocarboxylase synthetase, which activates acetyl-CoA-
carboxylase (and pyruvate carboxylase) by conjugating biotin to these enzymes242, NAD 
kinase, which catalyses the transfer of a phosphate group from ATP to NAD generating 
NADP forming an electron donor for biosynthetic reactions and malonyl CoA:ACP 
acyltransferase which catalyses the transfer of a malonyl moiety from malonyl-CoA to 
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the phosphopantethenate moiety of the acyl carrier peptide in the first step of fatty acid 
synthesis.   
 
PPARγ activation also increases the uptake of fatty acids by adipocytes257.  Evidence for 
the influence of PPARγ on fatty acid uptake can be seen within the U-13C-palmitate 
study; where an increase in the 13C-enrichment of palmitate in the PPARγ agonist treated 
3T3-L1 adipocytes compared to control 3T3-L1 cells was detected.  Increased expression 
of the insulin responsive fatty acid transporter solute carrier family 27 in PPARγ agonist 
treated cells is a further indication of the import of long chain fatty acids into adipose 
tissue undergoing high levels of TAG synthesis as a consequence of the activation of the 
nuclear receptor244. 
 
Evidence demonstrating decreased 13C-enrichment of TCA cycle intermediates and 
shorter chain fatty acids in U-13C-palmitate studies also suggests that PPARγ activation 
concurrently decreases flux through the fatty acid β-oxidation pathway alongside the 
upregulation of fatty acid synthesis.  Supporting this finding was the decreased 
concentration of carnitine in PPARγ agonist treated adipocytes.  Carnitine is required for 
the transport of fatty acids, in the form of acyl-carnitine from the cytosol to the 
mitochondrial matrix during β-oxidation. Transcriptomic analysis provides additional 
mechanisms by which activation of PPARγ may bring about the observed decrease in β-
oxidation.  The expression of acyl-CoA thioesterase 7 and nudix-type motif 19 
Coenzyme A diphosphatase, enzymes which catalyse the hydrolysis of medium and long 
chain acyl-CoAs to FFA and CoA and therefore prevent the β-oxidation of medium and 
long chain fatty acids once they are formed243, was upregulated in the treated adipocytes.  
Transcription of nuclear receptor corepressor (Ncor1) was also increased in the 
adipocytes treated with PPARγ agonist.  Ncor1 is a transcriptional repressor indicated in 
the repression of gluconeogenesis, oxidative and ketotic metabolism and lipolysis247.  
 
A distinct restructuring of the TAG pool occurred as a consequence of PPARγ activation; 
the length and desaturation of fatty acids esterified to TAGs in cultured adipocytes was 
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increased, reinforcing the data substantiating increased activity of the fatty acid elongase 
and the observed increases in the ∆-9 desaturase products in white adipose tissue.  This 
observation is consistent with previous studies that demonstrate that the gene for stearoyl-
CoA desaturase, the enzyme responsible for ∆-9 desaturation of fatty acids, is under 
PPARγ transcriptional control258, a finding supported by the microarray analysis 
conducted which found that the expression of the stearoyl-CoA desaturase 2 gene was 
upregulated in PPARγ agonist treated 3T3-L1 genes.  PPARγ also directly regulates the 
glycerol kinase promoter and therefore is expected to promote the esterification of fatty 
acids into TAGs259.  Microarray analysis indicated that lysophosphatidylcholine 
acyltransferases 3 acyltransferase expression was increased in adipocytes treated with 
PPARγ.  The enzyme catalyses the conversion of lysophosphocholines, 
lysophosphoserines and lysophosphoethanolamines into phosphocholines, 
phosphoserines and phosphoethanolamines, respectively245.  The protein favours 
polyunsaturated fatty acyl-CoAs as acyl donors.  Platelet activating factor 
acetylhydrolase 2 lipase transcription was also increased in the PPARγ activated 
adipocytes. This lipase is selective for phospholipids with short acyl chains at the sn-2 
position260.  The concentration of angiopoietin-related protein 4 mRNA was increased in 
the agonist treated 3T3-L1 cells; the protein product of which inhibits lipoprotein lipase 
and therefore inhibits lipolysis246.  Furthermore, the upregulation of the transcription of 
genes involved in calcium signalling as a consequence of PPARγ activation may play a 
role in defining the constituents of the complex lipid pool within the adipocytes.  An 
increase in intracellular calcium stimulates the activity of fatty acid synthase, stimulates 
lipogenesis, inhibits basal lipolysis, and promotes TAG accumulation within murine and 
human adipocytes261.    
 
Essential fatty acid metabolism was identified as altered following activation of the 
nuclear transcription factor.  The ω-3 and ω-6 fatty acid pathways are under the influence 
of PPARγ control, a result that not only corresponds to the previously discussed effect of 
activation of the nuclear receptor on fatty acid synthesis but also to the identification of a 
PPRE in the gene for the ∆-6 desaturase262, an enzyme intrinsic to both essential fatty 
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acid pathways.  Transcriptomic analysis further identified the increased expression of the 
∆-6 desaturase in adipocytes upon PPARγ activation. 
 
PPARγ activation was found to increase the cholesterol content of both white adipose 
tissue from ob/ob mice and cultured 3T3-L1 adipocytes.  Given that PPARγ activity 
upregulates the expression of oxidized LDL receptor 1 in adipocytes263; it appears that 
increasing cholesterol concentrations are brought about by stimulation of the uptake of 
oxidized LDL into adipocytes, a process that may be mediated through the sterol 
regulatory element binding transcription factor 2, so sequestering potentially harmful 
circulating cholesterol into the adipose tissue depository. 
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5.6 Conclusions 
In conclusion, it is proposed that PPARγ activation, in part, brings about its anti-diabetic 
effects on white adipose tissue via transcriptional control of an array of direct metabolic 
responses and indirect signalling mechanisms.  PPARγ activation in white adipose tissue 
leads to an upregulation of glycolysis and catabolism of other carbohydrate species. 
Subsequently the TCA cycle is downregulated, an effect especially apparent by the 
disparity between the decreases in concentration of the latter intermediates compared 
with an increase in concentration of intermediates at the start of the cycle, demonstrating 
fatty acid synthesis rather than oxidative catabolism.  In combination with de novo fatty 
acid synthesis, the cellular uptake of FFAs is increased; generating a pool of longer chain 
fatty acids which are incorporated into TAGs directly or else desaturated and 
incorporated into TAGs.  Concomitantly fatty acid breakdown via β-oxidation is 
downregulated upon nuclear receptor activation (Figure 5.7).   
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Figure 5.7: Diagram showing the effect of PPARγ activation on the integration of the 
energy metabolism pathways of 3T3-L1 adipocytes based on the 
combination of results from the metabolomic, transcriptomic and stable 
isotope labelling studies.  Red indicates an increase in concentration or 
expression in cells treated with the GW347845 PPARγ selective agonist. 
Blue indicates a decrease in concentration in cells treated with the 
GW347845 PPARγ selective agonist. 
 
The extensive metabolic pathway regulation found to be under PPARγ control in white 
adipose tissue identifies a mechanism that contributes to the observed normalisation of 
blood glucose levels and dyslipidaemia264, increase in glucose utilisation 236,252, and 
increase in body weight and subcutaneous adiposity previously reported in both human 
patients and rodent subjects treated with selective PPARγ agonists265,266.  This 
sequestration of glucose and lipid into the white adipose tissue, as a safely contained 
storage depot, may reduce the damaging potential of increased levels of circulating 
glucose and lipid, whilst reducing lipid and cholesterol accumulation in peripheral 
tissues267.  Given white adipose tissue appears to be the primary target for PPARγ agonist 
mediated insulin sensitisation268 these findings provide a possible means by which 
PPARγ activation influences peripheral tissue insulin sensitivity, by reducing the 
accumulation of fat in peripheral tissue and therefore lipotoxicity through increased 
storage of lipid in adipose tissue, in accordance with the adipose tissue expandability 
model269.  Through the dual mechanisms of augmenting facets of the calcium signalling 
pathway associated with insulin action and direct transcriptional regulation of metabolic 
enzymes PPARγ activation brings about metabolic changes that function to reinforce 
insulin sensitisation. 
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Chapter 6 
 
The Effects of PPARδ and PPARγ Activation on the Cori Cycle 
and Systemic Metabolism in the ob/ob Mouse  
 
 
6.1 Introduction 
 
The role of PPARδ in hepatic metabolism remains to be fully elucidated and relatively 
little research has focussed on the effects of activation of the nuclear receptor in the liver.  
Nevertheless, it has been shown that treatment of db/db mice with a selective PPARδ 
agonist resulted in suppression of hepatic glucose production and release227.  In addition 
PPARδ activation was found to increase hepatic glucose disposal, flux through the 
pentose phosphate pathway and to inhibit VLDL secretion from the livers of treated 
mice227.  The disparity of research conducted into the function of PPARδ in the liver in 
comparison to peripheral tissues, and especially skeletal muscle, may have occurred 
because PPARα is known to act primarily in the liver, whereas PPARδ mRNA is 
expressed at 10 and 50 times the concentrations of PPARα and PPARγ mRNA139, 
respectively, in skeletal muscle.  Administration of PPARδ agonists to rodents results in 
an increase in expression of genes involved in fatty acid oxidation, mitochondrial 
respiration, oxidative metabolism and slow twitch contractile apparatus, decreasing 
muscle fatigability171.  Treatment of L6 myotubes with GW610742, a PPARδ agonist, 
was shown to increase fatty acid oxidation whilst overexpression of PPARδ in C2C12 
myotubes induced genes involved in fatty acid uptake and catabolism including 
lipoprotein lipase, FAT and carnitine palmitoyl transferase I270.  Further to this, 
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an animal model of muscle specific PPARδ overexpression has been developed in which 
a remodelling of the soleus and tibialis anterior muscles in favour of oxidative fibres was 
observed271.  The activity of several oxidative enzymes was also increased in the mice; 
enzymes affected include citrate synthase and β-hydroxyacyl-CoA dehydrogenase.  
Together these findings are suggestive of a regulatory role for PPARδ in the control of 
the Cori cycle and the metabolic interactions of the liver and skeletal muscle.  Research 
conducted in this thesis, thus far, has been directed at the effects of both PPARδ and 
PPARγ activation in adipose tissue.  However, it is likely that the observed increases in 
glucose tolerance and insulin sensitivity upon PPARδ and PPARγ activation in vivo may 
crucially involve combined hepatic and peripheral metabolic effects.    
 
However, the ubiquitous expression of PPARδ may result in diverse and unwanted side 
effects upon activation of this receptor.  PPARδ activation has been implicated as a cause 
of muscle atrophy272.  The nuclear receptor has also been implicated in the acceleration of 
intestinal adenoma growth and increased growth in breast and prostate cancer cell lines, 
but conversely it also attenuates colon cancer176, 177, 178.  The role of PPARδ in 
development and carcinogenesis is complex and has been extensively reviewed179.   
 
It is hypothesized that the insulin sensitising effects of PPARδ activation are brought 
about, in part, by changes in systemic metabolism.  Given that TAG in liver contributes 
to insulin resistance it has been suggested that increased TAG oxidation in the liver, 
caused by PPARδ activation, may contribute to this improvement227.  In this chapter the 
effect of both the selective PPARδ agonist GW610742 and PPARγ agonist GW347845 
on the systemic metabolism of the ob/ob mouse is examined with specific focus directed 
at hepatic and skeletal muscle metabolism.  The ob/ob mouse model of insulin resistance 
is robust, well characterised and used extensively to study TIIDM and its therapies.  
However, it is worthy of note that it is a monogenic paradigm of leptin deletion, whereas 
TIIDM is a polygenic disorder. 
  
Chapter 6 
 
 187 
6.2 Aims and Objectives 
 
This study aims to use metabolomics to examine the changes that occur in hepatic 
metabolism following PPARδ activation and the impact detected systemically through 
metabolite changes in blood serum and skeletal muscle in the ob/ob mouse. 1H-NMR 
spectroscopy, GC-MS, UPLC-MS and DI-MS were used to examine metabolites from 
tissue extracts.  This study has used a metabolomics approach in conjunction with 
traditional clinical chemistry end points to investigate and define the global physiological 
and pharmacological effects of PPARδ and PPARγ activation through the metabolic 
characterisation of blood serum, skeletal muscle and liver tissue from a pharmacological 
compound treatment study performed in the ob/ob mouse model of insulin resistance.   
 
Analysis by multivariate statistics demonstrated that PPARδ activation profoundly 
affected glycolysis, gluconeogenesis, the TCA cycle and linoleic acid and α-linolenic 
acid essential fatty acid pathways. Although activation of both PPARδ and PPARγ led to 
increased insulin sensitivity and glucose tolerance; PPARδ activation was functionally 
distinct from PPARγ activation, and was characterised by increased hepatic and 
peripheral fatty acid oxidative metabolism, demonstrating the distinctive catabolic role of 
this receptor compared with PPARγ. 
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6.3 Materials and Methods 
6.3.1. Clinical Chemistry 
All clinical chemistry measurements were performed using an Olympus AU 400e 
analyser186.  Insulin measurements were performed by ELISA as described in Chapter 2 
Materials and Methods (section 2.2.2. Clinical Chemistry).   
 
6.3.2. Oral Glucose Tolerance Test 
OGTT was performed as stated in Chapter 2 Materials and Methods (section 
2.2.3.Oral Glucose Tolerance Test). 
 
6.3.3. Animal and Tissue Handling 
Animals were kept as is outlined in Chapter 2 Materials and Methods (section 2.2.1. 
Animal handling).  Briefly, the ob/ob mice were assigned to three groups of eight and 
dosed orally daily at 8 am with 0.5% Hydroxypropylmethylcellulose/0.1% Tween80 
vehicle control, a PPARδ agonist, GW610742 (30 mg/kg) and a PPARγ agonist, 
GW347845 (5 mg/kg).  Injection volume was adjusted daily according to body weight at 
10 ml/kg.   
 
Liver, skeletal muscle and serum were collected as summarised in Chapter 2 Materials 
and Methods (section 2.2.4. Tissue handling). 
 
6.3.4. Metabolite Extraction 
Metabolites were extracted from tissues using the modified Bligh and Dyer method187.  
The details are as in Chapter 2 Materials and Methods (section 2.3 3T3-L1 Cell, Primary 
Adipocyte and Tissue Metabolite Extraction). 
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6.3.5. 
1
H-NMR Spectroscopy Analysis 
All samples were analysed using a Bruker AVANCE II+ spectrometer operating at 
500.13 MHz for the 1H frequency using a 5mm Broadband TXI Inverse ATMA probe.  
All procedures are as depicted in Chapter 2 Materials and Methods (sections 2.6.1. 
Spectrometer, 2.6.2. Sample preparation, 2.6.3. 1-dimensional 1H-Nuclear Magnetic 
Resonance experimental method and 2.6.4. Processing 1-dimensional 1H-Nuclear 
Magnetic Resonance data). 
 
6.3.6. GC-MS Analysis 
Aqueous phase samples were derivatised as described in Chapter 2 Materials and 
Methods (section 2.7.1). 
 
Organic phase samples were derivatised as described in Chapter 2 Materials and 
Methods (section 2.7.2).   
 
GC-MS analyses were made using a Trace GC Ultra coupled to a Trace DSQ II single-
quadrupole mass spectrometer.  Parameters for the GC-MS analysis of aqueous phase 
metabolites and organic phase metabolites were as described in Chapter 2 Materials 
and Methods (sections 2.7.3.1 Gas Chromatography-Mass Spectrometry methods for 
aqueous phase samples and 2.7.3.2 Gas Chromatography-Mass Spectrometry methods 
for organic phase samples).  Derivatised aqueous phase samples were injected splitless 
and organic phase samples were injected with a split ratio of 8.  
 
GC-MS chromatograms were processed using Xcaliber (version 2.0; Thermo Electron) as 
outlined in Chapter 2 Materials and Methods (2.7.5. Processing Gas Chromatography-
Mass Spectrometry data). 
 
6.3.7. UPLC-MS Analysis 
Chromatography was performed using an ACQUITY UPLC® system  equipped with an 
Acquity UPLC 1.7 µm BEH C8 column (2.1×100 mm) coupled to a Micromass QTof-
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Ultima with a Z-spray electrospray source.  All chromatography and mass spectrometric 
parameters were as outlined in Chapter 2 Materials and Methods (section 2.8.1. 
Chromatography and mass Spectrometry parameters) 
 
6.3.7.1 Liver tissue preparation and chromatographic gradient 
The organic phase of liver was reconstituted in methanol-chloroform (2:1, 500 µl).  This 
was further diluted 7.5-fold prior to injection onto the C8 column (5 µl).  The column 
mobile phase was held at 70% solvent B for 0.5 min followed by an increase from 70%-
100% solvent B over 0.5-6.5 min.  The mobile phase was then held at 100% B for 3.5 
min.  Between 10 and 10.25 min the mobile phase was returned to 70% B and held for 
3.75 min to re-equilibrate the column.  The total UPLC cycle was 14 min.  The eluent 
flow rate was 600 µl/min.   
 
6.3.7.2 Serum preparation and chromatographic gradient 
The organic phase of serum was reconstituted in methanol-chloroform (2:1, 500 µl).  This 
was further diluted 4 fold prior to injection onto the C8 column (10 µl).  The column 
mobile phase was held at 70% solvent B for 0.5 min followed by an increase from 70%-
100% solvent B over 0.5-6.5 min.  The mobile phase was then held at 100% B for 3.5 
min.  Between 10 and 10.25 min the mobile phase was returned to 70% B and held for 
3.75 min to re-equilibrate the column.  The total UPLC cycle was 14 min.  The eluent 
flow rate was 600 µl/min.   
 
Tandem mass spectrometry procedures were as described in Chapter 2 Materials and 
Methods (2.8.3 Tandem mass spectrometry method). 
 
Data was processed using Micromass MarkerLynx Applications Manager as depicted in 
Chapter 2 Materials and Methods (2.8.4. Processing Liquid Chromatography-Mass 
Spectrometry data). 
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6.3.8. Direct Infusion Mass Spectrometry 
Mass spectrometric analysis was performed using a Thermo Finnigan LTQ equipped with 
a Finnigan Surveyor pump and Finnigan Micro AS Autosampler. 
 
6.3.8.1 Liver tissue 
The liver organic phase samples for DI-MS were reconstituted in 500 µl methanol:THF 
(2:1 v/v). 50 µl of each sample was aliquoted into a 96 well plate where the samples were 
diluted by the addition of a further 150 µl methanol:THF (2:1 v/v).  
 
Analysis was performed in negative ionisation mode.  All other direct infusion and mass 
spectrometric parameters were as described in Chapter 2 Materials and Methods 
(section 2.9.2. Direct infusion and mass spectrometry parameters). 
  
DI-MS chromatograms were processed using Xcaliber as outlined in Chapter 2 
Materials and Methods (2.9.3. Processing of direct infusion mass spectrometry data). 
 
6.3.9. Multivariate Analysis 
Multivariate data analysis was performed using SIMCA-P+ 11.0 (Umetrics AB, Umeå, 
Sweden).  NMR, DI-MS and UPLC-MS data sets were mean-centered and Pareto-scaled 
prior to analysis.  GC-MS data sets were scaled to univariate scaling. Data sets were 
analyzed using PCA, PLS and PLS-DA. Further details are summarised in Chapter 2 
Materials and Methods (section 2.11.6 Multivariate Statistical Analysis Methodology). 
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6.4 Results 
6.4.1. Clinical Chemistry 
All mice were examined ensuring they were physically normal and exhibited normal 
activity prior to both commencement and termination of the study.  The concentrations of 
both insulin and glucose were found to be significantly decreased in both PPARδ and 
PPARγ agonist treated serum, indicating that the insulin resistant status of the ob/ob mice 
is improved by PPARδ and γ activation. This was also confirmed by the OGTT.  The 
concentrations of β-hydroxybutyrate, total cholesterol and HDL-cholesterol were 
increased in the serum of PPARδ agonist treated mice, while non esterified fatty acids 
were decreased in concentration. While, serum TAG concentrations were increased in 
PPARδ agonist treated mice, this metabolite class decreased in PPARγ agonist treated 
mice (Figure 6.1).     
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Figure 6.1: Clinical chemistry measurements from the serum of control, GW610742 
PPARδ agonist and GW347845 PPARγ agonist treated ob/ob mice. A. 
Serum Insulin B. Glucose C. β-hydroxybutyrate D. TAG E. Non Esterified 
Fatty Acids F. HDL-Cholesterol G. Oral Glucose Tolerance Test H. Area 
Under Curve Oral Glucose Tolerance Test.* P < 0.05 with respect to 
vehicle control treated animals. 
 
6.4.2. Metabolomics 
1H-NMR spectroscopy and GC-MS analysis, combined with multivariate pattern 
recognition were used to profile metabolism within the liver, serum and skeletal muscle 
of ob/ob mice treated with a PPARδ agonist and a PPARγ agonist.  The different 
analytical techniques had varying sensitivities. High resolution 1H-NMR spectroscopy 
detected 20-25 metabolites in both liver and skeletal muscle. GC-MS detected 100-150 
defined peaks from aqueous phase samples and 30-40 defined peaks from organic phase 
samples.  Matching the mass spectra detected with those held in the NIST library 
identified 40-60% metabolites for aqueous extracts and ~70% for lipids from the GC-MS 
datasets. 
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Phospholipid targeted UPLC-MS detected 100-150 unique metabolite species in positive 
mode.  Identification of metabolite species was performed using MS/MS. 
Phosphatidylcholines were identified using the phosphocholine head group ion (detection 
of ion at 184 m/z). 
 
To assess metabolic changes in the dataset a common processing strategy was adopted 
throughout the analysis. To investigate metabolite perturbations common to PPARδ and 
PPARγ activation PCA and PLS-DA models were built for the individual tissues treating 
the δ and γ agonists as part of a common group.  Although the groups were shown to co-
cluster and separate from the control group in this supervised analysis, the majority of the 
Q2 values (testing model statistical robustness) were low, despite the δ and γ agonist 
treatment groups separating along the same scores plot axis.  While similar changes were 
detected in the concentration of a large number of metabolites for both treatments, these 
occurred with different magnitudes (Figure 6.2).  Activation of PPARδ in the liver and 
skeletal muscle caused a greater magnitude of changes compared to activation of PPARγ.  
These findings correspond to known tissue distribution of the PPAR subtypes and that the 
two receptors share a number of common metabolic effects.   
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Figure 6.2:  A. PLS-DA scores plot showing the clustering of GC-MS chromatograms 
from the organic fraction of the liver from mice treated with either a 
PPARδ or a PPARγ agonist compared with the control group. ●, PPARδ 
agonist treated, ◊, PPARγ agonist treated, ■, control (R2=0.59, Q2=0.82). 
B. PLS-DA scores plot showing the clustering of GC-MS chromatograms 
from the aqueous phase of skeletal muscle extracts from mice treated with 
either a PPARδ agonist or a PPARγ agonist compared with control 
animals. ●, PPARδ agonist treated, ◊, PPARγ agonist treated, ■, control 
(R2=0.24, Q2=0.32). C. PLS-DA scores plot showing clustering of GC-MS 
chromatograms from PPARδ agonist and PPARγ agonist treated mice 
serum aqueous phase metabolites following GC-MS analysis. ●, PPARδ 
agonist treated, ◊, PPARγ agonist treated, ■, control (R2=0.563, 
Q2=0.631). 
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Visual inspection of the 1H-NMR spectra and GC-MS chromatograms indicated 
differences between the control and treated groups. PCA and PLS-DA models were built 
for the individual tissues comparing the control group with the PPARδ agonist treated 
group and the control group with the PPARγ agonist treated groups.  Metabolites 
identified in the VIP/coefficients plots as significantly contributing to separation in the 
models were then considered to have changed globally.  Metabolite changes were then 
compared between agonists (Table 6.1). The metabolite changes in the individual tissues 
are considered below. 
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Table 6.1: Metabolite changes detected by GC-MS and 1H-NMR spectroscopy in 
liver, serum and skeletal muscle of control, PPARδ agonist and PPARγ 
agonist treated ob/ob mice.  Metabolites identified in the VIP/coefficients 
plots as significantly contributing to separation in the PCA and PLS-DA 
models built for the individual tissues.  The control group was compared 
with the combined PPARδ agonist and PPARγ agonist treated groups.  
The R2 and Q2 values for the individual models are shown. ↑, indicates a 
detected increase in metabolite concentration. ↓, indicates a detected 
decrease in metabolite concentration. 
 
6.4.3. Liver 
6.4.3.1 Metabolite changes common to PPARδ and PPARγ activation 
Activation of both PPARδ and γ caused increases in the concentrations of many amino 
acids including alanine, β-alanine, glutamate, glutamine, glycine, phenylalanine, proline, 
threonine, tyrosine and valine in liver tissue relative to tissue from control animals.  Fatty 
acid metabolism was also affected in the liver with an observed increase in the 
concentration of lauric acid and palmitoleic acid accompanied by a decrease in the 
concentration of cis-11,14-eicosadienoic acid in the PPARδ and γ treated mice.  The 
essential fatty acid pathways were altered by PPARδ and γ activation with an increase in 
the concentration of arachidonic acid and a concomitant decrease in linoleic acid and 
linolenic acid. In addition carbohydrate catabolism, anabolism and energy metabolism 
was influenced by the activation of both PPARδ and γ.  An increase in the concentration 
of acetic acid, β-hydroxybutyrate, galactonic acid, lactate and succinate and a decrease in 
fructose, galactose, glucose and glycerol were detected in the livers of treated mice. 
UPLC-MS analysis identified a decrease in the concentration of a number of TAGs and a 
concomitant increase in phosphatidylcholine species in both PPARδ and PPARγ agonist 
treated livers (Figure 6.3), (Table 6.2). Of the 14 species identified as increased in 
concentration following PPARδ activation 12 were identified as phosphatidylcholines.  
Twelve species of TAG were observed to decrease in concentration following PPARδ 
activation. 
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Figure 6.3: A. PLS-DA scores plot showing the clustering of the UPLC-MS 
chromatograms from the organic fraction of liver tissue from mice treated 
with a PPARδ agonist compared with control mice. ●, PPARδ agonist 
treated. ■, control (R2=0.877, Q2=0.574) B. PLS-DA scores plot showing 
the clustering of the UPLC-MS chromatograms from the organic fraction 
of liver tissue from mice treated with a PPARγ agonist compared with 
control mice. ◊, PPARγ agonist treated. ■, control (R2=0.996, Q2=0.852). 
C. PLS-DA scores plot showing the clustering of the UPLC-MS 
chromatograms from the organic fraction of serum from mice treated with 
a PPARδ agonist compared with control mice. ●, PPARδ agonist treated. 
■, control (R2=0.948, Q2=0.821) D. PLS-DA scores plot showing the 
clustering of the UPLC-MS chromatograms from the organic fraction of 
serum from mice treated with a PPARγ agonist compared with control 
mice. ◊, PPARγ agonist treated. ■, control (R2=0.985, Q2=0.864). 
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Table 6.2:  Complex lipid changes detected in liver of control, PPARδ agonist and 
PPARγ agonist treated ob/ob mice using UPLC-MS.  Lipids identified in 
the VIP/coefficients plots as significantly contributing to separation in the 
PCA and PLS-DA models built for the UPLC-MS analysis of the organic 
metabolite fraction. The control group was compared with the PPARδ 
agonist and PPARγ agonist treated groups from liver. 
(Glycerophosphatidylcholine PC) 
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DI-MS analysis of livers from PPARδ and PPARγ agonist treated ob/ob mice 
demonstrated an increase in the concentration of a range of glycerophosphoinositol 
species.  Several of the species increased in concentration were common to both the 
PPARδ and PPARγ treated animals (Table 6.3).  The increase in glycerophosphoinositols 
also coincided with the decrease in the free concentration of myoinositol in the livers of 
both treatment groups and may be indicative of the increased synthesis of the 
phospholipids. 
 
 
Table 6.3:  Glycerophosphoinositol (GPIns) species increased in concentration in the 
livers of PPARδ agonist and PPARγ agonist treated ob/ob mice detected 
using DI-MS.  Lipids identified in the VIP/coefficients plots as 
significantly contributing to separation in the PCA and PLS-DA models 
built for the DI-MS analysis of the organic metabolite fraction. The 
control group was compared with the PPARδ agonist and PPARγ agonist 
treated groups from liver.  GPIns species increased in concentration in 
both treatment groups are highlighted in red. 
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6.4.3.2 Metabolite changes unique to PPARδ activation 
While only a decrease in the concentration of the ketogenic amino acid, lysine 
distinguished the animals treated with the PPARδ agonist from the other groups for 
aqueous soluble metabolites, this group was more readily distinguished by lipid 
metabolites.  The PPARδ agonist produced an increase in the –CH3 and -(CH2)n lipid 
moieties, detected by 1H-NMR spectroscopy. A decrease was detected in the 
concentrations of 8,11-eicosadienoic acid, cis-10-heptadecanoic acid, myristic acid, 
myristoleic acid, oleic acid, palmitic acid, pentadecanoic acid and trans-11-eicosenoic 
acid.  The essential fatty acid pathways were also targeted with increases in arachidonic 
acid, dihomo-γ-linolenic acid, cis-4,7,10,13,16,19-docosahexaenoic acid and a decrease 
in γ-linolenic acid (Figure 6.4). 
 
 
Figure 6.4: PLS-DA scores plot showing the clustering of the GC-MS chromatograms 
from the organic fraction of liver tissue from mice treated with a PPARδ 
agonist compared with control mice. ●, PPARδ agonist treated. ■, control 
(R2=0.43, Q2=0.82). 
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The FFA composition of the liver, as detected by DI-MS, was also altered in livers from 
mice treated with PPARδ agonist.  There was an increase in the intermediates of the ϖ-6 
fatty acid pathway (dihomo-γ-linolenic acid and adrenic acid) and an increase in the 
intermediates and end products of the ϖ-3 essential fatty acid pathway (cis-
7,10,13,16,19-docosapentaenoic acid and cis-4,7,10,13,16,19-docosahexaenoic acid).  In 
addition there was an increase in incorporation of the ϖ-6 fatty acid pathway end product, 
arachidonic acid, into phospholipids and a concomitant decrease in the free concentration 
of this fatty acid.   
 
Given the increased ketogenesis and reduction in TAGs observed in the liver for both 
agonists it was deemed important to examine how these metabolic changes were 
influencing the metabolism systemically by analysing the serum. 
 
6.4.4. Serum  
6.4.4.1 Metabolite changes common to PPARδ and PPARγ activation 
Treatment with either of the two PPAR agonists induced changes in amino acid 
metabolism (increases in proline, tryptophan and tyrosine) and glycolysis/TCA cycle 
intermediates (increases in acetic acid, glyceric acid and succinate; decreases in fructose, 
galactose and glucose) reflecting those detected in the liver.  Also, in a similar manner to 
the liver, the largest changes occurred in lipid metabolism. The agonists caused increases 
in monopalmitin, bis-monostearin, myristic acid, palmitic acid, stearic acid, trans-9-
octadecanoic acid and trans-11-eicosanoic acid and decreases in cis-4,7,10,13,16,19-
docosahexaenoic acid and erucate.  Arachidonic acid from the ϖ-6 essential fatty acid 
pathway was decreased in the serum of treated animals.   
 
6.4.4.2 Metabolite changes unique to PPARδ activation 
Amino acids increased in the PPARδ agonist treated mice serum relative to control were 
aspartate and isoleucine. The concentration of the ketone body, β-hydroxybutyrate was 
increased as were the concentration of the TCA cycle metabolite fumarate and the 
glycolytic product lactate. Fatty acid metabolism was also affected in the serum with 
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increases in the concentration of 2-monostearin, palmitelaidic acid, palmitoleic acid and 
tetradecanoic acid.  The ϖ-6 essential fatty acid pathway intermediate, dihomo-γ-
linolenic acid was also increased in PPARδ agonist treated mice serum.  UPLC-MS 
analysis highlighted that the concentration of a range of TAGs was found to be elevated 
in PPARδ treated serum; this was the reverse of the observation upon PPARγ activation 
where the concentration of the same TAGs was found to be decreased (Table 6.4). 
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Table 6.4:  Complex lipid changes detected in serum of control, PPARδ agonist and 
PPARγ agonist treated ob/ob mice using UPLC-MS.  Lipids identified in 
the VIP/coefficients plots as significantly contributing to separation in the 
PCA and PLS-DA models built for the UPLC-MS analysis of the organic 
metabolite fraction. The control group was compared with the PPARδ 
agonist and PPARγ agonist treated groups from serum. The TAGs 
increased in the PPARδ agonist treated mice marked in red are equivalent 
to those decreased in the PPARγ agonist treated mice marked in blue.  
 
To examine the fate of the increased serum β-hydroxybutyrate produced by the liver 
through increased fatty acid oxidation following exposure to the PPARδ agonist and 
investigate the causes for the decrease in glucose in the blood serum of both agonist 
treated groups, the metabolome of skeletal muscle was examined. 
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6.4.5. Skeletal Muscle  
6.4.5.1 Metabolite changes common to PPARδ and PPARγ activation 
Amino acid metabolism was also altered in the skeletal muscle of PPARδ and γ agonist 
treated mice; concentrations of proline and threonine were increased and alanine and 
valine concentrations were decreased in treated mice relative to tissue from control 
animals.  Cis-10-heptadecanoic acid, cis-11,14-eicosadienoic acid, myristoleic acid, oleic 
acid and palmitoleic acid were increased and stearic acid was decreased in the skeletal 
muscle of the PPARδ and γ agonist treated mice.  The ϖ-6 essential fatty acid pathway 
was also altered with a decrease in linoleic acid and arachidonic acid. 
 
6.4.5.2 Metabolite changes unique to PPARδ activation 
In contrast to liver tissue amino acid metabolism, glycolysis and the TCA cycle were 
profoundly affected in the skeletal muscle of PPARδ agonist treated mice. Increases in 
the concentration of aspartate and α-glycerophosphoric acid and decreases in arginine, 
glutamine, glycine, methionine, norvaline, serine, glucose, lactate and succinate were 
detected (Figure 6.5). Fatty acid metabolism was changed in the skeletal muscle of 
PPARδ agonist treated mice, with an increase in the -CH3, COCH2 and -(CH2)n lipid 
moieties and cis-5,8,11,14,17-eicosapentaenoic acid, elaidic acid and margaric acid. 
There was a concomitant decrease in palmitic acid.  The ϖ-6 essential fatty acid pathway 
intermediate, dihomo-γ-linolenic acid was also increased.  
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Figure 6.5: A. PLS-DA scores plot showing the clustering of the GC-MS 
chromatograms from the aqueous extracts from skeletal muscle from mice 
treated with a PPARδ agonist compared with control mice. ●, PPARδ 
agonist treated. ■, control (R2=0.69, Q2=0.73). B. Comparison of the 
region of typical GC-MS chromatograms of control skeletal muscle tissue 
(black) and skeletal muscle tissue from mice treated with a PPARδ agonist 
(grey) containing the serine peak. C. Bar graph demonstrating the 
difference in the average integrated area of the Serine peak from control 
and PPARδ agonist treated liver. Standard error bars are shown. * P < 0.05 
with respect to vehicle control animals. 
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6.5 Discussion 
 
A range of complementary metabolic profiling approaches were used to study key tissues 
involved in type II diabetes from ob/ob mice treated with a PPARδ or a PPARγ agonist to 
understand the role of PPARδ in regulating systemic metabolism with a particular focus 
on hepatic and skeletal muscle metabolism.  In particular we investigated the core 
components of the Cori cycle to understand the implications altered liver metabolism has 
on muscle tissue.  While similarities were present between the two agonists, and in 
particular activation of both PPARδ and PPARγ resulted in an increase in the insulin 
sensitivity and glucose tolerance of the ob/ob mice, PPARδ induced a number of unique 
responses particularly in liver and skeletal muscle. These findings are consistent with the 
high level of PPARδ protein expression in these tissues273.  A decrease was detected in 
glucose and galactose in all tissues, and fructose in serum and liver from PPARδ agonist 
treated mice; the decrease in glucose in serum was confirmed by clinical chemistry.  
Concomitantly an increase in lactate was detected in the liver and serum of the treated 
mice, indicating a decrease in hepatic glucose production which has previously been 
observed following PPARδ activation227. It has been suggested that PPARδ activation 
increases glyceraldehyde-3-phosphate, formed from the 5-carbon sugar phosphates 
during the pentose phosphate shunt, which can then enter glycolysis227, explaining the 
observed reduction of glucose, galactose and fructose in the serum and skeletal muscle.   
 
During prolonged β-oxidation of fatty acids in the liver the production of acetyl-CoA can 
exceed the capacity of the TCA cycle.  The excess acetyl-CoA is converted to β-
hydroxybutyrate through ketogenesis in liver mitochondria.  The increased liver and 
blood serum concentrations of β-hydroxybutyrate indicate the PPARδ agonist stimulates 
ketone body formation for the peripheral tissue, a change which is also observed by 
clinical chemistry assays.  In addition acetic acid was increased in the treated livers; 
whilst a decrease in concentrations of non esterified fatty acids in the serum of PPARδ 
was indicative of increased tissue oxidative breakdown of fatty acids.  The concentration 
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of serum TAGs was increased in PPARδ agonist treated mice, as they are mobilised for 
catabolism in muscle. These observations are consistent with previous studies showing 
activation of PPARδ increases fatty acid β-oxidation274.  Furthermore activation of 
PPARγ lead to the reverse effect with a decrease in serum TAGs, consistent with this 
receptor being involved in regulating white adipose tissue storage of TAGs and adipocyte 
expandability275. The glucogenic amino acids (those that are precursors of glucose in 
gluconeogenesis), glycine, glutamate, glutamine, alanine, proline and valine and the 
amino acids which are glucogenic and ketogenic, threonine, tyrosine and phenylalanine 
were increased in the PPARδ agonist treated livers.  In contrast the concentration of the 
ketogenic amino acid (those that are broken down to acetyl-CoA and converted to ketone 
bodies), lysine was decreased.  These changes within the livers of PPARδ agonist treated 
mice indicate a decrease in gluconeogenesis and an increase in fatty acid oxidation and 
ketogenesis (Figure 6.6).  
 
Figure 6.6:  Metabolic pathways altered in PPARδ agonist treated liver from ob/ob 
mice. Metabolites increased relative to control tissue are red; metabolites 
decreased relative to control tissue are blue. 
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PPARδ agonist treated liver contained decreased linoleate and increased linoleate 
pathway intermediates, γ-linolenate and dihomo-γ-linolenate, and the pathway end 
product arachidonate (Figure 6.7).  The ∆ 6-desaturase introduces the initial double bond 
to linoleate forming γ-linolenate.  The ∆ 6-desaturase gene contains a PPRE and is known 
to be under PPARα transcriptional control223.  From this study the desaturase also 
appears to be under PPARδ transcriptional control.  Whilst it is worth considering that all 
pharmacological agonists are likely to exhibit some “off target” effects, this study has 
taken into account the high affinity, specificity and extensive characterisation of 
GW610742 for PPARδ, even over the highly related PPARα, which make the compound 
a very selective tool for the activation of the PPARδ nuclear receptor185. Van der Veen et 
al demonstrated that a dose of 20 mg/kg/day of GW610742 in mice gave an average 
plasma concentration of 1µM, given that the specificity of GW610742 for PPARδ is 28 
nM compared to 8900 nM for PPARα and >10,000 nM for PPARγ then the dose used in 
the current study saturates the PPARδ receptor whilst only minimally activating the other 
PPAR isotypes185.  Within the skeletal muscle linoleate was also decreased and dihomo-
γ-linolenate increased but arachidonate was decreased.  However, increased arachidonic 
acid metabolism is not necessary a contradictory result when PPARδ is activated.  The 
exact balance between the concentrations of these pathways presumably arise from the 
balance between increased β-oxidation and the actual activity of the synthetic pathway 
across the different tissues, as well as potential cross-talk between the three different 
PPARs. Thus, while synthesis of polyunsaturated fatty acids may be increased by PPARδ 
stimulation, increased β-oxidation will also deplete intermediates, and a new steady state 
will be achieved. 
 
 
Figure 6.7:  Linoleate pathway altered in PPARδ agonist treated liver from ob/ob 
mice. Metabolites increased relative to control tissue are red; metabolites 
decreased relative to control tissue are blue. 
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The α-linolenic acid essential fatty acid pathway was also altered in the liver of PPARδ 
agonist treated mice (Figure 6.8).  There was a decrease in the initial metabolite in the 
pathway, α-linolenic acid and a concurrent increase in the pathways product 
4,7,10,13,16,19-docosahexaenoic acid.  Two steps in the pathway are again catalysed by 
the ∆ 6-desaturase.  Also the final step in the pathway, the formation of 4,7,10,13,16,19-
docosahexaenoic acid from 6,9,12,15,18,21-C24:6, occurs via β-oxidation, which is 
upregulated in the livers of PPARδ treated mice.  Nevertheless as the intermediates in the 
pathway were not detected, the exact target of PPARδ cannot be identified 
unambiguously from this data. 
 
 
Figure 6.8:  Linolenate pathway altered in PPARδ agonist treated liver from ob/ob 
mice. Metabolites increased relative to control tissue are red; metabolites 
decreased relative to control tissue are blue. 
 
PPARδ mRNA is expressed in skeletal muscle at 10-fold higher levels than PPAR α and 
50-fold higher levels compared with PPARγ mRNA139.  The receptor is preferentially 
found in oxidative rather than glycolytic myofibers139.  A major metabolic change 
exhibited by the PPARδ treated skeletal muscle was a decrease in the concentration of the 
majority of the observed amino acids (Figure 6.9).  Since skeletal muscle lacks glucose-
6-phosphatase the amino acids will not have been used as substrates in gluconeogenesis.  
An alternative fate for the amino acids is as substrates for the TCA cycle, which was also 
affected.  The increased demand for TCA cycle substrates was also apparent from the 
decrease in succinate and concomitant increase in fumarate and malate.  Succinate is the 
substrate for complex II of the electron-transport chain which catalyses the formation of 
fumarate and reduces coenzyme Q.  PPARδ activation increases mitochondrial 
biogenesis, expression of electron transport chain components such as cytochrome c, 
cytochrome c oxidase and complex II and induces muscle fibre type switching to type I 
Chapter 6 
 
 212 
fibres171. Within the treated skeletal muscle the concentrations of adenine were decreased 
and those of adenosines and ribose sugars from the adenosines were increased.  
Therefore, the decrease in amino acids may relate to increased oxidative metabolism 
occurring in this tissue. In addition we detected an increase in the concentration of 
creatine and phosphocreatine in muscle tissue which reflects an increase in the high 
energy phosphate buffering capacity of the cell in addition to the increase in ATP also 
detected.  These changes are accompanied by a decrease in lactate concentration and 
increased β-oxidation, indicating a reduction in glycolysis and a switch to more oxidative 
metabolism.  PPARδ activation has been implicated as a cause of skeletal muscle 
atrophy272.  As demand for amino acids increases one mechanism indicated by our results 
is that proteins are broken down to supply substrates to the TCA cycle. 
 
 
Figure 6.9:  Metabolic pathways altered in PPARδ agonist treated skeletal muscle 
from ob/ob mice. Metabolites increased relative to control tissue are red; 
metabolites decreased relative to control tissue are blue. 
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PPARδ activation also reduced the degree of saturation of fatty acids in the skeletal 
muscle of the treated ob/ob mice.  Palmitate and stearate concentrations were found to be 
decreased and their monounsaturated forms palmitoleate and oleate concentrations were 
increased.  The enzyme catalysing these reactions, stearoyl-CoA desaturase, is under 
PPAR expressional control224. 
 
Activation of PPARδ further improved the dyslipidaemic state in the ob/ob mice by 
increasing the serum HDL cholesterol concentrations.  Activation of PPARδ increases the 
expression of the cholesterol efflux pump ATP-binding cassette transporter1, promoting 
the efflux of cholesterol from peripheral tissues which may lead to the observed increase 
in HDL cholesterol170.   
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6.6 Conclusions 
 
A global summary of the observed changes leads to the conclusion that PPARδ activation 
generates a systemic change in energy balance in which the Cori cycle is profoundly 
affected. A decrease in hepatic glucose production produces an increase in hepatic and 
circulating lactate concentrations and a drop in circulating blood glucose; hepatic 
metabolism begins to favour fatty acid β-oxidation and ketogenesis, in order to maintain 
energy supply to peripheral tissues the ketone bodies are released into circulation.  
Furthermore glucose is decreased within skeletal muscle alongside increased TCA cycle 
intermediates but without an observed increase in lactate, correlating with the observed 
increase in oxidative metabolism.  Therefore, the activation of PPARδ produces a marked 
switch from the Cori cycle to ketone and fatty acid metabolism between the liver and 
oxidative skeletal muscle which may contribute to the observed improvement in insulin 
sensitivity.  
 
In conclusion, to understand the global physiological and pharmacological effects of 
PPARδ activation, which may give rise to further applications for PPARδ agonists, 
compound treatment studies have been performed on an ob/ob mouse background.  The 
combined metabolomic study of liver, skeletal muscle and serum identified multiple 
changes in metabolism in the PPARδ agonist treated mice.  These changes showed that 
PPARδ activation profoundly affected glycolysis, gluconeogenesis, the TCA cycle and 
linoleic acid and α-linolenic acid essential fatty acid pathways, many of the changes were 
found to correlate well with known PPAR controlled gene expression. While some of 
these metabolic perturbations could be induced by a selective PPARγ agonist, there were 
also specific changes associated with PPARδ, demonstrating the complexity of the PPAR 
system and cross-talk between different receptors when considering systemic 
metabolism.
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Summary and Discussion 
 
 
7.1 General Discussion 
 
The PPARs are orphan nuclear receptors that function as transcriptional regulators in a 
ligand dependent manner.  They have been implicated in the expressional control of a 
plethora of genes vital to organogenesis, inflammation, cell differentiation and 
proliferation.  The receptors have also been recognised as master regulators of lipid and 
carbohydrate metabolism and as such have been identified as targets for the treatment of 
metabolic diseases and in particular dyslipidaemia, obesity, TIIDM and the metabolic 
syndrome.  Several classes of pharmacological agents currently available in the clinic 
function through PPAR agonism and include the fibrates, activators of PPARα used to 
treat dyslipidaemia, and thiazolidinediones, PPARγ agonists employed in the treatment of 
TIIDM.  Thus far a clinically available therapeutic directed at PPARδ has eluded full 
development and clinical release despite implications that the receptor has potential as a 
treatment for obesity, TIIDM and the associated metabolic syndrome.   In spite of their 
potential and widespread use as medication the mechanisms by which PPAR agonists can 
alleviate metabolic perturbations and bring about normalisation remain to be fully 
defined.  Both PPARδ and PPARγ are crucially implicated in the regulation of 
metabolism within white adipose tissue; consequently it was the aim of this thesis to use 
a metabolomics approach to investigate and define the metabolic effects of PPARδ and 
PPARγ activation in both in vivo adipose tissue and in an in vitro model of adipose tissue.
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To generate a metabolically phenotyped in vitro model of adipocyte differentiation and 
metabolism the metabolic changes occurring during differentiation of 3T3-L1 
preadipocytes as they develop into mature adipocytes was defined using a multiplatform 
metabolomic and 13C-isotope substrate labelling technique. The metabolic changes 
identified were then compared and contrasted to the metabolic differences between pre- 
and post-differentiation primary adipocytes.  Distinct periods in the differentiation 
process could be defined by changes in metabolite concentrations.  Alterations in 
metabolism, affecting a range of pathways, were ascertained to occur during adipocyte 
differentiation.  Affected pathways included the TCA cycle, glycolysis, the production of 
odd chain fatty acids by α-oxidation, fatty acid synthesis, fatty acid desaturation, 
polyamine biosynthesis and trans-esterification to produce complex lipids.  Moreover the 
usage of glucose in the generation of fatty acids during 3T3-L1 metabolism was 
confirmed utilising 13C-labelled glucose to monitor the metabolic flux through glycolysis, 
the TCA cycle and into fatty acid synthesis.  It was shown that upon synthesis, the fatty 
acids are subjected to desaturation by the ∆-9 desaturase or to α-oxidation, forming odd 
chain fatty acids as was confirmed through the use of U-13C-labelled palmitate.  Although 
the 3T3-L1 cell line is a widely utilised tool for the investigation of adipocyte biology it 
was found that, as with all immortalised cell lines, they do not behave identically to their 
primary cell line counterparts.  Nevertheless, the modifications in metabolism discovered 
between primary preadipocytes and primary differentiated adipocytes equated to many of 
the findings observed in the 3T3-L1 adipocytes.  Therefore it is hoped that alongside 
metabolically phenotyping an adipocyte model for use in the investigation of tissue 
specific PPARδ and PPARγ activation, the work conducted in this thesis will provide 
invaluable information for research conducted in the 3T3-L1 cell line, primary cell lines 
and even white adipose tissue when following the changes in metabolism associated with 
differentiation.   
 
To evaluate and characterise the systemic and tissue specific metabolic effects of PPARδ 
activation in adipose tissue, a multifaceted metabolomic method was used to examine the 
effects of PPARδ activation, using a high affinity pharmacological agonist, in white 
adipose tissue from the ob/ob mouse model of insulin resistance, and the 3T3-L1 
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adipocyte cell line within a cell culture system, generating an in vivo and an in vitro 
model of adipose tissue specific PPARδ activation.  In addition, to unambiguously define 
the mechanisms by which PPARδ alters the metabolism of adipose tissue, 13C-stable 
isotope substrate labelling studies using 1-13C-glucose and U-13C-palmitate, respirometric 
analysis using a Clark-type oxygen electrode and transcriptomic microarray analysis were 
performed on PPARδ agonist treated 3T3-L1 adipocytes.  In summary, possible 
metabolic mechanisms by which PPARδ activation actualises its observed anti-diabetic 
and anti-obesity effects were identified; activation of the nuclear receptor decreases fatty 
acid synthesis and fat storage within synthesised TAG depots and concomitantly 
mobilises complex lipid fatty acid stores.  Mobilisation of the TAG lipid energy stores 
was found to be accompanied by upregulation of not only fatty acid oxidation but also by 
carbohydrate oxidative metabolism in the white adipose tissue, a tissue not 
conventionally thought of as being energetic or oxidative.  Fundamental to this process is 
the consolidation and systematisation of the energy metabolism pathways, which PPARδ 
was identified as accomplishing by upregulating the transcription of a series of genes 
involved in glycolysis, the TCA cycle, the electron transport chain and fatty acyl β-
oxidation.  PPARδ activation in white adipose tissue was found to neither bring about 
exclusive stimulation of either fatty acid oxidation or carbohydrate oxidation but rather 
global oxidative metabolism; simultaneously reducing the quantity of TAGs and glucose 
in white adipose tissue.  Therefore, despite the absence of PPARδ agonists in the clinic, 
the nuclear receptor may still prove a powerful target for the treatment of the metabolic 
syndrome. 
 
It was an additional aim of this thesis to identify the potential metabolic effects of PPARγ 
activation in adipose tissue that may be contributing to the nuclear receptor’s anti-
diabetic potential.  Consequently a metabolomics study of PPARγ activation both in vivo 
in the ob/ob mouse, to determine the systemic effect of PPARγ activation on adipose 
tissue, and in vitro using the murine 3T3-L1 adipocyte cell line, to independently 
establish adipose tissue specific activation of the nuclear receptor, was conducted.  To 
delineate the metabolic changes established as associated with PPARγ activation in the 
Chapter 7 
 
 
 218 
metabolomic analysis and to explicitly define the pathways by which activation of the 
ligand binding transcription factor influences the metabolism of adipose tissue, 
mechanistic analyses were performed using 13C-stable isotope substrate labelling, 
employing 1-13C-glucose and U-13C-palmitate, and transcriptomic microarray analysis.  
Investigations led to the discovery that activation of the nuclear receptor in adipocytes 
leads to an upregulation of glycolysis and catabolism of other carbohydrate species. 
Correspondingly activity of the TCA cycle is decreased, an effect especially obvious in 
the later oxidative stages of the cycle as they are downregulated in preference of fatty 
acid synthesis from the early TCA cycle substrates.  In addition to de novo fatty acid 
synthesis, cellular FFA uptake is increased; propagating a pool of longer chain fatty acids 
which are integrated into TAGs or desaturated and incorporated into TAG’s.  
Preservation of the complex lipid pool is subsequently achieved via an inhibition of 
lipolysis.  Concurrently the breakdown of fatty acids via β-oxidation is reduced.  
Furthermore, PPARγ activation was implicated in the augmentation of calcium cellular 
signalling. The calcium signalling pathway is associated with insulin signalling and its 
downstream metabolic effectors; identifying a potential accessory mechanism for PPARγ 
activation mediated normalisation of blood glucose and dyslipidaemia in both human 
patients and murine subjects with the metabolic syndrome and TIIDM.  However, it was 
also discovered that PPARγ activation increases activity of the polyol pathway in 3T3-L1 
adipocytes; a pathway in which increased flux has been associated with the development 
of diabetic complications.  This finding casts a shadow over the use of thiazolidinediones 
and other PPARγ agonists in the clinic for the treatment of diabetes and the metabolic 
syndrome.  Nevertheless, the observed sequestration of glucose and lipid into the white 
adipose tissue, as a safely contained storage depot, was described as a possible 
mechanism by which PPARγ activation reduces the damaging potential of increased 
levels of circulating glucose and lipid, whilst simultaneously reducing lipid and 
cholesterol accumulation in peripheral tissues; demonstrating a means by which PPARγ 
activation may initiate insulin sensitisation, not only in the white adipose tissue but also 
in the peripheral tissue.  This thesis has proposed that through the dual mechanisms of 
augmenting facets of the calcium signalling pathway associated with insulin action and 
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direct transcriptional regulation of metabolic enzymes PPARγ activation brings about 
metabolic changes that function to reinforce insulin sensitisation. 
 
Further to these aims, this thesis was intended to use a metabolomics approach to 
investigate and characterise the systemic physiological effects of PPARδ and PPARγ 
activation by definition of the hepatic and peripheral metabolic changes that occur in the 
ob/ob mouse following activation of the nuclear receptors.  Consistent with many of the 
results from the studies of PPAR activation in adipocytes conducted in this thesis, a 
number of key metabolic pathways in liver and skeletal muscle were identified as 
affected by PPARδ agonism including glycolysis, gluconeogenesis, the TCA cycle and 
linoleic acid and α-linolenic acid essential fatty acid pathways.  Moreover, through 
systemic analysis, it was discovered that PPARδ activation generates a system wide 
change in energy balance, profoundly impacting on the Cori cycle.  Decreased hepatic 
gluconeogenesis was found to cause an increase in the concentration of hepatic and 
circulating lactate and a concomitant reduction in circulating blood glucose; to sustain 
energy balance hepatic metabolism switched to favour fatty acid β-oxidation and 
ketogenesis, the ketones were then released into circulation as a source of energy for the 
peripheral tissues.  Furthermore the concentration of glucose within skeletal muscle was 
found to decrease upon PPARδ activation.  Coinciding with this observation was a 
detected increase in TCA cycle intermediates, correlating with the increase in oxidative 
metabolism.  It was concluded that the activation of PPARδ produced a significant 
modification in energy metabolism from the Cori cycle to ketone and fatty acid 
metabolism between the liver and oxidative skeletal muscle.  Whilst some of these 
metabolic perturbations were also found to be induced by PPARγ activation and both 
activation of PPARδ and PPARγ lead to increased insulin sensitivity and glucose 
tolerance, activation of both nuclear receptors were identified as functionally distinct.  
Characterisation of PPARδ activation demonstrated the specific catabolic role of this 
receptor relative to PPARγ. 
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7.2 Future Directions 
 
The research described in this thesis could be expanded upon using various experimental 
approaches to further the characterisation and understanding of the physiological role 
played by the PPARs in the control of metabolism and consequentially to assess their 
potential as a therapeutic target for the treatment of a myriad of metabolic diseases 
including TIIDM, dyslipidaemia and the metabolic syndrome.  One such approach would 
be the development of additional tissue specific models of PPAR activation using cell 
lines, or even primary cells, derived from alternative metabolic tissues such as skeletal 
muscle, hepatic and cardiac tissue to complement that of the 3T3-L1 adipocytes studied 
in Chapter 4 and Chapter 5 of this thesis and to expand upon the observations made 
regarding systemic metabolism in Chapter 6 of this thesis. Although there are a number 
of robust cell lines available for the study of hepatocytes and skeletal and cardiac 
myocytes, it is worthy of note that, as with all immortalised cell lines, they do not behave 
identically to their primary cell line or in vivo counterparts. Extensively used skeletal 
muscle cell lines include the rat L6 and mouse C2C12 cell lines that are easy to cultivate 
and can be induced to differentiate forming multinucleated myotubes in culture dishes.  
However, the differentiation of these cells is halted and they fail to recapitulate their 
contractile function, or generate different fibre types276.  The Huh-7 and HepG2 cell lines 
have been widely employed for hepatocyte research, nevertheless these cells are derived 
from neoplastic tissues and are therefore de-differentiated from mature hepatocytes.  To 
surmount the disadvantages in the hepatocyte cell lines available primary human 
hepatocytes have also been utilised in the study of liver functions.  Even so primary 
hepatocytes can suffer from a rarity of supply, lack of homogeneity, mortality and 
intransigency to growth in culture277. Human hepatocyte lines have recently been 
developed that now retain a primary hepatocyte phenotype and may prove valuable for 
research into the metabolic processes that occur in the liver278.  Immortalised 
cardiomyocyte cell lines capable of proliferation in culture include the AT-1279 and 
MC29280 cell lines.  Alternative methods have been employed to generate cardiomyocyte 
cell lines including harvesting cells from transgenic mice expressing SV40 T-ag281 and 
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transformation of foetal cardiomyocytes with the SV40 oncogene282.  Again, these cell 
lines suffer from similar deficiencies the most common being a limited capacity to be 
passaged, de-differentiating in long term culture and deviation from a typical 
cardiomyocyte phenotype.  To circumvent these inadequacies, a mouse atrial 
cardiomyocyte cell line, HL-1 a derivative of the AT-1 line, has been developed which 
maintains the phenotype of adult mouse atrial cardiomyocytes whilst obtaining the 
capacity for serial passage283. Through the use of a selection of these cell lines and the 
application of metabolomic techniques employed in combination with 13C stable isotope 
substrate labelling, respirometry and transcriptomics, as detailed in Chapter 4 and 
Chapter 5 of this thesis, several tissue specific metabolic models of PPAR activation 
could be generated and studied. 
 
To further define the physiological role of PPAR activation metabolomic investigations 
of in vivo models of tissue specific PPAR activation and ablation would be a pertinent 
approach.  Although PPARδ knockout mice are viable they suffer from several 
developmental defects and homeostatic perturbations including placental abnormalities 
generating embryonic lethality, myelination defects, unusual skin inflammatory responses 
and reduced adipose tissue mass284,285.  In addition, tissue dependent metabolic effects are 
convoluted due to systemic changes.  However, tissue specific animal models of PPAR 
overexpression, activation and ablation have been developed.  Rodent models of 
overexpression of PPARδ in both adipose tissue, under the control of the enhancer-
promoter region of the adipocyte fatty acid binding protein (aP2) gene169, and in skeletal 
muscle171 have been developed to investigate the role that the nuclear receptor plays in 
these tissues. 
 
To elaborate on future research possibilities, an approach whereby the exact points of 
PPAR directed control in metabolic pathways can be identified is provided by the RNAi 
techniques.  Following on from the identification of pathways affected by PPAR 
activation in adipocytes, as outlined in this thesis, RNAi could be used to perturb the 
system and test potential PPAR control points in pathways highlighted by the 
metabolomic and transcriptomic analysis conducted in Chapter 4 and Chapter 5.  RNAi 
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provides a versatile tool, allowing knock-down of gene transcripts as opposed to knock-
out and high selectivity when compared to a variety of metabolic inhibitors.  The RNAi 
analysis could also be expanded to investigate PPAR control of metabolism in additional 
tissue specific cell lines as previously discussed.  
 
The research conducted in Chapter 3, Chapter 4 and Chapter 5 of this thesis 
demonstrated the potential of 13C labelled substrate studies to characterise the effect of 
PPAR activation on the spatio-temporal flux of metabolites through metabolic pathway 
networks.  In addition to the investigation of glycolysis, the TCA cycle, fatty acid β-
oxidation and fatty acid synthesis reported, the potential remains to investigate other 
metabolic pathways identified as affected by PPAR activation; a pertinent example would 
be to establish the fate of amino acids as likely substrates for the TCA cycle using 
myocytes incubated with 13C-labelled amino acids, this would substantiate speculation 
made in Chapter 6 regarding PPARδ activation in skeletal muscle.   
 
Finally, an extra dimension of metabolomic analysis could be achieved through LC-MS 
profiling of the polar, aqueous soluble metabolites to further define PPAR activation in 
adipose tissue culture and animal studies.  LC-MS conducted within this thesis has 
focussed on the more established lipidomic analysis.  However, studies of the polar 
metabolites using LC-MS are becoming more widespread within metabolomics with the 
technique under continual development286.  Currently many of the methods are targeted 
to biofluids, with the analysis of blood and urine most common287.  Although advances 
are being made in the analysis of tissue extracts288, the use of LC-MS investigation of 
polar metabolites would be advantageous in enlarging the coverage of the metabolome.   
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7.3 Conclusions 
 
The research conducted within this thesis emphasises the benefit of combining omic 
methods with mechanistic studies to further characterise metabolic changes observed 
within metabolomic experiments.  Moreover a multi-omic approach has been exploited, 
increasing the coverage of the strata defined by the central biochemical and molecular 
biological dogma to constitute a biological network; in doing so, the complex interactions 
between metabolites and genes can be further characterised, improving our understanding 
of the systems properties of biological networks and their perturbation. 
 
In conclusion, through the use of a multi-platform metabolomic technique, employed in 
conjunction with transcriptomic, metabolite flux and respirometric techniques, the 
metabolic influence of both PPARδ and PPARγ in adipose tissue has been further 
defined.  Although the metabolic effects of both PPARδ and PPARγ activation were 
indicative of an effective therapeutic target for the treatment of the metabolic syndrome, 
improving insulin sensitisation and glucose tolerance, the metabolic mechanisms initiated 
by receptor activation profoundly deviated.  PPARδ activation was distinguished by 
oxidative catabolism of metabolites identified as potentially deleterious in the diabetic 
state.  Conversely, PPARγ activation was identified by the sequestration of the same 
metabolites into safe storage depots.  The role of the PPARs as master regulators of 
metabolism has been accentuated and their latent capacity as targets for the treatment of 
metabolic diseases of global consequence inferred. 
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